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Fetal haemoglobin levels have a major impact on the severity of sickle cell disease 
(SCD) and Beta-Thalassaemia. Previous studies by our group shows that three loci – 
the HBS1L-MYB intergenic region (HMIP) on chromosome 6q23, BCL11A on 
chromosome 2p16 and the β globin cluster on chromosome 11 accounts for up to 50 % 
of the variation in HbF levels in non-anaemic Europeans. Recent work by our group 
indicated the presence of regulatory elements in HBS1L-MYB intergenic region (HMIP) 
evidenced by GATA-1 binding coinciding with strong histone acetylation, RNA 
polymerase II activity, and erythroid specific DNase I hypersensitive sites. Genetic 
studies and resequencing of two key individuals from the family that led to discovery of 
6q QTL revealed new SNPs in the HBS1L-MYB intergenic region. 
 
In silico predictions suggested that a couple of these SNPs altered binding of key 
transcription factors. We proposed that differential binding of these transcription factors 
mediated through these SNPs underlie the association with HbF control. 
 
Electrophoretic Mobility Shift Assays (EMSAs) and Chromatin immunoprecipitation 
followed by real time PCR (ChIP-qPCR) and HaploChIP showed that many of the 
genetically associated variants altered the binding of key transcription factors such as 
GATA-1, KLF1 and MYB that have crucial roles in globin regulation as well as 
regulation of erythropoiesis.  
 
We have also compared ex-vivo erythroid cell culture kinetics and expression profiles 
of individuals who are homozygous for the presence or absence of the allelic variant 
associated with HbF. MYB expression and maturation rate of erythroblasts were 
noticeably different whereas expression of HBS1L the other flanking gene was not 
different. We could also demonstrate unequal expression of MYB in individuals 
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heterozygous for the HMIP variants but the direction of the effect should be further 
investigated. 
 
These results further support the regulatory role of HBS1L-MYB intergenic 
polymorphisms on HbF and erythropoietic kinetics supporting our hypothesis that the 
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Haemoglobin is the protein in erythrocytes which acts as a transporter of oxygen and 
carbon dioxide to all body tissues. Haemoglobin is composed of two alpha-like and two 
beta-like protein chains, each bound to a hememoiety (Perutz et al 1960). 
 
Different types of haemoglobin are produced at different stages of human development 
with two developmental switches: Embryonic haemoglobin (Gower 1, ζ2ε2;Gower 2, 
α2ε2 and Portland, ζ2γ2) to fetal haemoglobin (HbF,α2γ2), and fetal to adult haemoglobin 
(HbA, α2β2 and HbA2, α2δ2). The first switch from embryonic to fetal haemoglobin 
occurs in the fetal liverwhile the second, from fetal to adult haemoglobin, occurs just 
before birth. Haemoglobin A (HbA, α2β2) represents more than 95% of the total 
haemoglobin in adults and remains the dominant form of haemoglobin throughout adult 
life (Stamatoyannopoulos 1972 ,Ho and Thein 2000) (Figure 1.1A). 
 
Each of the globin chains are encoded by genes found in two clusters. 
The beta-globin gene cluster is located on chromosome 11p; genes in the cluster are 
arranged in the order in which they are expressed during ontogeny:  
the embryonic ε gene, the fetal Gγ, Aγ genes and the adult δ and β genes, from 5I to 3I, 
respectively (Figure 1.1 B) (Collins & Weissman 1984, Ho and Thein 2000, Harju and 
McQueen 2002, Stamatoyannopoulos et al 2005). The major regulatory element of 
beta-globin gene cluster termed beta-locus control region (beta-LCR) is located further 
upstream of the genes. 
 
The α-like globin gene cluster is located on the tip of chromosome 16p and genes in 
the cluster are arranged in the order in which they are expressed during ontogeny: the 
embryonic α-like globin gene (ζ) and the adult α globin genes (α1 andα2) from 5I to 3I, 
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respectively (Figure 1.1 C). The genes are regulated by the upstream regulatory 






Figure 1.1: Globin expression. 
Expression of different forms of β-like globin genes in human development and the 
developmental switches (A).The β-like globin gene cluster and the locus control region 
(LCR) in human (B). The α-like globin gene cluster and the α-major regulatory element 
(α-MRE) in human (C). 
This graph is adapted from (Noordermeer & de Laat, 2008). 
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Haematopoiesis, the formation of blood cells, consists of a cascade of finely regulated 
events by which pluripotent haematopoietic stem cells (HSC) differentiate to all the cell 
types present in blood. These include erythrocytes, lymphocytes, megakaryocytes, 
granulocytes, and monocytes/macrophages. 
 
Stem cells that have self-renewing capability undergo two sequential differentiating 
processes in response to specific growth factors, interleukins, and hormones. The first 
is commitment, by which stem cells lose their self-renewing capability and differentiate 
to other cells with a more limited differentiating potential (which give rise to only one or 
sometimes two cell lineages). The second is differentiation, which allows the terminal 
differentiation of those cells committed to a specific lineage. Differentiation begins after 
they are committed to either the myeloid or the lymphoid lineage, as a myeloid 
progenitor cell or lymphoid progenitor cell, respectively. 
 
This process takes place at multiple sites throughout development:  Primitive 
haematopoiesis occurs during the earliest weeks of gestation, in the embryonic yolk 
sac; definitive haematopoiesis occurs in several locations. The aorta-gonads-
mesonephros (AGM) region is the initial site of definitive haematopoiesis followed by 
the liver and spleen. From around 2 months until 6-7 months of fetal life, the liver and 
spleen are the major haematopoietic organs, after which, the bone marrow begins to 
take over the task and eventually becomes the exclusive site of haematopoiesis 




Figure 1.2: Sites of haematopoiesis during human development. 
(Image adapted from M.Komorniczak, 2011) 
1.3 Erythropoiesis 
 
Erythropoiesis defines the process of differentiation and proliferation from 
hematopoietic stem cells (HSCs) to mature red blood cells (RBCs).The production of 
erythrocytes is the largest quantitative output of the haematopoietic system with an 
estimated production rate of 2x1011 erythrocytes per day. Erythropoiesis is composed 
of commitment and differentiation steps that restrict the differentiation potential and the 
proliferative capacity of the cells as they go through the erythroid-specific program of 
gene expression. Erythrocytes (red blood cells) are derived from the myeloid progenitor 
cells. Committed erythroid progenitors can be detected by their ability to form erythroid 
colonies in in vitro methyl cellulose culture, referred to as burst forming unit-erythroid 
(BFU-e). BFU-e's are the most immature haematopoietic cells that are already 
committed to the erythroid lineage. BFU-e develops into colony forming units-erythroid 
(CFU-e). CFU-e will differentiate into the first morphologically identifiable cell of the 
erythrocyte lineage, the pro-erythroblast, followed by successive differentiation into the 
basophilic erythroblast, the polychromatophilic erythroblast, and the acidophilic 
erythroblast, which is the last nucleated cell of the mammalian erythrocyte lineage. In 
the next stage of development, acidophilic erythroblasts lose the ability to divide, 
followed by extrusion of the nucleus givingrise to the reticulocyte.  
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Reticulocytes are released into the blood stream where they mature into erythrocytes 
(Gregory 1978, Philipsen & Wood, 2009) (Figure 1.3). 
 
 
Figure 1.3: Human erythroid differentiation. 
 
Erythroid differentiation of cells grown by using the two-phase liquid culture method.Figure 
adopted from Philipsen & Wood, 2009. 
 
1.3.1 Regulation of Erythropoiesis 
 
Erythropoiesis must be regulated positively and negatively to ensure a continuous but 
controlled production of red cells in order to provide oxygen at a physiologic level in 
peripheral tissues. 
 
A positive regulation is required to ensure a constant production of red blood cells 
because erythrocytes in circulation have a limited life span of 120 days. Towards the 
end of this time they are cleared from the circulatory system as new reticulocytes are 
continuously released into the peripheral circulation. However, a negative control is 
clearly required at several levels to avoid overproduction of erythroid cells and 
polycythemia, which may lead to hyper-viscosity and other problems. The process of 
erythropoiesis is orchestrated by a complex network of microenvironmental and growth 
factors that promote the survival, proliferation and/or differentiation of erythroid 
progenitors, and nuclear factors that regulate the transcription of genes involved in the 
establishment of the erythroid phenotype. 
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1.3.1.1 Regulation of Erythropoiesis at the Cellular Level 
 
The growth of erythroid progenitor cells is dependent on specific growth factors that act 
at all stages of erythroid maturation (BFU-E, CFU-E, erythroid precursors) to prevent 
apoptosis, induce proliferation, and promote or delay/inhibit differentiation. Delay in 
differentiation may play an important role by allowing self-renewal and expansion of 
erythroid progenitors before terminal maturation. As a result, production of red cells is 
increased. 
 
Several growth factors have been described as crucial in the regulation of 
erythropoiesis, such as interleukin-3 (IL-3), interlukin-6 (IL-6), granulocyte-macrophage 
colony stimulating factor (GM-CSF), insulin growth factor like 1 (IGF1), and 
glucocorticoids.IL-3 is a cytokine that promotes cell survival and proliferation by binding 
to IL-3R expressed on HSCs through to early progenitor cells. GM-CSF is required 
again from HSC to BFU-e stage and promotes proliferation. IGF1 synergizes with other 
cytokines to increase proliferation of early erythroid progenitors and may coordinate the 
production of red cells during development and increase of body mass. Similarly, 
glucocorticoids may contribute to the increase of erythroid production during stress 
erythropoiesis, delay differentiation enabling self-renewal and expansion of erythroid 
progenitors before terminal maturation (Bauer et al 1999; Migliaccio & 
Papayannopoulou 2001). However, the main factors involved in erythroid development 
are Stem Cell Factor (SCF) and Erythropoietin (Epo).  
 
At the cellular level, BFU-Es are highly dependent on stem cell factor (SCF) for their 
growth and differentiation, whereas CFU-Es are highly dependent on erythropoietin 
(Epo). Genetic and biochemical approaches have demonstrated that SCF and Epo, 
which act on their respective receptors, Kit and Epo-R, are required for erythroid cell 
production.  Studies have shown that mice with mutations in the SCF gene, or its 
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receptor gene Kit, develop severe anaemia characterised by depressed erythropoiesis. 
Epo and Epo-receptor (Epo-R) knockout mice die of failure of fetal liver erythrocyte 
generation (Figure 1.4). 
 
SCF receptor, c-Kit, is expressed in the majority of CD34+ haematopoietic progenitors 
and its expression is maintained at high levels during the stages of differentiation from 
BFU-E to CFU-E. At later stages of differentiation, during the maturation of CFU-E, c-
Kit expression progressively declines. Thus, SCF exerts its effects on erythroid 
progenitors during earlier stages of erythroid differentiation by inducing an increase of 
cell survival and proliferation of early erythroid progenitors. At the same time, SCF 
delays erythroid maturation and differentiation to allow self-renewal of early erythroid 
progenitors and precursors before they reach the stage where cells are no longer able 
to divide. At the later stages of differentiation, SCF prevents apoptosis and induces 
proliferation, in synergy with Epo (Broudy et al 1997).  
 
Epo is an essential growth factor in erythropoiesis which is dispensable at the earlier 
stages of erythropoiesis but its role dramatically increases during later stages. Epo 
drives the proliferation and expansion of the developing erythroid progenitors from 
BFU-e stage through to terminal differentiation to haemoglobinized cells. Epo 
administration dramatically increases the number of CFU-e’s and erythroid precursors 
up to the stage of basophilic erythroblasts, mainly by preventing their apoptosis. At the 
cellular level, Epo is responsible for the finely tuned homeostatic control of erythrocyte 
numbers by tissue oxygenation.   
 
Although the daily production of erythrocytes is tightly regulated, loss of blood due to 
bleeding or haemolysis leads to increased reticulocyte production within a few days.  
This is achieved by EPO secretionwhich increases the number of CFU-E and erythroid 
precursors up to the stage of basophilic erythroblasts, mainly by preventing their 
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apoptosis. As the increased reticulocyte production normalizes circulating 
erythrocytenumbers, the rate of new reticulocyte formation decreases to avoid 
reboundpolycythaemia.As the circulating erythrocyte numbers and oxygenation of 
tissues increase, the production of Epo decreases. Variation of Epo sensitivity at 
different stages of erythropoiesis is key in the prevention of over production of 
reticulocytes. . Erythroid progenitors and precursors exhibit a wide range of Epo 
sensitivities. At low Epo concentration cells with highest Epo sensitivity can prevent 
apoptosis by EPO administration (Sathyanarayana et al 2008). 
 
Epo interacts with its receptor Epo-R to trigger signaling pathways that regulate 
erythroid regulation. One of the main signaling molecules activated by Epo binding to 
Epo-R is STAT5. Activated STAT5 enhance gene activity involved in cell survival, 
proliferation, and differentiation. Studies have shown that STAT5 plays an important 
role in maintaining a high erythropoietic rate during fetal development and during stress 
responses in adult mice. Mutations affecting STAT5 activation affects stress 
erythropoiesis (Halupa et al 2005). 
 
Figure 1.4:  Dependence of erythroid progenitor cells to Epo and SCF at different 
stages of erythropoiesis. 
Figure adopted from Philipsen & Wood, 2009. 
 






At the transcriptional level, the expression pattern of erythroid-specific genes follows a 
precise timing in the regulation of erythroid differentiation. Studies on the cis and 
transacting factors that regulate the erythroid-specific genes have enlightened us of the 
complexity of transcriptional regulation of erythropoiesis. 
The action of critical transcription factors determines the selective expression of cell 
type-specific genes. These transcription factors can be either expressed constitutively 
or induced at a certain stage of cell differentiation (Orkin et al 1992; Mikkola and Orkin, 
2006). 
 
Studies suggested that the GATA family proteins have crucial roles in erythropoietic 
regulation. Presence of GATA motifs is crucial for the lineage specific expression of 
erythroid specific genes. Transcription factors GATA-1 and GATA-2 have crucial roles, 
both in erythrocytic determination and in terminal differentiation of erythropoiesis. 
During erythropoiesis, there is sequential but overlapping expression of GATA-1 and 
GATA-2. GATA-2 is expressed early in the erythroid lineage and its expression 
decreases with the increase of GATA-1 expression. GATA-2 is involved in the cellular 
proliferation of non-committed and committed erythroid progenitors, whereas GATA-1 
is critical for terminal maturation of erythroid cells. At the transcriptional level, GATA-2 
inhibits transcription of the GATA-1 gene and GATA-1 has the same effect on the 
GATA-2 gene. The regulatory network between GATA-1 and GATA-2 during 
erythropoiesis results in the sequential substitution of GATA-2 by GATA-1 in the 
regulatory regions of numerous erythroid specific genes (Tsai et al 1994; Tsai and 
Orkin, 1997; Ferreira et al 2005). 
 
GATA-1 transcriptional activity is also dependent on protein-protein interactions. Many 
proteins have been shown to interact physically with GATA-1 including Friend of 
GATA-1 (FOG-1), LIM domain only 2 (LMO- 2), T-cell acute lymphocyticleukaemia 1 
(TAL-1), growth factor independent 1B transcription repressor (Gfi-1b) and Spleen 
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proviral integration oncogene (SP1).  FOG-1, a multitype zinc finger protein, specifically 
interacts with the amino zinc finger of GATA-1 and is especially important for GATA-1 
activity. Studies suggested that function of GATA-1 in erythropoiesis is linked to FOG-1 
and this was evidenced by the observation that a single amino-acid change in the 
GATA-1 amino zinc finger, which abolishes interaction with FOG-1, is lethal in mice 
due to severe anemia (Cantor et al 2005). 
 
The Myeloblastosis viral oncogene homolog (MYB) transcription factor plays crucial 
roles in regulation of proliferation and cell lineage commitment of erythroid progenitor 
cells. It is required for maintenance of proliferation by exerting a direct role in cell cycle 
control. MYB is highly expressed in immature haematopoietic cells and is down-
regulated as the cells differentiate. Expression of MYB blocks differentiation in 
neuroblastoma cell lines, suggesting down-regulation of MYB is also required for 
terminal differentiation (Westin et al1982, Ohet al 1999) (Figure 1.5).  
 
Another key factor,Kruppel-like factor 1(KLF1), is required for the last steps of erythroid 
differentiation. It directly regulates genes involved in haemoglobin metabolism and 
membranestability. KLF1 knockout mice die from anemia, supporting the role of KLF1 
during erythropoiesis (Bieker et al 2005). 
 
1.4 Control of Globin gene expression 
 
Expression of the globin genes are strictly regulated at all levels, so that synthesis of 
the alpha-like and beta like globin chains are balanced throughout human 
development. Imbalanced globin chain synthesis caused by the reduction of one of the 






Figure1.5: Diagram of hematopoiesis, illustrating the multiple defects observed 
in mouse models of MYB deficiency. 
 
 (↓): A decrease in the frequency of the designated cell type/maturation stage in the 
absence of MYB.  
 
(↑): Cell populations whose frequency is increased by the loss of MYB function.  
(Figure adopted from K.T. Greig et al / Seminars in Immunology 2008). 
 
 Abbreviations: LMPP, lymphoid-primed multipotent progenitor; CMP, common myeloid 
progenitor; GMP, granulocyte–macrophage progenitor; CLP/ELP, common lymphoid 
progenitor/early lymphoid progenitor; Mep, Myeloid erythroid progenitor; Meg, 
megakaryocyte. 
 
The expression pattern of globin genes depends on local cis-acting sequences at the 
promoter sequences. The globin gene promoters share a number of characteristic 
  26
sequences at specific distances from the transcriptional start site (TSS). These 
sequences include TATA, CCAAT and CACCC which are situated 30, 70-78, and 80-
140 bp upstream of the TSS, respectively. The TATA and CCAAT sequences are 
found in many eukaryotic promoters while the CACCC sequence exists predominantly 
in erythroid specific genes. Importance of these sequences for normal globin gene 
expression has been demonstrated by the presence of natural mutations at these sites 
that lead to down regulation of the globin genes causing thalassaemia. Other 
regulatory sequences that control the globin genes include the enhancer and silencer 
elements within the HBB complex that interact with protein complexes to influence 
promoter activity and transcription of target genes (Forrester et al 1987; Grosveld et al 
1987; Higgs et al 1990). Remote cis-acting sequences, such as the locus control region 
(LCR) of the β-globin gene cluster and the major regulatory element (MRE) of the α-
globin gene cluster are also crucial for the expression ofthe globin genes (Higgs et al 
1990). 
 
The function of a powerful upstream enhancer of the β-globin loci, the locus control 
region (LCR), was identified as essential for high level expression of these genes 
(Tuan et al 1985; Forrester et al 1986; Grosveld et al 1987; Bender et al 2000) 
Molecular experiments such as DNAse Hypersensitivity assays enlightened us with the 
active parts of the β-globin locus. Genes that have an ‘open’ chromatin structure 
(euchromatin) are transcriptionally active, whereas transcriptionally silent genes have a 
‘closed’ chromatin structure (heterochromatin). Open chromatin is hypersensitive to 
nuclease digestion while closed chromatin is resistant to DNase I digestion. Thus, 
transcriptionally active sites can be identified by their hypersensitivity to DNase I.  In 
1980s Tuan et al and Groudine et al discovered the 5 hypersensitive sites that are 
located upstream of the έ-globin gene (Figure 1.6). These sites are phylogenetically 
conserved sequences and they play a crucial role in the regulation of the beta globin 
gene locus (Forrester et al 1986, Stamatoyannopoulos et al 2005). There are 2 more 
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hypersensitive sites that are positioned further upstream but only hypersensitive sites 1 
to 5 were shown to be erythroid specific (Stamatoyannopoulos et al 2005). 
 
 
Figure 1.6:  5 hypersensitive sites located upstream of the έ-globin gene. 
Figure adapted from Noordermeer & de Laat, 2008. 
 
The LCR spans a 16kb region which starts 5kb upstream of έ-globin gene. It   has 
important functions, such as enhancement of transcription, remodeling the 
chromosome structure through histone modifications, acting as an insulator to regulate 
enhancer promoter interactions and enabling the correct positioning of the beta globin 
locus in the nucleus (Stamatoyannopoulos et al 2005, Ragoczy et al 2006). 
 
Various studies supported the importance of the LCR for globin regulation; as 
evidenced by results that deletions of the β-LCR in transgenic mice leads to reduction 
of globin gene expression by 100-fold. Another study showed that deletion of individual 
HS sites in the β-LCR disrupts the activation of globin genes proving that an intact LCR 
is necessary for activation of the globin genes (Milot et al 1996, Bender et al 2000). 
 
At the transcriptional level, specific sequences in the promoters compete with other 
promoters to interact with the Locus Control Region (LCR) through binding of 
transcription factors. Binding of these transcription factors is regulated through 
remodeling of the chromatin by various histone modifications that enables activation of 
different parts of the globin locus during development. Acetylation and methylation are 
the histone modification observed at the beta globin locus. Acetylation mainly harbors 
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an open state of chromatin thus acts as an activator. On the other hand methylation 
may act both as an activator and repressor depending on the site that is methylated. 
According to Berger et al methylation of lysines at positions 4, 36 and 79 on the third 
histone (H3) correlates with activation while methylation of lysines at positions 9 and 27 
mainly leads to repression (Berger et al 2007). 
 
1.4.1 Globin gene activation by the β-LCR 
 
Several models have been proposed to explain how the β-LCR functions to activate the 
downstream globin genes and of these, the looping model is the most widely accepted 
(Figure 1.7). This model suggests that the HS sites of the β-LCR fold into a 
holocomplex, bringing the LCR closer to the appropriate gene and thereby the 
transcription factors bound to the LCR are delivered to the gene locus to interact with 
the basal transcriptional apparatus and activate globin gene expression (Ellis et al 
1996; Fraser et al 1993; Stamatoyannopoulos 2005; Wijgerde et al 1995).  
 
Studies have demonstrated the interaction of the LCR with downstream globin gene 
promoters via the looping model. Carter et al (2002) used an RNA FISH method called 
RNA TRAP to tag and recover chromatin near the murine β-globin gene 
whichrecovered HS1, HS2 and HS3 together with the β-globin gene. This 
demonstrated that the HS sites and β-globin gene were in close proximity. A further 
study used chromatin conformation capture (3C) to measure the proximity of LCR 
sequences and active globin genes in erythroid cells. Clustering of active regulatory 
elements at these sequences was referred to as an active chromatin hub (ACH) 
(Tolhuis et al 2002). 
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Figure 1.7: The looping model of gene activation at the β-globin locus. 
The LCR holocomplex is formed with transcription factors and other transcriptional 
apparatus. The holocomplex loops over the globin genes, bringing the transcriptional 
apparatus closer to the globin genes for transcription of the preferential gene (the β-
globin gene in this example). Image adapted from Vieira et al 2004. 
 
1.4.1.1 Gene switching mechanisms 
 
Two mechanisms - autonomous silencing and gene competition - were proposed in 
order to explain how certain genes are switched off while others remain turned on. 
Gene competition was first investigated in transgenic mice in which the β-LCR was 
linked to either theγ-globin (µLCR Aγ) or the β-globin (µLCR β) gene, alone. In both 
cases, the genes failed to show developmental expression, i.e. the β-globin gene was 
expressed in cells throughout all developmental stages including the embryonic cells.In 
other words, β-globin gene expression throughout development was as it would be in 




When the LCR, γ and β genes were linked together in the same construct                
(µLCR Aγψβδβ), developmental expression of the genes followed. The γ-globin gene 
was predominantly expressed in embryonic erythrocytes and theβ-globin gene was 
highly expressed in adult mice erythrocytes. γ and β-globin genes were expressed 
similarly in fetal liver erythroblasts, similar to the human perinatal stage (Enver et al 
1990). The investigators concluded that the γ and β genes compete to interact with the 
LCR (Enver et al1990). During fetal life, proximity to the β-LCR leads to preferential 
expression of the γ-globin gene. During adult life the γ-globin gene is autonomously 
silenced and the LCR interacts with the next downstream gene i.e. β-globin.  
 
Similar experiments in transgenic mice showed that mice carrying the embryonic ε-
globin gene do not express the gene at all, but when the ε-globin gene is linked to the 
LCR (µLCR ε) the gene is expressed at high levels, indicating the ε-gene expression is 
dependent on the LCR. At the same time, ε-globin gene expression was not observed 
in yolk sac erythropoiesis, suggesting all the components needed to turn off a gene are 
contained within the gene or adjacent sequence. This concept is called ‘autonomous 
silencing’ (Raich et al 1990). Transcription factors bind on silencing sequences at the 
proximal and distal ε-globin gene promoters to form a silencing complex which turns off 
ε-globin gene expression by disrupting interactions between the gene and LCR 
(Stamatoyannopoulos 2005). Autonomous silencing is thought to be the principal 
mechanism for turning off genes, though gene competition is also contributing. 
 
1.4.2 Transcription Factors 
 
Transcription factors play a crucial role in globin switching. They bind to specific 
recognition sequences or binding motifs and help in the activation or repression of 
genes acting as trans regulators. Several transcription factor-binding motifs have been 
characterized within the β-globin locus and are essential for the formation of the active 
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locus and activation and control of individual genes. The core regions of the 
hypersensitive sites in the LCR are particularly rich in such motifs and include binding 
sites for the erythroid specific transcription factors KLF1, GATA-1, TAL-1 and NF-E2 as 
well as ubiquitous factors such as SP1 (Goodwin et al 2001; Ho & Thein 2000). Table 












GATA-1 is the master regulator of erythropoiesis 
and key factor for globin switching 
Kruppel-like factor 
1 (KLF1)* 
CACCC KLF1 has crucial  roles in cell proliferation, 
differentiation and survival  
KLF1 acts as an activator of BCL11A which 






YAAC(G/T)G MYB have crucial roles in regulation of 
proliferation and cell lineage commitment of 
erythroid progenitor cells 





(TAL1 / SCL) 
CAGATG Member of pentameric complex that regulates 
erythroid differentiation and gene expression. 
SCL plays an essential role in early 
haematopoiesis. 
LIM domain only 2 
(LMO2) 
CAGGTG It acts as an adaptor protein that mediates 
interactions between different classes of 





TCA(T/C) NF-E2 binding is important for transcriptional 





GGCCGG BCL11A acts as a repressor of  γ-globin 
It is also essential for normal B and T cell 
development and lymphogenesis.  
 
Friend of GATA-1 
(FOG1)* 
Cofactor FOG-1 plays an essential role in erythropoiesis 
and megakaryopoiesis  
Essential cofactor that acts via the formation of a 
heterodimer with GATA-1 
SRY (sex 
determining region 
Y)-box 6 SOX6 
5′-WWCAAW-
3′ (W=A/T) 
SOX6   play a role in the silencing of the mouse 
embryonic globin genes 
 








CAAT DRED binds with high affinity to DR1 sites in the 
human embryonic (ε-) and fetal (γ-) globin gene 
promoters 
TR2/TR4 forms the core of a large DRED 
complex that represses embryonic and fetal 
globin transcription in definitive erythroid cells 
Table 1-1: Key transcription factors in haematopoiesis and erythropoiesis. 







GATA binding transcription factor 1(GATA-1) is required for globin gene switching and 
erythroid cell maturation and mainly expressed in erythroid and megakaryocytic 
lineages .It is a member of the GATA zinc finger family of transcription factors which 
bind to nucleic acid consensus sequence (T/A)GATA(A/G) (Evans & Felsenfeld 1989; 
Tsai et al 1989).  
GATA-1 binds to sites in the globin gene promoters and HS site cores of HS1-5 which 
contain the GATA-1 recognition sequence (Orkin 1992). GATA-1 can function both as a 
repressor or an activator of gene expression and the function is partly dependent on its 
interactions with other proteins. 
 
GATA-1 can interact with itself as well as other transcription factors including KLF1 and 
SP1 and can form large multiprotein complexes with TAL1, E47, LDB1, and LMO2. 
Strong positive correlation between occupancy of DNA by GATA1 and TAL1 was also 
shown (Crossley et al 1995; Merika & Orkin, 1995; Wadman et al 1997; Morceau et al 
2004; Cheng et al 2009). Thus, GATA-1 is involved in many aspects of globin locus 
activity. It is also involved in the establishment of the active chromatin domain in the 
locus and the formation of hypersensitive sites (Orkin et al 1992; Pomeratz et al 1998; 




Krüppel-like factor 1 or KLF1 (previously known as erythroid Krüppel-like factor, EKLF) 
was identified by subtractive hybridization and found to be an erythroid cell-specific 
transcription factor, homologous to the Krüppel family of transcription factors which 
have roles in cell proliferation, differentiation and survival (Miller & Bieker, 1993). KLF1 
contains three zinc fingers at the C-terminus which bind to a CACCC sequence. 
CACCC sequences are repeated in erythroid enhancers and promoters, including the 
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β-globin gene promoter (Miller & Bieker, 1993). This sequence is noted as a site of 
point mutations that give rise to β-thalassaemia. It is reported by Feng et al(1994) that 
KLF1 is unable to transactivate in the presence of these point mutations due to a 
decrease in binding affinity for these target sites. The KLF1 protein binds to the β-
globin promoter with 8 fold higher affinity than to the γ-globin promoter (Donze et al 
1995). These studies suggested KLF1 is acting as a stage-specific, β-globin-specific 
transcription factor, and most likely to be important in the fetal to adult (γ to β) 
haemoglobin switch.  
 
Further studies in mice revealed that Klf1-/- mice die around day 14-15 of gestation due 
to anaemia caused by the failure to express β-globin. Moreover, the embryos showed 
features of β-globin deficiency as found in β-thalassaemia. Klf1-/- embryos appeared 
normal during the embryonic yolk sac stage of haematopoiesis, but became fatally 
anaemic during early fetal life, at the precise time of the switch from embryonic to fetal-
liver erythropoiesis (Nuez et al1995 & Perkins et al 1995).The activation of the different 
β-globin like genes is mediated in part through the β-globin LCR region. KLF1 binding 
enhances the interaction between the β-globin promoter and the LCR and so the 
interaction between the γ-globin promoter and LCR decreases (Miller & Bieker 1993, 
Donze et al 1995). 
 
The human β-globin locus was studied in Klfknockout/human β-locus transgenic mice 
(Wijgerde et al 1996). The ε and γglobin genes were expressed normally in  
Klf1-/-foetuses, with a complete lack of β-globin expression. In Klf1+/- /β-globin 
transgenic mice, there was a shift in the β  toγ ratio caused by an increase in the 
number of actively transcribed γ genes and a decrease in transcribed β genes. The 
authors proposed that the reduction in klf1 in the Klf1+/-mice reduced the time the LCR 
was in contact with the β-globin gene. Because KLF1 does not directly bind γ-globin 
promoter, an increase in γ-globin is due to the shift in interaction of the LCR from        
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β-globin gene promoter toγ-globin gene promoter (Wijgerde et al1996). This was 
accompanied by changes in chromatin structure at the β-globin gene promoter, and 
HS3 of the β-LCR. 
Following this work, KLF1 was found to be required for the activity of 5’HS3 of the β-
globin LCR by binding directly to the core fragment within HS3 (Gilemans et al 1998). 
Increasing levels of KLF1 lead to changes in the balance from γ to β-globin gene 
expression, which results in an earlier switch of the globin genes and the amount of 
KLF1 also influences the rate of the switching process (Tewari et al 1998). 
These studies, collectively demonstrate the importance of KLF1 in the γ to β globin 
switch and LCR-β-globin gene interactions.  
 
Recently it has been proposed that KLF1 has a direct role in BCL11A activation. Borg 
et al (2010) mapped the cause of HbF persistence in a Maltese family to chromosome 
19 and found a heterozygous nonsenseKLF1 mutation in family members with high 
levels of HbF.  BCL11A expression was downregulated in the erythroid progenitor cells 
of these family members; moreover, γ-globin expression was upregulated. Further, 
knockdown of KLF1 in primary human erythroid progenitor cells resulted in an increase 
in γ-globinand a decrease in BCL11A. KLF1binding was shown at the BCL11A 
promoter, demonstrating the direct role of KLF1 on BCL11A. These findings conclude 
that HbF persistence here is caused by KLF1 haploinsufficiency. KLF1 activation of 
BCL11A was confirmed by others (Zhou et al 2010), proposing a new model for globin 





Figure 1.8: Regulation of globin genes by KLF1. 
KLF1 acts as an activator of BCL11A which represses expression of γ-globin. Hence 
there is a negative correlation between the expression levels of KLF1 and γ-globin. 




The MYB gene (also known as c-Myb) was first identified as the cellular homologue of 
v-Myb, an oncogene found in two avian retroviruses that induce leukemia.  
 
The MYB gene is highly conserved through evolution (Lipsick, 1996); the major product 
of the human gene is a 75kDa nuclear protein of 636 amino acids. The MYB protein is 
expressed in most haematopoietic tissues and is highly expressed in immature 
haematopoietic cells (Gonda et al 1982, Westin et al 1982).  
 
The MYB protein (75 kDa) has an isoform of 89 kDa (cMYB-9A) caused by a splice 
variant which leads to an insertion of 363 base pairs (bp) between exon 9 and 10 (exon 
9A) The p89 form of MYB displays higher transactivation activity, however little is 
known about its functional relevance. Jiang et al confirmed that the pattern of MYB-9A 
expression was similar to that of the total MYB expression in erythroid progenitors. 
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Following the molecular cloning of Myb, numerous studies performed in cell lines 
implicated this gene in the proliferation, survival and differentiation of hematopoietic 
cells. The earliest of these was a null allele (MYB−) that established MYB as an 
essential gene for definitive hematopoiesis. Further evidence that MYB also plays a 
physiological role came from studies of mice that lack MYB, which die embryonically 
with failures of erythroid and myeloid development. Studies also suggested that lack of 
MYB did not alter the generation of HSCs but failure of erythropoiesis was due to a 
defect in expansion and/or differentiation of these cells (Mucenski et al 1991, Sumner 
et al 2000). 
 
Efforts were made to identify MYB target genes, by measuring differentially expressed 
genes between MYB-/- null mutants and wild-type cells. The GATA-1 transcription factor 
was found to be down-regulated in the MYB-/- cells, giving clues to the involvement of 
MYB in regulation of haematopoiesis. Interaction of MYB and GATA-1 during 
haematopoiesis was speculated following this result. In 1996 Briegel et al suggested an 
antagonistic relationship between GATA-1 and MYB. This was later supported by 
studies showing that GATA-1 and MYB crosstalk during red blood cell differentiation 
through GATA-1 binding sites in the MYB promoter (Lin et al 1996, Bartunek et al 
2003). 
 
Until recently the direct role of MYB on the regulation of the γ-globin gene was elusive. 
It was proposed that MYB influences HbF and F cells levels via altering erythroid 
kinetics (Jiang et al 2006).  It is evident that MYB is involved in cell proliferation and 
differentiation; low MYB levels correlate with accelerated erythroid maturation. Another 
mechanism whereby MYB can influence HbF levels via KLF1 activation of BCL11A is 
proposed .The study suggests a coorporation between MYB and KLF1; in which MYB 
supports erythropoiesis through the transactivation of KLF1 and LMO2 expression 
(Bianchi et al 2010). 
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1.4.2.4 BCL11A  
 
BCL11A is a highly conserved zinc finger gene; it is expressed in hematopoietic 
progenitors, down-regulated during myeloid differentiation (Saiki et al2000) and is 
essential for normal B and T cell development (Liu et al2003). BCL11A binds to GC-
rich motifs and mediates transcriptional repression (Senawong et al2005, Sankaran et 
al2008).  It is also involved in lymphoid malignancies through translocation or 
amplification events (Fell et al1986, Richardson et al 1992, Satterwhite et al 2001). 
BCL11A mutations have also been associated with B-cell malignancies (Liu et al 2006).  
 
It has been shown that BCL11A acts as a repressor of HbF production. Knockdown 
ofBCL11Ain primary human erythroid cells led to a dramatic elevation of the levels of  
γ-globin and HbF (Sankaran et al 2008). However, this did not affect overall erythroid 
differentiation. BCL11A has also been shown to bind to discrete sites in the β-globin 
gene cluster, indicating a direct role of BCL11A in globin gene regulation (Sankaran et 
al 2008, Jawaid et al 2010). Studies using a human β-globin locus YAC transgene and 
a Bcl11a -/- mouse, showed that in the absence of Bcl11a, developmental silencing of 
the human γ-globin genes is impaired in the definitive erythroid lineage. Intermediate 
silencing in a Bcl11a+/- mouse suggests that not only is BCL11A a developmental-stage 
specific repressor, but the effect is quantitative (Sankaran et al2009). Also, differences 
in BCL11A expression patterns between mouse and humans may be responsible for 
their divergent expression of β-like globin genes (Sankaran et al2009). 
 
At least four BCL11A transcripts exist, giving rise to different protein isoforms: extra-
long (XL; 5.9kb, 125kD), long (L; 3.8kb, 100kD), short (S; 2.4kb, 35kD) and extra short 
(XS; 1.5kb, 25kD). Exons 1& 2 are common to all four isoforms, exon 3 & 4 to isoforms 
XL, L and S. Isoforms L and S share exon 5 and isoform XS contains exon XS (Liu et 
al 2006) (Figure 1.9). 
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Figure 1.9: Four major BCL11A isoforms, XL, L, S and XS 
Image adapted from Liu et al 2006. The role of these different isoforms is largely 
unclear. Studies have shown that the shorter isoforms appear in primitive erythroid 
cells, whereas the larger forms appear in later developmental stages of erythroid 
maturation, when γ-globin expression is reduced (Sankaran et al2008).  
1.4.2.5 NF-E2 
 
NF-E2 is an erythroid-specific DNA-binding protein that recognizes motifs (GCTGA 
(G/C) TCA) in the 5’HS2 of the β-globin LCR (Talbot & Grosveld 1991, 
Stamatoyannopoulos et al 1995).  
 
NF-E2 binding sites are important for transcriptional activation and formation of HS 
sites in the LCR (Forsberg et al 2000; Ney et al 1990). Experimental evidence also 
shows NF-E2 binding sites are important for chromatin remodelling activity and 
necessary for ε-globin gene expression and formation of HS2 (Gong et al 1996). 
1.4.2.6 SCL (TAL1) 
 
T-cell acute lymphocytic leukaemia protein 1 (TAL 1 or SCL), a member of the basic 
helix-loop-helix (bHLH) family of transcription factors, was first identified by its 
involvement in recurrent chromosomal translocations in patients with T-cell acute 
lymphoblastic leukaemia (ALL) (Begley et al 1989). 
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At the molecular level, TAL-1 acts through both DNA-binding dependent and 
independent mechanisms and can activate or repress transcription. SCL 
heterodimerizes with E proteins, such as E2A, and binds to E-boxes (CANNTG).These 
sequences are found in cis-acting regulatory elements of erythroid-specific genes in 
conjunction with GATA-binding motifs. The orientation of the E box (CANNTG or 
CAGATG) and presence of GATA-1 motif are important for enhancing TAL1/SCL 
binding affinity. 
Studies demonstrated that a pentameric transcription factor complex is formed 
between SCL, LM02, GATA-1, E47 and LDB1 that regulates erythroid differentiation 
and gene expression. It was also suggested that GATA1, SCL, and KLF1 in 
combination, delineate active chromatin and enhancer states   (Wadman et al 1997, 
Tallack et al 2010) (Figure 1.10). 
 
At the cellular level, studies demonstrated that SCL-/- ES cells fail to contribute 
to all hematopoietic lineages in adult chimeric mice and Scl-/- mice die during 
embryogenesis with a complete absence of yolk sac blood, indicating that SCL plays 
an essential role in early haematopoiesis (Porcher et al 1996;). 
 
1.4.2.7 LMO2 (RBTN2) 
 
LMO2 (RBTN2) is a LIM domain-containing protein that has been implicated in the 
pathogenesis of certain T cell ALLs. Studies suggested that SCL and LMO2 physically 
interact with high affinity evidenced by the similarities in the loss of function phenotype 
between these transcription factors (Warren et al 1994) 
LMO2 was a part of pentameric complex formed between SCL/E2A, LM02, GATA-1, 
and another LIM-containing protein, LDB1, and it was suggested that its function is to 
act as a bridge together with LDB1 between SCL/E2A heterodimer bound to an E-box 




LIM domain-binding protein 1 (LDB1) is a nuclear protein that contains an N-terminal 
dimerization domain and a C-terminal LIM interaction domain. LDB1 binds to LIM-
homeodomain (LIM-HD) and LIM-only (LMO) proteins. It acts as an adaptor protein that 
mediates interactions between different classes of transcription factors and their 
cofactors. LDB1 have been implicated in long-range gene regulation and in regulation 
of erythropoiesis as a partner of GATA-1 (Cantor and Orkin, 2005, Tallack et al 2010). 
Understanding the control of globin genes is crucial in the struggle to find new targets 




Figure 1.10: Pentameric complex formed between SCL, E2A, Lmo2, Ldb1 and 
GATA-1. 
Schematic representation of cis-acting regulatory DNA from a hypothetical erythroid 
target gene containing an E-box motif (CAGGTG) and GATA-binding motif (GATA) 
separated by nine nucleotides. SCL and its heterodimeric partner, E2A, are shown 
interacting with an E-box sequence and GATA-1 interacting with a GATA motif. These 
complexes are connected via interactions with LMO2 and Ldb1(Figure adapted from 







Disorders of haemoglobin results from mutations affecting either the structure of 
haemoglobin (giving rise to haemoglobin variants) or quantitative reduction of the 
globin chain synthesis (giving rise to thalassaemia) (Weatherall & Clegg, 2001 ;Thein& 
Clark 2004). 
 
A reduction in alpha globin production causes α-thalassaemia, the most severe form 
being Bart’s hydrops fetalis (--/--) when there is a complete absence of alpha globin 
resulting in death in-utero. Α-thalassaemia carriers (αα/--, α-/ α- and αα/ α-) are 
normally asymptomatic; individuals with HbH (--/α-) have transfusion-independent 
anaemia (Higgs, 1993). Βeta-thalassaemia and Sickle Cell Disease(SCD), which 
become manifested soon after birth, are severe conditions that cause a great public 
health burden particularly among African, Asian and Mediterranean 
populations(Weatherall et al 2001). 
 
An estimated 300,000 new-borns with these disorders are born worldwide each year, 
the majority of which have SCD. These are prevalent in tropical and sub-tropical 
regions where carriers have a survival advantage to Falciparum malaria, but these 
disorders have spread to most countries by population migration. β-thalassaemia is 
most common in Asia, the Mediterranean and Middle East, and SCD predominates in 
Africa, the Mediterranean and parts of India (World Health Organization, fact sheet 




Beta-thalassaemia is characterised by the quantitative deficiency of functional β-globin 
chains, the majority being caused by mutations in the β-globin gene or within its 
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flanking sequences. The continuing production of α-globin chains leads to an excess of 
α-chains that aggregates and form inclusion bodies. The inclusion bodies cause 
damage to the cell membranes and premature death of erythroid precursors in the 
bone marrow i.e. ineffective erythropoiesis. Cells that enter the microcirculation 
containing inclusion bodies suffer physical damage with haemolysis as a consequence. 
Haemolysis is further caused by an increase in reactive oxygen species that damage 
cell membranes. Ineffective erythropoiesis and haemolysis causes a reduction of 
erythrocytes and consequently anaemia .Erythropoiesis is thus expanded to 
compensate for the lack of functional red blood cells and causes hyperplastic marrow; 
an increased proliferation of  progenitors in the bone marrow (Weatherall et al 1998; 
Thein et al 1998; Schier et al 2002). 
 
The clinical complications of β-thalassaemia result from the severe anaemia and 
ineffective erythropoiesis which are directly related to the degree of globin chain 
imbalance. A large part of the variation is caused by variations of the β-thalassaemia 
alleles but co-existing mutations or variations affecting the levels of α and γ-globin are 
important contributors. Thus, co-inheritance of α-thalassaemia which reduces the α/β 
globin chain imbalance produces a milder condition. A persistent increased production 
of γ-globin chain reduces chain imbalance by combining with the excess α-globin to 




Alpha-thalassaemia is characterised by the deficiency of functional α-globin chains 
caused mainly by deletions that removes one or both of the α-globin genes. As a 
consequence, there is an excess of β-chains in adult life, and γ-chains in fetal life but 
these are capable of forming soluble tetramers. The solubility of these tetramers makes 
α- thalassaemia a less severe disease. However these tetramers are unstable and 
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cause haemolysis in the peripheral circulation and a variety of clinical manifestations 
(Higgs et al 1993; Schrier et al 2002). 
 
1.5.3 Sickle Cell Disease 
 
Sickle cell disease results from the presence of sickle haemoglobin (HbS) which is 
caused by a single point mutation in the sixth codon of the β-globin gene (CAG→CTG) 
substituting glutamic acid for valine. HbS (α2βs2) polymerises in its deoxygenated form 
through hydrophobic interaction between βs-chains causing a rigid sickle-like shape of 
erythrocytes that are trapped in microcirculation causing organ damage. Sickled cells 
are also highly fragile with a shortened life span, leading to haemolytic anaemia. 
 
The potential and rate of polymerisation is directly proportional to the concentration of 
HbS in the cell. The presence of other haemoglobins in a cell reduces HbS 
concentrations and is therefore a limiting factor on polymerisation. Individuals 
heterozygous for HbS (HbAS; sickle trait) are generally without symptoms as the HbS 
concentration is below the threshold concentration for polymerisation. Likewise, 
expression of HbF limits the extent of polymerisation. In addition to diluting the 
concentration of HbS in the cell, γ-globin has a direct inhibitory effect on polymerisation 
as mixed tetramers containing a γ-chain (α2γβs) do not participate in polymerisation. 
Even modest changes in HbF expression can therefore have profound effects on 
clinical disease (Pauling et al 1949; Noguchi et al 1993; Stuart & Nagel, 2004). Hence, 






1.6 Fetal Haemoglobin & Hereditary Persistence of HbF 
 
Globin switching is subjected to strict regulation at various levels. The switch from HbF 
to HbA is normally completed during infancy by approximately 6 months of age. Fetal 
haemoglobin binds oxygen more strongly than adult haemoglobin which facilitates the 
oxygen transfer from mother to foetus. The air to blood transfer in the lungs is more 
efficient than the blood to blood transfer in the placenta and the high oxygen affinity of 
fetal haemoglobin is no longer required after birth (Miller et al 2005). 
 
Occasionally, in the context of certain pathological conditions or rare mutations, the 
level of HbF can be elevated. While increased levels of HbF in healthy individuals are 
of no consequences,increased HbF levels in individuals with SCD and β-thalassaemia 
are highly beneficial. This ameliorating effect of fetal haemoglobin in β –globinopathies 
makes the variability and persistence of fetal haemoglobin in adulthood a clinically 
important feature (Rochette, Craig & Thein, 1994; Weatherall & Clegg, 2001). 
The switch from fetal to adult haemoglobin is not complete, in thatadults continue to 
express  low levels of HbF, that are concentrated in a small percentage of erythrocytes 
referred to as F cells(Boyer et al 1975). Although present at a low concentration, the 
levels of HbF vary considerably with the majority of individuals having HbF levels of 
less than 1%. Individuals with higher levels are said to have a persistent increased 
production of HbF referred to as hereditary persistence of fetal haemoglobin (HPFH). 
There are two types of HPFH. Pancellular HPFH refers to the even distribution of HbF 
in erythrocytes, with clearly recognisable increase of 10-35% HbF. These are caused 
by mutations (deletions or point mutations in the γ-globin promoter) affecting the β-
globin gene cluster. Heterocellular HPFH reflects the uneven distribution of HbF among 
the red blood cells. Individuals with heterocellular HPFH represent the upper tail of the 
natural continuous distribution of HbF with HbF levels >0.8%. Heterocellular HPFH is 
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inherited as a complex trait (Forget et al 1998 , Wood et al 2001; Thein & Menzel, 
2009). 
 
1.6.1 Stress Erythropoiesis and Reactivation of HbF 
 
At times when the demand for oxygen is greater, such as anaemia and tissue hypoxia 
(during fetal development), erythroid progenitor cells, induced by an increase in Epo, 
have the ability to rapidly proliferate, releasing large numbers of erythrocytes into 
circulation. This process is called ‘stress erythropoiesis. A γ-globin to β-globin switch 
also occurs within early progenitor cells (Papayannopoulou et al 1986). While we see a 
small number of F-cells in normal erythropoiesis, during stress erythropoiesis more 
cells terminate maturation prematurely while still expressing γ-globin, and are released 
into circulation while still expressing predominantly HbF as F-cells, thus increasing HbF 
levels (Stamatoyannopoulos et al 2005). 
 
The elucidation of the molecular basis for γ-globin silencing in the adult stage in 
particular has been the focus of intense investigation, since it has been observed that 
coinheritance of genetic conditions that confer elevated γ-globin synthesis can 
significantly alleviate the symptoms of β-haemoglobin disorders. 
 
After the cloning and mapping of globin genes it was reported that γ-globin was DNA 
methylated in adult erythroid progenitors but it was not methylated in fetal erythroid 
progenitors (Fritsch et al 1980, Flavell et al 1980). This report led to the clinical trials of 
5-Azacytidine that can reverse DNA methylation increasing expression of γ-globin in 
phlebotomized primates (De Simone et al 1982). 
 
While 5-azacytidine reverses DNA methylation activity, it also has an inhibitory activity 
on cell cycle; especially in the S-phase. This led to trials using other S-phase inhibitors 
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such as hydroxyurea, another S-phase inhibitor with encouraging results. Hydroxyurea 
has been used to treat SCD patients since the early 1990s, and is the only licensed 
drug for the disease; but seems to have variable effects in increasing HbF in β-
thalassaemia patients. Currently many drugs are under investigation for use as HbF 
inducers but none are close to being used as therapeutics for haemoglobinopathies. 
This makes understanding the γ-globin to β-globin switch and control of HbF production 
even more important. Understanding the mechanisms of HbF regulation and control 
can provide insights on reactivation of HbF for targeted therapies of the β-
haemoglobinopathies. 
 
1.7 Quantative Trait Loci Influencing HbF Levels 
 
HbF behaves as a quantitative trait with a continuous spectrum of variation contributed 
by several factors (Thein & Craig, 1998).Multiple factors contribute to the variance in 
HbF levels in the population, including age, sex (2%) and environmental factors (9%), 
but an overwhelming 89% is attributed to genetic factors referred to as quantitative trait 
loci (QTL) (Garner et al 2000). Cis-acting factors in the β-globin locus account for 10-
30% of the trait variation but transacting regulatory factors from other loci play an even 
more substantial role accounting for more than 50% of the variance.  
 
Previous studies by our group showed that three loci – the HBS1L-MYB intergenic 
region (HMIP) on chromosome 6q23, BCL11A on chromosome 2p16 and the β globin 
cluster on chromosome 11 accounts for up to 50 % of the variation in HbF levels in 
nonanemic Europeans, 35% of the genetic variance in F cell levels is controlled by the 
two loci; HMIP (19%)and BCL11A (15%)( Menzel et al2007). 
Association of these 3 loci with HbF production has been validated by different groups 
in different populations: healthy and with β thalassaemia or sickle cell anaemia (Lettre 
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et al 2008, So et al 2008, Sedgewick et al 2008,Uda et al 2008, Creary et al 2009, 
Makani et al 2011). 
 
1.7.1 Chromosome 11 Xmn1-Gγ Polymorphism 
 
The Xmn1-Gγ C-T polymorphism occurs at position -158 upstream of the Gγ-globin 
gene on chromosome 11p. Xmn1-Gγ has long been implicated as a QTL influencing 
HbF production through clinical and family studies. The T allele was shown to be 
associated with elevated HbF levels. This polymorphism is present in about 30% of the 
population, and results in a slight increase in HbF levels in healthy individuals. 
However, the presence of this polymorphism in SCD and β-thalassaemia patients 
results in even higher HbF levels (Thein et al1987). 
 
 
1.7.2 2p15 BCL11A Locus 
 
To identify additional QTLs, our group conducted a genome wide association study 
(GWAS) in a Northern European cohort of 179 individuals with contrasting extreme F 
cell values (Menzel et al 2007). 
 
This study picked up the already known HbF associated loci at the Xmn1-HBG2 site 
and HMIP on chromosome 6q23, and in addition identified a third, previously unknown 
QTL on chromosome 2p15, close to a gene encoding the zinc finger protein BCL11A.  
(The strongest association lay at a 14 kb region in intron 2 of BCL11A, with the second 
cluster spanning 67 kb in the 3’ region of BCL11A, 8-7 kb downstream of exon 5 
(Menzel et al 2007)(Fig1.11). 
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The 2p15 QTL was estimated to contribute 15% of overall trait variance for HbF levels 
(Menzel et al 2007). The peak of association within BCL11A was later confirmed by 
other groups (Lettre et al 2008, Sedgewick et al 2008, and Udaet al 2008).  
 
Studies showed that variants in intron 2 of BCL11A that are strongly associated with 
HbF was significantly more frequent in patients with β-thalassaemia intermedia, leading 
to the conclusion that these variants influences a milder phenotype. Thus, BCL11A has 
important effects in haemoglobinopathies as well as non-anaemic individuals (Uda et 
al) .These studies collectively confirm that the genetic variants at the 2p15 QTL 
influence HbF levels in SCD and lie within intron 2 of the BCL11A gene (Figure 1.11). 
 
 









1.7.3 Chromosome 6q QTL 
 
The QTL on chromosome 6q23 was initially identified by linkage analysis in an 
extended Asian family with β-thalassaemia.  The family was identified through the 
proband that had very mild thalassaemia intermedia despite being homozygous for   
β0 thalassaemia with a complete absence of HbA (Thein et al 1989). He was able to 
compensate for the lack of HbA due to the ability to produce HbF. His steady state total 
haemoglobin ranged from 11-12 gr/ dl, almost all of which was HbF. Family studies 
showed that several members of the extended family, with and without thalassaemia, 
had variable increases in HbF levels of up to 3.4% in healthy members and up to as 
much as 24% in β-thalassaemia heterozygotes (Thein & Weatherall, 1989, Thein et al 
1994). 
 
Segregation studies showed that the genetic determinant for this innate ability to 
produce HbF was inherited independently of the β-globin gene complex. Family and 
linkage analysis studies mapped the HbF locus to a region spanning 1.5 Mb on 
chromosome 6q23. Five protein coding genes, ALDH8A1, HBS1L, MYB, AHI1, and 
PDE7B reside in this 1.5-megabase (Mb) candidate interval of 6q23.  
None of these genes harboured any causative mutationsin the coding sequence of 
these genes. (Thein et al 1994; Close et al , 2004). 
 
Further experiments focused on the differences in the 6q23 transcriptome existing 
between erythroid precursors of individuals with and without high HbF levels.  
An expression profile of these five genes in erythroid progenitor cells of 12 high HbF 
and 14 low HbF individuals showed that MYB and HBS1L are quantitative trait genes, 
with variable expression in erythroid progenitor cells of healthy adults. There was a 
clear correlation of elevated HbF with low levels of MYB and HBS1L in erythroid cells. 
Furthermore, over expression of MYB inhibited γ-globin gene expression when 
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compared with the parental cell line. However, overexpression of HBS1L had no effect 
on γ-globin gene expression. 
 
The 6q HbF QTL was then validated in a large panel of European twins. Higher 
resolution genotyping in Europeans refined the locus to a region of 79 kb between the 
HBS1L and MYB gene. The analysis revealed that this was a major QTL which 
accounted for 35% of total F-cell variance in the family.  
 
The 6q QTL exists as a set of single nucleotide polymorphisms (SNPs) spanning a 
region of ≈ 79kb that includes the intergenic region 5i to MYB and HBS1L , and  5i  part 
of the HBS1L gene.The SNPs are distributed in three linkage disequilibrium (LD) 
blocks referred to as HBS1L –MYB intergenic polymorphism (HMIP ) blocks 1, 2, and 
3. The 3 blocks completely account for the HbF variance attributed to the 6q QTL, with 
SNPs in HMIP-2 (24kb) showing the strongest effect and accounting for the majority of 




Figure 1.12 :  QTL in chromosome 6q23 and HMIP blocks 1-3. 
Image adapted from Thein et al 2007. 
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Genetic variants in the HBS1L-MYB interval on chromosome6q have been shown to be 
highly associated, not only with HbFlevels, but also with the control of other erythroid 
and non-erythroid hematologic traits. Our group showed significant 
impact of HMIP variability on several types of peripheral blood cells: erythrocyte, 
platelet, and monocyte counts as well as erythrocyte volume and hemoglobin content 
in healthy individuals of European ancestry (Menzelet al 2007). 
 
Recent work by our group indicated the presence of regulatory elements in HBS1L-
MYB intergenic region (HMIP) evidenced by GATA-1 binding coinciding with strong 
histone acetylation, RNA polymerase II activity, and erythroid specific DNase I 
hypersensitive sites. Wahlberg et al (2009) identified DNase I hypersensitive sites in 
HMIP block 2 suggesting the presence of regulatory elements in the HBS1L-MYB 
intergenic region further supported by the presence of erythroid specific transcripts.   
Recent genome-wide datasets generated by the ENCODE consortium validated the 
presence of DNase hypersensitive sites in erythroid K562 cells and revealed numerous 
enhancer chromatin signatures. A strong positive correlation between MYB expression 
levels and intergenic regulatory activity could be demonstrated; while no clear 
correlation with HBS1L expression was observed. 
 
Analysis of the region for transcription factor binding and chromatin modification using 
chromatin immunoprecipitation on microarray (ChIP-chip) indicated five GATA-1 
binding sites in block 2 (Wahlberg et al 2009, Jawaid et al 2010). 
 
The mechanism of how the QTLs affect HbF levels is still to be clarified. It would seem 
that BCL11A has a direct repressive effect on γ-globin gene while that of the HBS1L-




1.8 Aims & Objectives 
 
The overall aim of this project is to carry out functional analysis of the 6q QTL; to 
investigate and identify the causative SNPs in the region and their mechanism of 
action. The analysis was concentrated on the HMIP-2region which showed the 
strongest association to HbF levels. 
My immediate objectives were: 
1. To investigate the best culture method for obtaining homogenous and 
synchronized cells (Chapter 3). 
2. To perform expression profiling of critical transcription factors of 
interest(Chapter 3). 
3. To investigate transcription factor binding at the HMIP locus using prediction 
tools in order to find out if any of the high scoring SNPs alter binding of key 
transcription factors(Chapter 4). 
4. To investigate the potential differential binding of transcription factors to newly 
revealed SNPs using EMSAs (Chapter 5). 
5. To perform ChIP-qPCR experiments to quantify GATA-1 binding to previously 
demonstrated targets (Chapter 6). 
6. To perform ChIP-qPCR experiments to investigate MYB and KLF1 binding to 
targets suggested by in-silico tools. 
7. To investigate differential transcription binding with individuals that are +/+ i.e. 
(homozygote for the presence of SNPs associated with elevated HbF levels) 
and -/- (homozygote for the absence of SNPs associated with elevated HbF 
levels)  by performing ChIP-qPCR and Allele specific ChIP (Chapter 6). 
8. To investigate if there is unequal expression of flanking genes i.e. (MYB and 
HBS1L) in individuals heterozygous for the HMIP variants in order to show the 
direct correlation between the intergenic variants and the expression of flanking 
genes (Chapter 7). 
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2.1 Erythroid Cell Cultures 
 
Three different methods of liquid culture were performed during the project for primary 
human erythroid progenitor cells, two of which were adopted from the original method 
described by Fibach et al (Fibach et al 1989). The other method was adopted from Van 
Den Akker et al (Haemotologica 2010). Table 2.1 compares key points of three culture 
methods. 





Plastic Cells are incubated in 
flasks. 
Cells are incubated 
in flasks. 
Cells are incubated in 
petri dishes or 6 well 
plates for better 
aeration. 
Base Medium Biological Foetal Calf 
Serum (FCS) 




Stemspan is used as 
base medium. Batch 
variable 
Stemspan is used as 




Cytokines Conditioned medium 
includes key 
cytokines needed for 








(lipids, IGF1) are 
included in phase I 
and phase II to 
induce proliferation 
Media volume 10-25 ml depending 
on cell counts 
10-25 ml depending 
on cell counts 




Cell concentration is 
1million cells /ml 
during phase I 
Cell concentration is 
1million cells /ml 
during phase I 
Cell concentration is 
5-10million cells /ml 
during Phase I 
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Cyclosporin is used to 
kill T-lymphocytes 
Cyclosporin is used 
to kill T-lymphocytes 
Cyclosporin is not 
used to kill T-
lymphocytes. 
Histopaque layering 







phase 1 and 2 by 
changing the flasks 
Macrophages are 
depleted during 
phase 1 and 2 by 
changing the flasks 
Macrophages are 
depleted during 
phase 1 and 2 by 
changing the petri 
dishes 
Table 2-1: Comparison of three erythroid culture methods 
 
2.1.1 Two-Phase Fibach Culture 
 
50 mls of peripheral blood in EDTA was diluted 1:1 with PBS. This was layered onto a 
density gradient centrifugation liquid- Histopaque-Ficoll (Sigma-Aldrich, UK) and 
centrifuged to separate the blood components. The buffy coat containing lymphocytes 
and progenitor cells was collected and washed with PBS. The washes were performed 
till the supernatant is transparent. 
 
The cells were counted and cultured in flasks at 1-2 million/ml in Phase I medium 
[DMEM-Alpha modified medium (Sigma, Poole, UK), 5 U/ml penicillin, 5 µg/ml 
streptomycin, 1µg/ml cyclosporin A, 2mM L-Glutamine, 10% foetal calf serum (Sigma, 
Poole, UK) and 10% conditioned medium from cultures of 5637 bladder carcinoma cell 
line (ATCC)] at 37° in 5% CO2 for 6 days. 
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24 hours later the entire culture suspension was transferred to a fresh flask in order to 
remove adherent monocytes in the first flask. After 6 days in phase I culture, the cells 
were centrifuged and resuspended in Phase II medium [DMEM alpha modified 
Medium, 5 U/ml penicillin, 5 µg/ml streptomycin, 1 U/ml human recombinant 
erythropoietin [EPO; Eprex UK] and 10 ng/ml SCF, 2mM L-Glutamine 30% Foetal calf 
serum , 10-5M β-Mercaptoethanol, 10-6 mol/l dexamethasone ,0.3mg/ml 
Holotransferrin(ICN) , 1% Bovine serum albumin (Sigma, Poole, UK). The cells were 
maintained at a concentration of 1 million/ml for up to 15 days.  
 
2.1.1.1 Preparation of conditioned medium 
 
5637 cells were cultured in DMEM alpha modified medium,5 U/ml penicillin, 5 µg/ml 
streptomycin, 2mM L-Glutamine and 15% Foetal calf serum. Medium was changed 
after formation of a monolayer and cells were incubated for another week. Supernatant 
was centrifuged at 1000rpm for 5 minutes, filter sterilised and stored at -20˚C for future 
use. 
This conditioned medium includes cytokines which favours cell growth. It was replaced 
by stem cell factor in Phase II. 
 
2.1.1.2 Preparation of Bovine Serum Albumin (BSA) 
 
50 gm of BSA (Fraction V) powder was dissolved in deionised water overnight. The 
dissolved BSA was incubated with 5gm of resin (Bio-Rad) for 30-60 minutes at room 
temperature. The solution was filtered and incubated with more resin until no colour 
change of resin was observed which suggest all the chemicals in the solution are taken 
away with the resin. After the final filtering an equal volume of double concentrated 
alpha medium (Sigma) was added to the solution and it was stored in 50ml aliquots at  
-20˚C for future use. BSA was used in the second phase and improper preparation 
leads to problems such as limited cell proliferation. 
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2.1.2 Two-Phase erythroid culture using Stem Span 
 
This liquid culture technique was adapted from the original method described by Eitan 
Fibach (Fibach et al 1989), with modifications as detailed in Jiang et al 2006. 
50mls of peripheral blood was collected and centrifuged to separate the blood 
components. The yellow plasma interface is the component containing lymphocytes 
and progenitor cells and is called the buffy coat. This was collected and layered onto a 
density gradient centrifugation liquid- Histopaque-Ficoll (Sigma-Aldrich, UK) and 
centrifuged to separate red and white blood cells. The lymphocytes and other 
mononuclear cells remain at the plasma-histopaque interface from where they are 
collected and washed in PBS. Cells are counted and cultured in flasks at 1-2 million/ml 
in Phase I media (Stem Span Medium [Stem Cell Technologies, Canada], 10U/ml 
penicillin, 10µg/ml streptomycin, 1µg/ml cyclosporin A, 25ng/ml interleukin 3 [IL-3; 
Sigma, UK] and 50ng/ml human stem cell factor [SCF; Sigma, UK]) at 37° in 5% CO2.  
24 hours later the entire culture suspension is transferred to a fresh flask, leaving 
behind the adherent monocytes in the first flask. 
 
After 7 days in phase I, the culture is moved to a 50ml falcon tube, centrifuged and the 
cell pellet re-suspended in Phase II medium (Stem Span Medium, 10U/ml penicillin, 
10µg/ml streptomycin, 2U/ml human recombinant erythropoietin [EPO; Sigma, Poole 
UK] and 50ng/ml SCF) and maintained at a concentration of 1 million/ml for up to 20 
days. 
 
2.1.3  Three-Phase erythroid culture 
 
This method was described by Van Den Akker et al (Haemotologica 2010) and kindly 
provided to our group. 50mls of peripheral blood in EDTA was diluted 1:1 with PBS and 
layered onto a liquid density gradient (Histopaque 1.077) (Sigma-Aldrich, UK) and 
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centrifuged to separate the blood components. The buffy coat containing lymphocytes 
and progenitor cells was collected and washed with PBS. 
Cells were counted and cultured in 6 petri dishes at 5-10 million/ml in Phase I 
StemSpan medium containing: IL-3 – 1ng/ml, human recombinant erythropoietin [EPO; 
Eprex UK] – 2U/ml, Stem cell factor – 40ng/ml, Dexamethasone - 1μM, Insulin growth 
factor 1(IGF1) – 40ng/ml, Cholesterol rich mix 50μg/ml, 5 U/ml penicillin, 5 µg/ml 
streptomycin for 5 days. Daily petri dish changes were performed to minimize number 
of monocytes that adhere to the petri dishes. On day 2 cells were centrifuged and 
resuspended in fresh medium. 
 
After 6 days in phase I, the culture is moved to a 50ml falcon tube, centrifuged and the 
cell pellet re-suspended in Phase II media. Cells are counted  and cultured in petri 
dishes at 0.5-1.0 million/ml in Phase II StemSpan media containing: human 
recombinant erythropoietin [EPO; Eprex UK] – 2U/ml, Stem cell factor – 40ng/ml, 
Dexamethasone - 1μM, Insulin growth factor 1(IGF1) – 40ng/ml, Cholesterol rich mix 
50μg/ml, 5 U/ml penicillin, 5 µg/ml streptomycin for 7-25 days. 
 
Differentiation can be induced after a minimum of 7 days in phase II which involved 
collecting the cells and culturing them in phase III StemSpan medium containing: 
Human recombinant erythropoietin [EPO; Eprex UK] – 10U/ml,  Insulin growth factor 
1(IGF1) –, 5 U/ml penicillin, 5 µg/ml streptomycin, Holotransferrin 1mg/ml ,Insulin 
10ng/ml,thyroid hormone 1µM , 3 %human OAB serum (male)  for 2-7 days. Phase III 
proved to be very crucial; since the very large amount of erythropoietin in the medium 
leads to accelerated differentiation of the erythroid cells which makes it really hard to 
harvest them at specific stages. We needed cells at earlier stages i.e. 
(proerythroblasts, basophilic normoblasts). Because of this cells were not transferred to 
phase III for induced differentiation. 
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2.1.4  Cell morphology 
 
Cytospins of erythroid cells were made by spinning 1x105 cells in a 100-200µl volume 
onto glass slides. Slides were then stained using Giemsa staining set (Hema “Gurr”, 
VWR, Lutterworth, UK.), and viewed with 40x objective under the microscope (Zeiss 
Axiolab). 
 
2.1.5 Flow Cytometry 
 
Fluorescence activated cell sorting (FACS) - a specialized type of flow cytometry was 
used to test erythroid cell purity using cell surface markers GPA and CD71. 
Glycophorin A (GPA) and CD71 are human red blood cell membrane proteins 
(Furthmayr et al 1975). GPA protein is highly expressed on the surface of mature 
erythroid cells, while CD71 is expressed in proliferating eryhtroid cells. Detection of 
GPA and CD71 indicates the purity of late erythroid progenitor cells in the culture. 
2 µl Fluorescent antibodies against human CD71 (fluorescein isothiocyanate [FITC] 
conjugated, BD Biosciences, Oxford, UK) and anti-human Glycophorin A (GPA, R-
phycoerythrin [RPE] conjugated, DAKO, Glostrup, Denmark) were added to 1x106 
erythroid cells washed in PBS and resuspended in 100µl PBS. Both antibodies were 
added for a double staining and one sample is without antibody to serve as a negative 
control. Cells and antibody were incubated for 30 minutes in the dark, after which they 
were washed twice with PBS and resuspended in a final volume of 1ml PBS. FACS 
analysis of 10,000 cells was acquired using Becton Dickinson flow cytometer and Cell 
Quest software (Becton Dickinson, Oxford, UK). 
2.2 K562 Cell Culture 
 
K562 cell lines were maintained in RPMI-1620 medium (Sigma-Aldrich, Poole, UK) with 
the addition of 10% of fetal calf serum (FCS) (PAA-laboratories, Somerset, UK]), 2 mM 
of L-glutamine (Sigma-Aldrich, Poole, UK), 0.1 mg/ml of streptomycin and 18 units/ml 
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of penicillin (Sigma-Aldrich, Poole, UK). Cells were cultured in incubators at 37 °C and 




2.3.1 Protein extraction 
 
5x106 cells were collected, centrifuged and re-suspended in 250µl RIPA cell lysis buffer 
(20mM Tris-HCl, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1mM EDTA 
0.1% SDS) and 12.5µl 20X protease inhibitor (1 Complete EDTA-free Protease 
Inhibitor Cocktail tablet [Roche, UK] dissolved in 500µl H2O). 
 
2.3.2 Nuclear Protein Extraction 
 
Proteins were extracted using the Thermoscientific NE-PER Nuclear and Cytoplasmic 
Extraction Kit. Before starting the experiment protease inhibitors were added to the 
reagents in order to prevent any possible degradation of proteins. Cells in the 
suspension were harvested by centrifuging at 500xg for 5 minutes. The cell pellet was 
washed with PBS.1-10 x 106 cells were transferred to a 1.5 ml microcentrifuge. The 
cells were pelleted by centrifugating at 500xg for 3 minutes. Ice cold cytoplasmic 
extraction reagent I (CER I) was added to the cell pellet. The ratios in table 2.2 were 
applied. 
Packed Cell Volume (μl) CER I (μl) CER II (μl) NER (μl)
10 100 5.5 50
Table 2-2: Optimal volumes of reagents. 
 Reagent volumes were determined according to the packed cell volume. Each reagent 
was added according to the ratios shown in the table. 
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The cell pellet was suspended by vigorous vortexing for 15 seconds followed by 10 
minute incubation on ice. Ice cold CERII was added and the tube was vortexed 
vigorously for 5 seconds followed by 1 minute incubation on ice. The tube was vortexed 
for another 5 seconds and the cells were centrifuged at 16000xg for 5minutes.  
Supernatant containing the cytoplasmic extract was discarded and the pellet  
re-suspended in ice cold nuclear extraction reagent (NER) buffer according to 
previously mentioned ratios. The cells were incubated on ice for 40 minutes and 
vortexed vigorously every 10 minutes for better suspension. After pelleting the cells by 
centrifugation at 16000xg for 10minutes the supernatant containing the nuclear 
proteins were transferred to a pre-chilled tube, snap frozen by liquid nitrogen and 
stored at -80˚C after quantification. 
 
2.3.3  Quantification of proteins 
 
Proteins in nuclear extracts were quantified using a NanoDrop Spectrophotometer ND-
1000 (NanoDrop Technologies, Wilmington, USA). Nanodrop program AB280 was 
calibrated with controls and quantification was performed. 
 
2.3.4 Protein electrophoresis and transfer 
 
Samples were denatured for 10 mins in a heat block at 95°C. 25µg of each protein 
(25µl) and  10µl SeeBlue protein marker (Invitrogen) were loaded on a NuPAGE 10% 
Bis-Tris precast gel (Novex, Invitrogen) in MOPS SDS running buffer (Novex, 
Invitrogen). The gel was run overnight at 20V using the Novex Invitrogen Surelock X-
Cell electrophoresis system, to separate proteins. Proteins were transferred from gel to 
nitrocellulose membrane (Amersham Hybond ECL membrane, GE Healthcare) for 2 
hours at 55V (X-Cell blot module, Novex Invitrogen) in transfer buffer (3.04g Tris, 14.5g 
glycine, 200mls methanol 800mls H20).  
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The nitrocellulose membrane was transferred to a 50ml falcon tube and non-specific 
binding was blocked with a buffer containing 5% dry milk (Marvel) in PBS-Tween (5 
PBS tablets dissolved in 5mls Tween-20 and 995mls H20) for a minimum of 2 hours at 
4°C with constant rolling.  
 
2.3.5 Antibody probing 
 
The membranes were then incubated in 50ml falcon tubes overnight in a buffer 
containing 5% milk and the primary antibody at 4°C with constant rolling.  
The following morning after washing 3 times for 10 mins in PBS-Tween the membranes 
were incubated in a buffer containing 5% milk and the secondary antibody at room 
temperature for 1 hour 15mins with constant rolling. This was followed again by three 
10 min washes in PBS-Tween.  
 
2.3.6 Target protein detection 
 
Target proteins were detected by an enhanced chemiluminescence kit (Amersham 
ECL Plus western blotting detection system, GE Healthcare). Following the 
manufacturer’s instructions, the membrane was incubated with ECL reagents for 5 
mins and drained off. The membrane was wrapped in Saran wrap and placed in an 
exposure cassette.  In a dark room the membrane was exposed to high performance 
chemiluminescence film (Amersham Hyperfilm ECL, GE Healthcare) for varying 
amounts of time (between 10 seconds to 3 mins) and the film was developed using the 
Compact X4 X-Ray film processor (Xograph Imaging Systems, UK) 
To re-probe with another primary antibody, membranes were re-incubated in a buffer 
containing 5% milk to block primary antibody before incubating in another antibody 
overnight as before. 
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2.4 Transcription Factor Predictions at Chromosome 6q QTL 
 
In-silico prediction for transcription factor binding was performed on the SNPs in the 
chromosome 6q QTL. Transcription factor prediction tools (matinspector and jaspar) 
were used to predict transcription factor binding sites around the SNPs. Further 
comparison of predicted binding sites with the alternative alleles of candidate SNPs 




Each SNP is uploaded to the tool with 25bp of flanking sequences from each side as 





Í                        25bp                    ÎÍ25bpÎ 
Figure 2.1: Sequence uploaded to prediction tools encompasses the SNP flanked 
by 25 base pair of nucleotides at each side. 
 
Matrix similarity threshold was set high i.e. (0.700) to make the results easier to 
interpret since setting the threshold low will lead to excessive amount of matches. 
Predictions were made for all transcription factor families in the matrix (TRANSFAC 
6.0).The same protocol was repeated with the wild type sequence. The results were 
compared to see if any transcription factor binds differentially to the sequences in the 
presence of alternative alleles of the SNPs. Any major difference affecting matrix 
similarity was presented as demolishment of binding site of the transcription factor 
suggesting differential binding. 
 
  65
2.4.2 Jaspar (Consite) 
 
Transcription factor predictions highlighted some SNPs which altered the 
binding of transcription factors. Further predictions were performed for 
those SNPs to confirm altered binding. Consite, a prediction tool belonging 
to Jaspar (another transcription factor database) was used. 
 
Each SNP is uploaded to the tool with 25bp of flanking sequences from each side as 
shown in figure 2.1. Matrices belonging to the transcription family of interest were 
chosen. Some transcription factor families were not present in the matrices available. 
 
2.5 Electrophoretic Mobility Shift Assays (EMSA) 
 
2.5.1 Oligo Design 
 
25 base pair oligonucleotides were designed where SNPs and predicted binding motifs 
are at the center of the oligo to provide appropriate amount of flanking sequence for 
efficient transcription factor binding (Appendix). 
 
Table 2.1 in appendix two shows the designed oligonucleotides and SNPs covered by 
the oligonucleotides. Oligonucleotides were either unlabeled or biotin labeled. 
 
2.5.2 Annealing of oligonucleotides 
 
Oligonucleotides were suspended in annealing buffer (10mM Tris, 50mM NaCl, 1mM 
EDTA ph7.7) and equal molar concentrations of forward and reverse oligonucleotides 
were added to a 1.5 ml tube to make a 100 pmoles/µl stock. The mix of forward and 
reverse oligonucleotides was incubated at 95oC in a heat block for 3 minutes and 
cooled down to room temperature slowly on a bench top. 
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2.5.3 Preparation of Binding reactions 
 
Initial binding reactions were prepared with controls provided with the Thermo Scientific 
Lightshift Chemiluminescent EMSA Kit (Pierce). The kit included nuclear extracts from 
Epstein - Barr Virus Nuclear Antigen expressing (EBNA) cell lines where the control 
protein was highly expressed. Unlabelled and biotin labelled nucleotides were also 
provided. Binding reactions were prepared according to manufacturer’s instructions 
(Table 2.3). After optimization, binding reactions were prepared with nuclear extracts 
from K562 cells or human primary erythroid cells, and oligonucleotides that encompass 
the SNPs of interest. 
 








Ultrapure Water ---- 12 μl 11 μl 9 μl 
10X Binding Buffer  1X 2 μl 2 μl 2 μl 
50% Glycerol  2.5% 1 μl 1 μl 1 μl 
100 mM MgCl2  5 mM 1 μl 1 μl 1 μl 
1 μg/μl Poly (dI•dC)  50 ng/μl 1 μl 1 μl 1 μl 
1% NP-40  0.05% 1 μl 1 μl 1 μl 
Unlabeled oligonucleotide 4 pmol ----- ----- 2 μl 
Nuclear Extract  1 Unit ----- 1 μl 1 μl 
Biotin labeled  
oligonucleotide 
20 fmol 2 μl 2 μl 2 μl 
Total Volume ---- 20 μl 20 μl 20 μl 
Table2-3: Binding Reactions for EMSA 
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Three different binding reactions were prepared. The first reaction (negative control) 
was prepared without any extract. The second reaction was prepared with the extract 
provided with the kit. In the third reaction, unlabelled oligonucleotides were included as 
cold competitors to differentiate between specific and nonspecific protein-nucleic acid 
complexes. Reactions without cold competitors were incubated at room temperature for 
20 minutes. Cold competitions were performed by addition of 20-200 folds unlabelled 
oligo as the cold competitor and the reaction was incubated 5 minutes at room 
temperature followed by 20 minute incubation at room temperature with the biotin 
labelled oligo. The details for each binding reaction will be presented at chapter 5. 
 
2.5.4 Gel Preparation and Pre-running 
 
Native polyacrylamide gel was prepared with the following recipe : 2ml 5X TBE ,  4ml 
%30 bis-polyacrylamide , 0.625ml %80 glycogen ,13.375 ml water, 0.300mlAPS , 20ul 
TEMED. Gel was cast and the electrophoresis unit filled with 0.5X TBE. Pre-run was 
performed at 100 V for 30-60 minutes using NOVEX-Invitrogen, X-Cell Sure Lock, 
Invitrogen). 
 
2.5.5 Electrophoresis of Binding Reactions 
 
After the incubation, 5μl of 5X loading dye (thermoscientific) was added to each 20μl 
reaction. 20μl of each sample was loaded to the wells and electrophoresis reaction was 
performed at 100V for 90-120 minutes at room temperature. 
 
2.5.6 Electrophoretic Transfer of Binding Reactions 
 
Sponges, biodyne membrane and filter papers were soaked in 0.5X TBE before the 
transfer. Transfer sandwich was prepared as shown in figure 2.4. Transfer was 











Figure2.2: Set up of transfer chamber sandwich for the transfer of protein-DNA 
complexes. 
 
2.5.7 Cross-linking of Transferred DNA to Membrane 
 
Cross-linking was performed at 120 mJ/cm2. Commercial UV-light instrument equipped 
with 254 nm bulbs was used as the cross-linker. 
 
2.5.8 Detection of Biotin-labelled DNA by Chemiluminescence 
 
Blocking buffer (thermoscientific) and 4X wash buffer (thermoscientific) was warmed to 
37˚C before performing the detection. Membrane was blocked by adding 20 ml of 
Blocking Buffer and incubating for 15 minutes at room temperature with gentle shaking. 
Conjugate blocking buffer was prepared by adding 66.7 μl Stabilized Streptavidin-
Horseradish Peroxidase Conjugate to 20 ml Blocking Buffer (1:300 dilutions). The 
blocking buffer was replaced with conjugate blocking buffer and membrane was 
incubated for 15 minutes at room temperature with gentle shaking. 1X was buffer was 
prepared by adding 30ml 4X wash buffer to 90ml ultrapure water (sigma).Membrane 
was transferred to a new container and 4 washes were performed using 25ml of 1X 
wash buffer and incubating for 5 minutes at room temperature with gentle shaking. 
 
2 Sponges 
4 Filter papers 
PVDF membrane 
Gel 





Membrane was transferred to a new container and 30ml Substrate Equilibration Buffer 
was added. Membrane was incubated for 5 minutes at room temperature with gentle 
shaking.Working Solution was prepared by adding 6 ml Luminol/Enhancer Solution to 6 
ml Stable Peroxide Solution. Membrane was removed from previous buffer and excess 
buffer on the membrane was removed carefully. Membrane was placed DNA side 
down onto a puddle of the Working Solution and incubated 5 minutes at room 
temperature. 
 
Membrane was removed and excess buffer was taken away gently by using a paper 
towel. Membrane was wrapped in Saran wrap and bubbles and excess buffer on the 
membrane was pushed out of the wrap by rolling. 
 
Exposure was performed under red light. A piece of film (Kodak Biomax light film 
chemiluminescence for biological imaging) was placed on top of the membrane and 
saran wrap and the cassette closed firmly. The membrane was left to expose in the 
cassette for an appropriate time varying from 5 seconds to 2 minutes depending on the 
strength of the signal. 
 
2.6 Chromatin immunoprecipitation (ChIP) 
 
ChIP experiments were carried out using the EZ-ChIPTM kit (cat# 17-371) according to 
manufacturer’s protocols with minor modifications (modifications kindly provided by Dr. 
David Garrick from the MRC molecular haematology unit, Oxford). All protease 





2.6.1 Cell-protein cross linking 
 
The process of cross-linking links DNA to protein so that the DNA can be co-
precipitated with the protein using a specific antibody. 5x107 erythroid cells were taken 
for cross-linking in 10ml growth medium with 1% formaldehyde (Sigma-Aldrich, UK), 
and incubated for 10 min at room temperature with rolling.  125mM Glycine was added 
to quench the formaldehyde and then cells were washed in 5ml of cold PBS with 
protease inhibitors and centrifuged at 1000 rpm for 10 min at 4°C, twice. The pellets 
were divided into 5 aliquots of 1x107 cells and stored at -80°C.  
 
2.6.2 Cell lysis 
 
5x107 cross-linked cells were lysed in 1ml SDS-lysis buffer (EZ-Magna ChIPTM Kit (cat. 
# 17-409) (Upstate-Millipore, UK) with protease inhibitor and incubated on ice for 15 
min, vortexing every 5 mins. The cells were spun at 800 x g for 5 mins at 4°C and the 
pellet re-suspended in 1ml nucleus lysis buffer (EZ-Magna ChIPTM kit) with protease 
inhibitors. 
2.6.3 Chromatin fragmentation by sonication 
 
Cell/nuclei lysates (5x107 cells/ml equivalent) were sonicated with a Vibra Cell 
sonicator (Sonics, US) set at power 2 for 15x10 seconds using a small probe (2mm in 
diameter) to achieve DNA fragment lengths of 500-1000bp. 
 
The samples were kept on ice during sonication and left to rest on ice for 30secs in-
between each round of sonication to avoid overheating with protein denaturation as a 
consequence. To remove insoluble material, samples were spun at 10,000 x g for 10 




2.6.3.1 Gel analysis of sonication 
 
For analysis of sonication efficiency, 5µl of sonicated material was collected and de-
cross-linked over night at 65 °C after the addition of 90µl of H2O and 4µl 5M NaCl. 
Following de-crosslinking, 1µl RNase A (10µg/µl) was added and the sample was 
incubated at 37 °C for 30-60 min to degrade RNA. Subsequently 2µl of 0.5M EDTA, 4µl 
Tris-HCl (1 M, pH 6.5) and 1µl Proteinase K (10µg/µl) was added followed by 2 h 
incubation at 45 °C to degrade proteins. 10µl of chromatin samples were analysed on 
1.5 % w/v agarose gels. 
 
2.6.4 Immunoprecipitation (IP) 
 
Sonicated chromatin was diluted 10 times in ChIP dilution buffer supplied in the kit that 
also provided protease inhibitors. 2 x 10µl of sample was removed and stored at 4°C 
as input sample and kept until the following day. 
 
10-15µg of antibody was added to the diluted chromatin (equivalent to 1x107 cells) for 
each immunoprecipitation (IP) and 40µl of protein-G magnetic beads (EZ-Magna 
ChIPTM kit) were added and incubated overnight at 4°C on rotation. The beads were 
pelleted in the cold room (to keep proteases cold) using a magnetic tube rack and the 
supernatant discarded. Beads were then washed by re-suspending the bead pellet in 
1ml of wash buffer supplied in the kit, incubated for 5 min at 4°C and pelleted again by 
standing for 1 min on the magnet, the wash was discarded and pellet re-suspended in 
the subsequent wash buffer and incubated again. Washes were performed in the 
following order: 
1. Low salt immune complex wash buffer (0.5ml) 
2. High salt immune complex wash buffer (0.5ml) 
3. LiCl immune complex wash buffer (0.5ml) 
4. TE buffer  (0.5ml)  
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The last TE wash was performed at RT. In order to elute the bound chromatin, 200µl of 
elution buffer (containing 10µg/ml Proteinase K) was added to re-suspend each sample 
and the two input samples from the previous day. All samples were incubated at 62°C 
for 3 hours with constant rotation. In this step the elution buffer separates the chromatin 
from the antibody and beads, the heat reverse-crosslinks the chromatin protein from 
the DNA and the Proteinase K treatment destroys the proteins. Samples were then 
incubated at 95°C for 10 min and the beads were pelleted using the magnetic rack, the 
DNA is now in the supernatant which is transferred to a fresh tube. 
 
2.6.5 Purification and ethanol precipitation of ChIP material 
 
200µl of 1:1 phenol/chloroform-isoamylalcohol mixture was added to the final 
supernatant that contains the DNA. The samples were vortexed and spun at 13000 
rpm for 1 min. The aqueous top layer was transferred to a fresh tube containing 20µl of 
3M sodium acetate and 20µg glycogen (Roche, UK). DNA was precipitated at -20°C 
overnight and pelleted by centrifugation at 14 000 rpm for 40 min at 4°C. Pellets were 
washed with 150µl 70% EtOH followed by centrifugation at 14 000 rpm for 10 mins at 
4°C. Dried pellets were re-suspended in 20µl of water. 
2.6.6 Analysis of ChIP Material 
 
Immunoprecipitated chromatin was analysed with different methods depending on the 
experiment and the analysis include:  Real time quantitative PCR (qPCR), Snapshot 
and Restriction Enzyme Digestion. 
 
2.6.6.1 Analysis by real time PCR 
 
Purified ChIP DNA was measured using the NanoDrop® Spectrophotometer ND-
1000(NanoDrop Technologies, USA) and analysed for fold enrichment with control 
primers and primers for targets (Appendix) using real time SYBR Green PCR which 
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measures double stranded DNA generated. 0.4-0.5μl (~20ng) of ChIP sample and 
input sample was mixed with 2-4pmol each of forward and reverse primer, and 5μl of 
SYBR Green PCR master mix (Applied Biosystems, UK) in a 10 µl reaction volume. All 
samples were analysed in duplicate using standard real time PCR conditions; 50°C for 
2 min, 95°C for 10 min, 95°C for 15 sec and 60°C for 1 min repeated for 40 cycles. 
 
Fold enrichment for an antibody (ab) at a specific primer target (amplicon) in ChIP 
samples was calculated relative to isotype control (IgG) and normalised against 
negative control NEFM using the following formula:  
Nonspecific adjustment (dCt) = Ct Ab – Ct IgG 
Fold Enrichment: 2-dCt 
Fold enrichment for a negative control is also calculated (ideally should be 1). Fold 
enrichment of the target site is then normalised to fold enrichment of the negative 
control. 
2.6.6.2 Analysis by Snapshot 
 
To quantify allelic differences of transcription factor binding around target regions 
encompassing SNPs of interest and key transcription factors Snapshot analysis of 
ChIP was performed as described in Chapter 2.8.Snapshot reactions are 
electrophoresed on a DNA Sequencer (Applied Biosystems, UK). Peak heights of each 
allele were determined using Gene Marker V2 2.0 demo software (Soft Genetics LLC) 
and ratio of the heights of allele was calculated. Input samples were analysed by 
Snapshot in parallel with ChIP samples from the same individual. For each experiment, 
the ratio of alleles for input and ChIP material were calculated independently. Ratio of 




2.6.6.3 Analysis by Restriction Enzyme Digestion 
 
Purified Immunoprecipitated chromatin and input was PCR amplified. PCR products 
are column purified with Qiagen Nucleotide Removal Kit (Qiagen) according to 
manufactures instructions. 
 
The purified PCR products are digested with an appropriate restriction enzyme, in this 
case 2 units of MaeIII (Roche), at 55°C for 3 hours and digested PCR products of ChIP 
and input were electrophoresed on a 3% w/v agarose gel. The gel was scanned with 
Image Quant 5.2 and the density of each band was calculated for ChIP and input 
separately resulting in ratios for digested and undigested bands. The ratio with ChIP 
material was normalized to the ratio of digested and undigested bands of input. 
 
2.7 Gene expression 
 
All DNA, RNA and protein concentrations were measured on a Nanodrop® 2000 
spectrophotometer (Thermo Scientific). The thermal cycler used throughout was the 
PTC-200 Peltier thermal cycler (MJ Research). 
2.7.1 Total RNA extraction and DNase Treatment 
 
Total RNA was extracted from cells using TRIReagent (Sigma, Poole, UK) according to 
the manufacturer’s instructions. One ml of TRI-reagent was used to lyse between 5-10 
x106 cells; for less than 5x106 cells, a minimum of 0.5ml of TRI-reagent was used. RNA 
was resuspended in 100µl of DEPC-treated water (Applied Biosystems, Ambion) and 
stored at -80°C. After quantification by Nanodrop the RNA samples were DNase 
treated using Ambion® TURBO DNA-free™ Kit (Applied Biosystems, Ambion) to 
remove genomic DNA prior to reverse transcription. 5µl of 10X TURBO DNase buffer 
and 1µl of TURBO DNase was added to 5µg of RNA in a 50µl reaction volume and 
incubated at 37°C for 30 mins. 5µl of DNase inactivation reagent was added to the 
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reaction and incubated for 5 mins at room temperature and mixed at least 3 times over 
the 5 min incubation period. Finally the DNase I-treated sample was centrifuged at 
1000 x g for 1.5 min and transferred to a fresh tube.  
 
2.7.2 Reverse Transcription 
 
First strand cDNA was generated from RNA by using SuperscriptTM III Reverse 
Transcriptase (Invitrogen, Paisley, UK). Reactions were set up with 500ng RNA, 1μl 
sigma random hexamers (0.5μg/μl) and 1μl dNTPs (10mM) in a 13μl volume and 
incubated on a PCR block at 65˚C for 5 min. 4μl of 1st strand buffer (5x), 1μl DTT (0.1 
M), 1μl SuperscriptTM III RT (200U/μl) and 1μl water were added to a final volume of 
20μl. The reactions were incubated on a PCR block at 50˚C for 60 mins followed by 
70˚C for 15 mins and cooling to 4˚C.The cDNA was diluted with water to a total volume 
of   50μl and stored at -20°C. 
2.7.3 Analysis by Real Time PCR 
 
Custom designed primers and probes for TaqMan real time PCR analysis were ordered 
from Applied Biosystems (UK) (Appendix). Primer probe mixes for BCL11A 
(Hs00256254- Invitrogen, UK), MYB and housekeeping genes HPRT1 (Hs99999909) 
and GAPDH (Hs99999905) were ordered as ready-made gene-expression assays from 
Applied Biosystems.10µl reactions were set up with 2μl cDNA, 1.5pmol each of forward 
and reverse primer, 2pmol of fluorescent probe and 5μl of TaqMan PCR master mix 
(Applied Biosystems, UK) . In case of KLF1 and GATA-1, SYBR green real time PCR 
was performed with custom designed primers (Appendices) in a volume of 10µl that 
included  2 μl cDNA, 1.5pmol each of forward and reverse primer, and 5μl of SYBR 
green master mix (Applied Biosystems, UK). All prepared reactions were run on an ABI 




Step1) 50°C for 2 min,  
Step 2) 95°C for 10 min,  
Step 3) 95°C for 0.15 min and 60°C for 1 min repeated for 40 cycles. 
Real time PCR measures the number of cycles to reach the threshold of fluorescence 
detection. The cycle at which the threshold is reached is called the threshold cycle or 
CT, which provides a value for the starting copy number of a DNA target. A lower CT 
value means fewer amplification cycles were required to reach the threshold of 
fluorescence detection and therefore the higher the starting amount of our specific DNA 
sequence. Expression of target gene and the housekeeping gene were each 
normalized to appropriate negative control. Relative expression of target gene was 






2.8.1 Standard PCR and Enzyme Purification 
 
DNA was specifically amplified by standard PCR. 25µl reactions were set up with 5µl of 
DNA, 10µM each of forward and reverse primers (Appendix), 10mM dNTPs, 2.5µl 
MgCl2, 2.5µl 10X buffer and 0.4µl of AmpliTaq Gold. The reactions were run on a 
thermal cycler under the following conditions; 
Step1) 94°C for 10 min  
Step 2) 94°C for 0.30 min  
Step 3) 55°C for 0.30 min 
Step 4) 72°C for 0.30 min 
Step 5) Repeat steps 1-4 for 30 cycles 
Step 6) 72°C for 2 min 
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PCR product was initially visualized by agarose gel electrophoresis of a small amount 
of the product. Once PCR quality was confirmed, all the remaining PCR product was 
enzyme purified  with 2 units Exonuclease I (New England Biolabs) and 5 units rAPid 
Alkaline Phosphatase (Roche)  at 37 °C  for 60min followed by 75 °C  for 15min to 
remove free primers and deoxynucleotide triphosphate (dNTP). 
 
2.8.2 Primer extension 
 
Primer extension reactions was prepared in a total volume of 10 µl with2 µl enzyme 
purified PCR products, 10µM of appropriate extension primer (Appendix) and 1 µl of 
Abi Prism Snapshot Mix (Applied Biosystems, UK) according to manufacturer’s 
introductions .Single base extension was performed using conditions: 96 °C for 10sec, 
50°C for 5sec, 60°C for 30sec repeated for 25 cycles. 
 
 
2.8.3 Electrophoresis and data collection 
 
2 µl of primer extension reaction was mixed with 8µl of formamide, vortexed well and 
spun down. Samples were then transferred to a 96-well plate and pulse spun to 
1000rpm. Samples on the plate were then denatured for 2 minutes at 95˚C on the 
thermal cycler. The plate was then set up and run on the sequencing machine 3130xl 
Genetic Analyser (ABI Prism by Applied Biosystems) as per the manufacturer’s 
instructions. Data was analysed using Gene Marker V2 2.0 demo software (Soft 
Genetics LLC).  
 
Ratio of the peak heights of each allele of test samples i.e. (ChIP or cDNA) and 
controls i.e. (Input or genomic DNA) were determined .Ratio of the alleles (relative 
expression) of the test samples was then normalized to controls. 
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2.9 DNA Sequencing 
 
2.9.1 Standard PCR and column purification 
 
DNA was specifically amplified by standard PCR. 25µl reactions were set up with 5µl of 
DNA, 10µM each of forward and reverse primers (Appendix 1, Table 11.3, 11.4 & 
11.7), 10mM dNTP, 2.5µl MgCl2, 2.5µl 10X buffer and 0.4µl of AmpliTaq Gold. The 
reactions were run on a thermal cycler under the following conditions; 
Step1) 94°C for 10 min  
Step 2) 94°C for 0.30 min  
Step 3) 55°C for 0.30 min 
Step 4) 72°C for 0.30 min 
Step 5) Repeat steps 1-4 for 30 cycles 
Step 6) 72°C for 2 min 
PCR product was initially visualized by running a small amount of the product on an 
agarose gel. Once PCR quality was confirmed, all the remaining PCR product was 
column purified as per the protocol outlined in the Promega Wizard SV Gel and PCR 
Clean-up System instruction booklet. DNA concentration was then measured by the 
Nanodrop®. 
 
2.9.2 Cycle sequencing 
 
Sequencing reactions were carried out using the ABI PRISM Big Dye Terminator v3.0 
Ready Reaction Cycle Sequencing Kit following protocols as outlined in the user’s 
manual. 20µl reactions were set up with 200-300ng of DNA, 3.2pmol primer and 4µl of 
5 X buffer and 2µl of Terminator Ready Reaction Mix. Reactions were run on a thermal 
cycler according to manufacturer’s protocol (Applied Biosystems, Warrington, UK). 
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2.9.3 Electrophoresis and data collection 
 
Reactions were transferred to 1.5ml eppendorf tubes containing 16µl deionized water 
and 64 µl of 95% ethanol. Samples were vortexed and incubated at room temperature 
for 15 mins, followed by a 20 minute spin at maximum speed. Supernatant was 
discarded and sample washed with 400µl of 70% ethanol and spun again for 10 mins. 
Supernatant was again discarded and pellets dried at room temperature. 
 
The pellets were re-suspended in 20µl of formamide, vortexed well and spun down. 
Samples were then transferred to a 96-well plate and pulse spun to 1000rpm. Samples 
on the plate were then denatured for 2 minutes at 95˚C on the thermal cycler. The plate 
was then set up and run on the sequencing machine 3130xl Genetic Analyser (ABI 
Prism by Applied Biosystems) as per the manufacturer’s instructions. Data was 
analysed using the DNA sequence analysis programme Sequencher® version 4.6 
(Gene Codes Corporation, Ann Arbor, MI USA http://www.genecodes.com). 
2.10 Allele specific Gene expression 
 
2.10.1 Informative SNP Selection and Genotyping 
 
Informative SNPs were selected according to their frequency i.e. (> 0.300). Ideally 
exonic SNPs should be selected as informative SNPs but because of the lack of high 
frequency exonic SNPs in MYB gene an intronic SNP rs210796 with frequency >0.300 
was selected. In the case of HBS1L gene an exonic SNP rs13064 with frequency > 
0.300 was present and it was selected as the informative SNP for allele specific 
expression analysis.  All selected SNPs were genotyped as the part of HapMap project. 
 
Healthy unrelated adults of diverse ethnic backgrounds were recruited. HbF levels 
were measured by high-performance liquid chromatography (BioRad Variant; BioRad, 
Hemel Hempstead, UK) and F cells as previously described (Jiang et al Blood 2006) 
using blood in EDTA .Genomic DNA was isolated from peripheral blood of these 
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individuals and genotyped for the SNPs in block 2 of the HBS1L – MYB interval of 6q, 
for SNP rs210796 in intron 4 of the MYB gene and the SNP rs13064 in exon 17 
ofHBS1L gene. Individuals were genotyped with Snapshot as described (2.7) and 
results are validated with sequencing of genomic DNA from the same individual (2.8). 
 
2.10.2 Erythroid Cultures and cDNA preparation 
 
Individuals with the appropriate genotypes for SNPs in HMIP-2, HBS1L and MYB were 
recruited and erythroid cultures were performed using three-phase erythroid culture 
method as previously described (2.1.3). 
Total RNA was extracted from erythroid progenitors at phase II day 4  using 
TRIReagent (Sigma, Poole, UK) as described in 2.6.1.Total RNA was DNAse treated 
(2.6.2) and reverse transcribed into cDNA using random hexamers (2.6.3). 
 
 
2.10.3 Snapshot and Analysis 
 
Snapshot protocol was performed with genomic DNA and cDNA samples in parallel as 
described in 2.8. Data was analysed using Gene Marker V2 2.0 demo software (Soft 
Genetics LLC). Ratios of the peak heights for two alleles were determined separately 
for genomic DNA and cDNA in test samples and controls. Allele ratio of cDNA was then 











Erythropoiesis defines the process of differentiation and proliferation from 
hematopoietic stem cells (HSCs) to mature red blood cells (RBCs). 
Erythrocytes (red blood cells) are derived from the myeloid progenitor cells. Committed 
erythroid progenitors referred to as burst forming unit-erythroid (BFU-e's) are the most 
immature haematopoietic cells that are already committed to the erythroid lineage. 
BFU-e develops into colony forming units-erythroid (CFU-e). CFU-e will differentiate 
into the first morphologically identifiable cell of the erythrocyte lineage, the pro-
erythroblast, followed by successive differentiation into the basophilic erythroblast, the 
polychromatophilic erythroblast, and the acidophilic erythroblast, which is the last 
nucleated cell of the mammalian erythrocyte lineage (Figure 3.1). 
During mammalian development, erythropoiesis occurs successively in the yolk sac, 
the foetal liver and the bone marrow. Erythropoiesis is composed of commitment and 
differentiation steps that restrict the differentiation potential and the proliferative 
capacity of the cells as they go through the erythroid-specific program of gene 
expression. Combinations of growth, microenvironmental and trans-acting factors that 
have crucial roles in promoting survival of erythroid progenitors regulate erythropoiesis. 
At the molecular level, trans-acting factors regulate transcription of genes involved in 
the regulation of the delicate balance between the opposing effects of proliferation 
promoting factors maintaining the renewal capacity of immature erythroid progenitors 
and differentiation-inducing factors required for successful terminal maturation of 




Figure3.1: Cytokines are involved in lineage commitment during haematopoiesis. 
Figure adopted from (Bauer et al). 
 
3.1.2 Erythroid Cell Cultures 
 
The study of human erythropoiesis in vitro requires a robust culture system that 
consistently and reliably generates large numbers of immature erythroblasts that can 
be induced to differentiate synchronously. The conditions of culture systems are 
developed to mimic the natural environment of erythropoiesis. The cells yielded using 
these culture systems are very similar to their in vivo counterparts. This means 
morphological changes and gene expression changes accompanying erythroid 
differentiation can be studied in these cells.In vitro models of human erythropoiesis are 
useful tools in studying normal and pathologic erythroid maturation, in addressing the 
pathophysiological mechanisms underlying RBC diseases and in testing the effects of 
various pharmacological agents.  
They are also useful at providing us with cells at different stages of maturation for 
analysis of the different transacting factors that are active at different stages of 
erythropoiesis. 
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Erythroid progenitor cells (CD34+) can be isolated from various sources including bone 
marrow aspirates, fetal livers, cord blood and peripheral blood buffy coats. CD34 is a 
cell surface glycoprotein and functions as a cell-cell adhesion factor which is expressed 
in erythroid progenitor cells. There are also commercially available CD34+ cells that 
are obtained by cell sorting.  
In our erythroid cell cultures, we use peripheral blood as the source. Peripheral blood 
buffy coat displays two main advantages:  
• Easy accessibility 
• homogenous population of BFUe meaning a uniform starting point for 
culturesLeberbauer et alalso suggested that cell differentiation is more 
synchronised with samples from peripheral blood compared to cells sorted for 
CD34+ (Fibach et al 1989 and Leberbauer et al 2005). 
The isolated cells can be grown in different types of assay media. Semi-solid medium 
colony forming assays were commonly used but they have limiting characteristics such 
as immobility of the cells which limits cell interactions and continuity of the culture 
which limits addition of different factors at different stages. A two-phase liquid culture 
was applied by Fibach and colleagues to overcome these limitations. The group 
proposed a two-phase liquid culture system that supports the growth and maturation of 
human erythroid progenitor cells.  The original Fibach method was modified by Jackie 
Sloan-Stanley (WIMM, Oxford) and we applied her method with her generous help. 
Three different methods of liquid culture were performed during the project for isolation 
of erythroid progenitor cells. Two methods (two modified Fibach methods) consists of 
two phases while the third method has three phases in which Phase II of the first two 
methods is separated as phase II and phase III.  Results presented in this chapter used 
erythroid progenitor cells derived from the modified three-phased culture method; but 
other cultures method will be discussed for comparison. We needed cells at early 
stages i.e. (proerythroblasts, basophilic normablasts) so the cells were not transferred 
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to phase III as differentiation was not required for our study. Table 3.1 compares key 
steps of three different methods. 





Plastic Cells are incubated 
in flasks. 
Cells are incubated 
in flasks. 
Cells are incubated in 
petri dishes or 6 well 
plates for better 
aeration. 
Base Medium Biological Foetal Calf 
Serum(FCS) 




Stemspan is used 
as base medium. 
Batch variable 
Stemspan is used as 




Cytokines Conditioned medium 
includes key 
cytokines needed for 








(lipids, IGF1) are 
included in phase I and 
phase II to induce 
proliferation 
Media volume 10-25 ml depending 
on cell counts 
10-25 ml depending 
on cell counts 




Cell concentration is 
1million cells /ml 
during phase I 
Cell concentration is 
1million cells /ml 
during phase I 
Cell concentration is 5-
10million cells /ml 
during Phase I leading 




Cyclosporin is used 
to kill T-lymphocytes 
Cyclosporin is used 
to kill T-lymphocytes 
Cyclosporin is not used 
to kill T-lymphocytes. 
Histopaque layering 







phase 1 and 2 by 
changing the flasks 
Macrophages are 
depleted during 
phase 1 and 2 by 
changing the flasks 
Macrophages are 
depleted during phase 
1 and 2 by changing 
the petri dishes 
Table 3-1: Comparison of three erythroid culture methods 
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3.1.2.1 Two-Phase Fibach Culture 
 
50 mls of peripheral blood in EDTA was diluted 1:1 with PBS. This was layered onto a 
density gradient centrifugation liquid- Histopaque-Ficoll (Sigma-Aldrich, UK) and 
centrifuged to separate the blood components. The buffy coat containing lymphocytes 
and progenitor cells was collected and washed with PBS. The washes should be 
performed till the supernatant is transparent but there is fine balance between washing 
the cells and losing them so in the case of a small cell pellet fewer cell washes should 
be performed. 
 
The cells were counted and cultured in flasks at 1-2 million/ml in Phase I medium 
[DMEM-Alpha modified medium (Sigma, Poole, UK), 5 U/ml penicillin, 5 µg/ml 
streptomycin, 1µg/ml cyclosporin A, 2mM L-Glutamine, 10% foetal calf serum (Sigma, 
Poole, UK) and 10% conditioned medium from cultures of 5637 bladder carcinoma cell 
line (ATCC)] at 37° in 5% CO2 for 6 days. 
 
Because of the biological background of Foetal calf serum each batch should be tested 
since some of the batches can inhibit cell growth. The concentration of cells is crucial 
for a successful cell culture since diluted cultures limits cell interactions and crowded 
cultures lead to apoptosis. 
 
The first phase isolates erythroid progenitor cells by depleting all other cell types while 
expanding growth of the progenitor cells. Cyclosporin A was used in depleting 
lymphocytes. 24 hours later the entire culture suspension was moved to a fresh flask, 
this step removes adherent monocytes in the first flask. Monocytes are included in the 
buffy coat with the CD34+ cells during isolation. The default pathway of the early 
committed Myeloid/Erythroid pathway is towards monocytes. Excessive numbers of 
monocytes disrupt the homogeneity of the culture and alter proliferation/differentiation 
  87
patterns of the CD34+cells. On the other hand, complete depletion of monocytes in the 
culture is not advisable since monocytes/macrophages are essential sources of iron for 
the differentiating erythroblasts so they should be diluted by changing the flasks 
instead of being depleted by chemicals. After 6 days in phase I culture, the cells are 
centrifuged and resuspended in Phase II medium [DMEM alpha modified Medium, 5 
U/ml penicillin, 5 µg/ml streptomycin, 1 U/ml human recombinant erythropoietin [EPO; 
Eprex UK] and 10 ng/ml SCF, 2mM L-Glutamine 30% Foetal calf serum , 10-5M β-
Mercaptoethanol, 10-6 mol/l dexamethasone ,0.3mg/ml Holotransferrin(ICN) , 1% 
Bovine serum albumin (Sigma, Poole, UK) and the cells are maintained at a 
concentration of 1 million/ml for up to 15 days. The second phase promotes the 
proliferation and maturation of the erythroid progenitor cells. This selection is achieved 
by administration of key growth factors including erythropoietin (EPO) and stem cell 
factor (SCF). 
 
3.1.2.1 Two-Phase erythroid culture using Stem Span 
 
This method is an adaption of the original Fibach method where biological Foetal calf 
serum is substituted with semi-synthetic Stem Span and cytokines such as IL3 and 
stem cell factor replaces the 5637 cells conditioned medium. Even though Stem span 
is semi-synthetic, it still contains biological reagents with batch variation so each batch 
should be tested before proceeding. 
 
50 mls of peripheral blood in EDTA is centrifuged to separate the blood components. 
The buffy coat which contains the lymphocytes and progenitor cells at the yellow 
plasma interface is collected and layered onto a density gradient centrifugation liquid: 
Histopaque-Ficoll (Sigma-Aldrich, UK) and centrifuged to separate red and white blood 
cells. The lymphocytes and other mononuclear cells remain at the plasma-histopaque 
interface from where they are collected and washed in PBS. Cells are counted and 
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cultured in flasks at 1-2 million/ml in Phase I medium (Stem Span Medium [Stem Cell 
Technologies, Vancouver, Canada], 10 U/ml penicillin, 10 µg/ml streptomycin, 1µg/ml 
cyclosporin A, 25 ng/ml interleukin 3 [IL-3; Sigma, Poole, UK] and 50 ng/ml human 
stem cell factor [SCF; Sigma, Poole, UK]) at 37° in 5% CO2.24 hours later the entire 
culture suspension is transferred to a fresh flask, this step removes adherent 
monocytes in the first flask. 
 
After 7 days in phase I culture, cells are  centrifuged and resuspended in Phase II 
medium (Stem Span Medium, 10 U/ml penicillin, 10 µg/ml streptomycin, 2 U/ml human 
recombinant erythropoietin [EPO; Sigma, Poole UK] and 50 ng/ml SCF) and 
maintained at a concentration of 1 million/ml for up to 20 days. The critical steps of the 
original two phase Fibach Culture are also valid in this method. The concentration of 
the cells and reduction of excess monocytes are crucial steps. Cyclosporin A was used 
to deplete lymphocytes as in the first method. 
 
2.1.3 Three-Phase erythroid culture 
 
This method was described by Van Den Akker et al (Haemotologica 2010) and kindly 
provided to our group. I have followed the protocol with few adaptations. The main 
advantage of the method is that more cells can be harvested at the end of the protocol 
allowing the use of smaller volume of blood.25 mls of peripheral blood in EDTA is 
diluted 1:1 with PBS and layered onto a liquid density gradient (Histopaque 1.077) 
(Sigma-Aldrich, UK) and centrifuged to separate the blood components. The buffy coat 
containing lymphocytes and progenitor cells is collected and washed with PBS. 
Cells are counted and cultured in petri dishes at 5-10 million/ml in Phase I StemSpan 
medium containing: IL-3 – 1ng/ml, human recombinant erythropoietin [EPO; Eprex UK] 
– 2U/ml, Stem cell factor – 100ng/ml, Dexamethasone - 1μM, Insulin growth factor 
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1(IGF1) – 40ng/ml, Cholesterol rich mix 50μg/ml, 5 U/ml penicillin, 5 µg/ml 
streptomycin for 5 days. 
 
After 6 days the cells are centrifuged and resuspended in Phase II StemSpan medium 
containing: human recombinant erythropoietin [EPO; Eprex UK] – 2U/ml, Stem cell 
factor – 40ng/ml, Dexamethasone - 1μM, Insulin growth factor 1(IGF1) – 40ng/ml, 
Cholesterol rich mix 50μg/ml, 5 U/ml penicillin, 5 µg/ml streptomycin for 7-25 days. 
Cells are cultured in petri dishes at 0.5-1.0 million/ml. Differentiation can be induced 
after a minimum of 7 days in phase II which involved collecting the cells and culturing 
them in phase III StemSpan medium containing: 
Human recombinant erythropoietin [EPO; Eprex UK] – 10U/ml, Insulin growth factor 
1(IGF1) –, 5 U/ml penicillin, 5 µg/ml streptomycin, Holotransferrin 1mg/ml,Insulin 
10ng/ml,thyroid hormone 1µM , 3 %human serum (male)  for 2-7 days.This method 
differs from the 2-phase methods described and has different critical steps (see Table 
3.1 for summary of differences between the 3 methods). Briefly, in the 3-phase method 
the cells are cultured at very high concentrations in phase I in petri dishes or plates for 
a better aeration of the culture. If an excessive population of lymphocytes is observed, 
a histopaque layering is performed to remove the lymphocytes avoiding the use of 
cyclosporine- A in the medium. One critical point is to maintain the monocytes at a 
minimal level. The strategy to maintain low monocyte levels rely on the adherence 
property of the monocytes. The adherence of the activated monocytes to the surface of 
petri dishes is enabled by a specific coating (CELLSTAR surface treatment) of the 
plastic dish (Figure 3.2).  
 
The media include cytokines such as insulin growth factor like 1 (IGF1) and cholesterol 
rich mix that were not present in pervious culture systems. Table 3.2 summarizes 
functions of cytokines used in phase I and phase II.In Phase III, the high dose of 
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erythropoietin in the medium increase the differentiation rate of erythroid cells which 
make it difficult to harvest them at specific stages.  
 
For each ChIP experiment 106 cells were required which can easily be rich with this 
method. We assessed cell development based on the morphology analysis of cell 
cytospins. The purity and maturation of cells was further analysed by flow cytometry. 





Figure 3.2: Monocyte / Macrophage depletion by petri dish changes according to 










Reagents Final Conc. Phase I Phase II Function 
Stemspan  - 100ml 100ml It is a serum free expansion 
medium specifically for culture 








200μl 200μl EPO drives the proliferation 
and expansion of the 
developing erythroid 
progenitors from BFU-e stage 
through to terminal 
differentiation. 
Interleukin 3 (IL3) 1ng/ml 100μl - IL-3 is a cytokine that 
promotes cell survival and 
proliferation of HSCs and early 
progenitor cells. 
Stem Cell Factor 
(SCF) 
100ng/ml 400μl 400μl Induces cell survival and 
proliferation of early erythroid 
progenitors and prevent 
apoptosis at later stages. 
Dexamethasone 
(Dex) 
1μM 100μl 100μl It activates proliferation of 
immature erythroid progenitor 
cells and delay differentiation. 
Insulin growth 
factor like 1 
(IGF1 ) 
40ng/ml 100μl 100μl IGF1 increase proliferation of 








50μg/ml 500μl 500μl Induces cell survival and 
proliferation of early erythroid 
progenitors. 
L-Glutamine 1:100 1ml 1ml Glutamine supports the growth 
of cells that have high energy 
demands 
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3.2  Results 
 
Maturity and differentiation stage of the erythroblasts were monitored by morphology in 
cytospins and expression of cell surface antigens by FACS. 
 
3.2.1 Analysis of cell morphology 
 
During Phase II, the cells are maintained at a concentration 1*106/ml to allow 
proliferation of erythroid progenitors. Cell differentiation was monitored daily by cell 
cytospins (see chapter 2 for full methods).  
 
Small round erythroid progenitor cells were visible in the culture from day 0 of Phase II 
with the presence of some prepro-erythroblasts which increased in number by day 2. 
The cell cytospin taken on day 4 showed the majority of the cells in the culture were 
now pro-erythroblasts. As the cells developed into polychromatic erythroblasts (day 7) 
they reduce in size and the nuclei become more condensed. By day 9 the cells were 
smaller yet with a pale cytoplasm as the dark nuclei move to one side of the cell known 
as orthochromatic erythroblasts. Soon the nuclei were expelled from the cells as seen 











Figure3.3: Differentiation of primary human erythroid progenitor cells. 
Cytospins of cells taken in Phase II day 0-13 of the culture system adapted from Van 
Den Akker et al (Haemotologica 2010). Morphological stages of cells are marked out 




3.2.2 Expansion of erythroid progenitor cells in Phase I of culture 
 
We isolate erythroid progenitors (CD34+) from peripheral blood buffy coats containing 
mononuclear cells such as lymphocytes, monocytes and progenitor cells. The first 
phase of culture isolates erythroid progenitor cells and allows their growth by depleting 
all other cell types. 
 
Expansion of erythroid progenitor cells was monitored by fluorescence activated cell 
sorting (FACS). On the day of isolation (day0) the percentage of erythroid progenitors 
(CD34+) was less than 10 %. After two days in phase I majority of adherent cells 
(monocytes) were depleted by frequent petri dish changes leading to an increase in the 
percentage of CD34+ cell: 18 % at day 2 and 32 % CD34+ cells at day 5 (Figure 3.4). 
 
 
Figure 3.4: Percentage of CD34+ progenitor cells during primary human erythroid 
progenitor cell cultures by FACS analysis. 
The percentage of CD34+ cells in Phase I day 0, day 2, and day 5 of the modified 
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3.2.3 Purity and differentiation of erythroid cells in Phase II of culture 
 
We used two human erythroid cell surface proteins to monitor cell development and 
purity. Glycophorin A (GPA) is an erythroid specific protein and is up-regulated as the 
cells develop into erythrocytes. Transferrin receptor protein 1 (CD71) (Furthmayr et al 
1975) is highly expressed on the surface of all proliferating haematopoietic cells 
including erythroid progenitors during the early stages of development.  
 
At early stages of culture (day 4) cells start to proliferate, 82 % of the cells express 
CD71 but only very few express GPA (Figure 3.5). 
 
At phase II day 9 of the culture, CD71 expression on cells is high (82% on day 4 to 
95% on day 9), the maximum that it would reach.  
GPA is expressed later as the cells differentiate down the erythropoietic pathway. We 
see a rapid increase in GPA expression from day 4, when 14% of cells analysed are 
positive to 73% on day 11 when the highest level of GPA positive cells is observed. 
GPA positive, CD71 negative cells would appear if further differentiation of the cells is 
induced by transferring the cells to phase three (Figure 3.5). 
 
3.2.4 Gene expression profiles 
 
For ChIP experiments, we need to harvest cells at the peak expression stage for the 
transcription factor of interest. We constructed expression profiles of the different 
genes by RT-PCR of RNA extracted from erythroid cells at sequential days of Phase II. 
Ct values were normalised to the house-keeping gene HPRT. Figure 3.6 presents 








Figure 3.5: Differentiation and purity of primary human erythroid progenitor cells 
by FACS analysis. 
Cells in Phase II day 4-11 of modified three-phase culture are double stained with 
antibodies against CD71 and GPA. The y-axis shows CD71 expression and the x-axis 
shows GPA expression. Lower left box: double negative cells. Upper left box: CD71 
positive, GPA negative cells. Upper right box: GPA and CD71 positive cells. Lower 
right box: GPA positive, CD71 negative cells. Markers (black lines) separating each 
field were set according to single stained and unstained control samples from the same 
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MYB was highly expressed at early stages of erythroid culture (day2-day4) when 
majority of the cells are pro-erythroblasts. As cells differentiate becoming basophilic or 
polychromatic erythroblasts MYB expression is down regulated remaining at a low level 
after day 7 (Figure 3.7). 
 
GATA-1 was up-regulated as cells developed, reaching the peak expression on day 9. 
This coincides with the stage where all cells are erythroblasts and GPA is highly 
expressed. As the cells further differentiate into orthochromatic erythroblasts and start 
enucleating GATA-1 expression is down-regulated (Figure 3.7). 
 
KLF1 expression follows a similar pattern to that of GATA-1 expression, reaching a 
peak on day10. The main difference fromGATA-1expression is that KLF1 is not down-
regulated as much as GATA-1 around day 13 (Figure 3.7). 
 
This data shows that two genes (KLF1 andGATA1) of interest are at peak expression 
around day 9 and 10 of culture in phase II. This coincides with the high levels of GPA 
expressing cells (~70%, Figure 3.5) at the polychromatic erythroblast stage (Figure 
3.6). 
 
On the other hand cells should be harvested at early stages (day 4) for MYB related 
experiments when majority of the cells are highly proliferating thus expressing high 








Figure 3.7: Relative expression profile of MYB, GATA-1 and KLF1 in erythroid 
progenitors from phase II day1-13. 
Results are analyzed by RT-PCR in duplicate using gene specific primers on erythroid 
RNA from a single erythroid culture. Individual designated as -/- is homozygous for the 
absence of HMIP block 2 SNPs associated with elevated HbF. Data were normalized 




























































3.2.5 Erythroid Culture Kinetics of individuals with different genotypes 
 
For the next objective, we wanted to obtain erythroid progenitor cells from individuals 
that are either homozygous (+/+) for the haplotype associated with high HbF across the 
6q QTL (blocks 1, 2 and 3) or homozygous for the absence of the SNPs associated 
with increased HbF levels (-/-). Our initial objective was to investigate differences in the 
erythroid culture kinetics between these individuals. 
 
We used two human erythroid cell surface proteins: Glycophorin A (GPA) and 
transferrin receptor protein 1 (CD71) to monitor proliferation and differentiation of 
erythroid progenitors. 
 
The results suggested that differentiation of erythroblasts was accelerated in +/+ 
individuals. In a +/+ individual percentage of GPA positive cells was 9% at day 4 and it 
reaches 80 % in 7 days at day 11 compared to that for a -/- individual where 
percentage of GPA positive cells  reaches 72 % at day 11 from 14 % at day 4 (Figure 
3.8 A). The difference became striking when results from each individual were 
corrected for the percentages in CD71 positive cells and then normalised to day 4 of 
each individual. Figure 3.8 B demonstrates relative increase of GPA positive cells 
intraindividually confirming the accelerated increase of GPA positive cells in the +/+ 
individual. 
The differential increase in monocytes between the two genotypically different 
individuals (-/- and +/+) was also monitored using cell surface antigen CD14, a specific 
marker for monocytes. The results suggested an increased number of CD14 positive 
cells in +/+ individuals at two stages of phase II (day4 and day11). The increase in 
monopoiesis can be the result of inefficient commitment of early progenitors to 
erythroid pathway since cells that are not committed to erythroid lineage commits to 





Figure 3.8: Differentiation and proliferation curves from +/+ and -/- individuals. 
A: Differentiation and proliferation kinetics of primary human erythroid progenitor cells 
was analysed by FACS analysis. Cells in Phase II day 4-13 of modified three-phased 
culture are double stained with antibodies against CD71 and GPA. B: Relative increase 
of GPA+ cells corrected any changes in CD71 % and then normalized to day 4 of each 
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Figure3.9: Percentage of monocytes in primary human erythroid progenitor cell 
cultures is monitored by FACS analysis using an antibody against cell surface 
antigen CD14, which is a specific marker for monocytes and macrophages. 
 
Our second objective was to harvest erythroid progenitors for ChIP experiments to 
investigate altered transcription factor binding. To ensure that we harvest the erythroid 
progenitor cells from the +/+ and -/- individuals at equivalent stages of gene expression 
we initially obtained a profile of gene expression in cells from individuals of both 
genotypes. Expression profiles suggested that day 9 or 10 would be optimal for GATA-
1 and KLF1 when they are at their peak of expression. In the case of MYB, day 4 would 
be optimal as it is the peak of expression. Cells cultured from individuals of both 
genotypes shared a similar expression pattern in terms of peak of expression for MYB 
gene. MYB expression peaks at early stages of phase II than gradually decrease with 
both genotypes but +/+ individuals had a different pattern of MYB expression at later 
stages of erythroid culture (day 5–day 10) when compared to that of -/- individuals. For 
validation the cells were also closely monitored by FACS analysis as previously 
described. In performing ChIP on erythroid progenitor cells at similar stages of 
expression we ensure any difference observed in transcription factor binding is due to 
the alteration of binding by the SNPs and not because of differential expression of 





























Monocytes ( CD14 + cells ) in culture


















































































The functional experiments of the project depend on material from primary erythroid 
progenitors. Three different methods of liquid culture were performed during the project 
for isolation of erythroid progenitor cells in order to investigate the best culture method 
to obtain large number of homogenous and synchronized cells for expression and 
transcription factor binding studies. 
 
Initial cell culture experiments were performed using Stem Span in the two-phase 
erythroid culture system, an adaption of the original Fibach method. Here the biological 
Foetal calf serum is substituted by semi-synthetic Stem Span and cytokines such as 
IL3 and stem cell factor replaces the 5637 cells conditioned medium. 
 
Even though Stem Span is semi-synthetic, batch variation was observed and that led to 
a challenging time with the cultures i.e. some batches were inhibiting erythropoiesis 
and promoting monopoiesis some of our cultures, monocyte were as high as 50 % in 
the cultures. Despite the frequent flask changes it was difficult to deplete monocytes 
and macrophages during phase I as monocytes and macrophages that differentiate 
from progenitor cells are not activated and do not adhere to the flasks. Previous PhD 
student Karin Wahlberg tried depleting monocytes by use of a lysosomotropic agent, l-
leucin methyl ester (LME), which causes selective death of monocytes in culture. LME 
treated cultures contained no macrophages on day 0 of phase II. A high amount of cell 
death was observed from day 6 of phase II with no viable cells visible on cytospins at 
day 10. In contrast, the control culture (no LME) had a small number of macrophages 
on day 0 of phase II and erythroid precursor cells had developed to a homogenous 
population of pro-erythroblasts at day 6.  
This led us to conclude that limited numbers of macrophages are beneficial to erythroid 
cell development in vivo and in vitro preventing us from completely depleting them 
(Chasis & Mohandas 2008, Leimberg et al2005). 
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Another problem with cultures containing higher numbers of macrophages was 
accelerated differentiation. We have observed formation of erythroblast islands around 
macrophages that differentiate faster. It is known that macrophages are involved in 
erythroid development in vivo in the bone marrow by interacting with erythroid 
precursors in so called erythroblastic island consisting of a central macrophage 
surrounded by erythroblasts (Chasis and Mohandas, 2008). In vitro studies have 
demonstrated that macrophages promote proliferation and maturation of erythroid 
precursors in serum free cultures (Leimberg et al 2005) and macrophages have been 
shown to express erythroid potentiating cytokines (Bergamaschi et al 1993) including 
erythropoietin (Vogt et al 1989). 
 
Because of the challenges of this culture method we decided to try the Fibach method 
that was modified by Jackie Sloan-Stanley (WIMM, Oxford). We applied her method 
with her generous help. Successful cultures were performed with this culture system 
but the major limitation was the limited number of cells that we could harvest. The lack 
of additional cytokines in the method limited proliferation of erythroblasts. For the 
purpose of ChIP experiments we needed a large number of homogenous populations 
of primary human erythroid cells at synchronised stages of expression.  
 
Due to the limited number of cells we obtained using the Fibach method we had to 
increase the number of starting cells i.e. the amount of peripheral blood. Another 
challenge was the biological background of foetal calf serum. Each batch need to be 
batch tested since some of the batches could inhibit cell growth.  
The third culture method that was applied in the project was described by Van Den 
Akker et al (Haemotologica 2010). I have followed the protocol with some small 
adaptations. This method is different from the traditional Fibach method as mentioned 
in the previous section. The main advantage is that more cells can be harvested at the 
end of the protocol allowing the use of a smaller volume of blood. 
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In the two-phase methods, Phase II includes reagents that favour both proliferation and 
differentiation of erythroid cells. In the three-phase culture, Phase II favours 
proliferation mainly where cells expand with limited differentiation due to the low 
concentration of erythropoietin while Phase III favours differentiation of erythroid cells 
due to the presence of tenfold more erythropoietin. Cell proliferation is limited at this 
stage due to lack of stem cell factor in the Phase III medium. 
 
The three-phase culture system yields better cell numbers due to two main reasons. 
The method takes advantage of CD34- cells becoming CD34+ and commitment to the 
erythroid lineage during phase I. Apart for the small number of CD34+ progenitors, the 
mononuclear fraction contains mainly CD34- cells, monocytes and lymphocytes. Two 
main approaches have been used to enrich the fraction of progenitors over other cell 
types. In the 2-phase system (Fibach et al 1989;Pope et al 2000) mononuclear cells 
are grown in culture conditions that favour expansion of the progenitor cells followed by 
the depletion of contaminating monocytes and lymphocytes. The remaining progenitors 
are grown in a second phase in the presence of EPO resulting in erythroid proliferation 
and differentiation. The other approach of enriching progenitors selects the  progenitors 
in the mononuclear cell fraction using antibodies for the surface marker CD34 (Keller et 
al 2006;Ronzoni et al 2008). Purified progenitors are cultured directly in the presence 
of Epo. The phase one of the three-phased method includes Epo and increased 
concentration of IL3 in order to direct CD34- cell to become CD34+. The cell 
interactions are crucial for this stage so cells are kept at high concentrations. 
 We observed significant increase in the proportion of CD34+ cells at the end of phase 
one (Figure 3.4). The second reason is the presence of the additional cytokines that 
induce proliferation (Table 3.2). 
Jiang et al suggested that individuals with elevated HbF levels had accelerated 
differentiation and relatively lower levels of MYB expression compared to individuals 
with normal or low HbF. We wanted to substantiate these findings with our culture 
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system with primary erythroid cultures from individuals that are either homozygous 
(+/+) for the haplotype associated with high HbF across the 6q QTL (blocks 1, 2 and 3) 
or homozygous for the absence of the SNPs associated with increased HbF levels (-/-).  
 
Our results confirm Jiang’s initial observations of accelerated differentiation and 
relatively increased monopoiesis in +/+ individuals that have higher HbF levels (Figure 
3.8). One possible explanation for the accelerated differentiation is the difference 
inMYB expression profiles between these individuals. The commitment of 
haematopoietic stem cells to the erythroid lineage is dependent on distinct threshold 
levels of MYB. Reduced MYB levels favours commitment of haematopoietic 
progenitors to the megakaryocytic (platelet precursor) and monocytic lineages over the 
erythroid lineage (Emambokus et al 2003;Lu et al 2008). Consequently, accelerated 
erythropoiesis as a response to relatively low MYB levels generates prematurely 
terminated erythroid cells synthesising more HbF (Jiang et al 2006). Thus, modulations 
in MYB levels could well underlie the variation in erythroid, platelet and monocyte 
counts as well as HbF levels associated with HMIP. 
Increased number of monocytes present with +/+ individuals can also promote 
accelerated maturation of erythroid precursors. It is known that macrophages are 
involved in erythroid development in vivo in the bone marrow by interacting with 
erythroid precursors in so called erythroblastic island consisting of a central 
macrophage surrounded by erythroblasts (Chasis and Mohandas, 2008).  
In vitro studies have demonstrated that macrophages promote proliferation and 
maturation of erythroid precursors in serum free cultures (Leimberg et al 2005) and 
macrophages have been shown to express erythroid potentiating cytokines 
(Bergamaschi et al 1993) including erythropoietin (Vogt et al 1989). 
Our second objective was to harvest erythroid material for transcription factor binding 
experiments to investigate altered transcription factor binding. To ensure that we 
harvest the erythroid progenitor cells from the +/+ and -/- individuals at equivalent 
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stages of gene expression we initially obtained a profile of gene expression in cells 
from individuals of both genotypes. Expression profiles suggested that day 9 or 10 
would be optimal since GATA-1 and KLF1 are highly expressed at these days. Also 
there is no significant difference between individuals of different genotypes in terms of 
expression. As validation the cells were also closely monitored by FACS analysis as 
previously described. In performing ChIP on erythroid progenitor cells at similar stages 
of expression we ensure any difference observed in transcription factor binding is due 
to the alteration of binding by the SNPs and not because of differential expression of 
transcription factors (Figure 3.9).  
 
Performing primary erythroid culture experiments proved to be challenging. I have 
noted some of the crucial steps for fellow colleagues during optimizations stages: 
 
• Reagents with biological backgrounds should be batch tested. 
• Most reagents are fragile and should be kept in frigde once thawed; yet the 
reagents should not be kept in the fridge for more than a month. 
• Media volumes are also critical and evaporation of medium should not be 
ignored when media volumes are decided. 
• Cell concentrations vary accorrding to the phase of culture. Cells are incubated 
at high cell concentrations at phase I to trigger cell interactions while cell 
concentration should be lower in phase II to enable efficient prolifereation. 
I have decided to use the three phase culture system after trying all three culture 
systems because of the following advantages: 
• This system yields better cell numbers allowing the use of a smaller volume of 
blood and the harvest of the cells at different stages. 
• Introduction of EPO at phase I induces proliferation leading to a shorter time 

































The chromosome 6q locus consists of a large number of single nucleotide 
polymorphisms (SNPs). To enable us in determining the key regulatory elements more 
efficiently for transcription factor binding studies we have performed in-silico predictions 
for potential regulatory regions  
4.1.1 Chromosome 6q QTL 
 
The QTL on chromosome 6q23 was identified by linkage analysis in an extended Asian 
family with β-thalassaemia. The 6q QTL exists as a set of single nucleotide 
polymorphisms (SNPs) spanning a region of ≈ 79kb that includes the intergenic region 
5i ofMYB and HBS1L genes.The SNPs are distributed in three linkage disequilibrium 
(LD) blocks referred to as HBS1L –MYB intergenic polymorphism (HMIP ) blocks 1, 2, 
and 3. The 3 blocks completely account for the HbF variance attributed to the 6q QTL 
with SNPs in block 2 (24kb) showing the strongest effect and accounting for the 
majority of the variance. To direct us to the important spots for transcription factor 
binding studies in the chromosome 6q we seek aid from in silico experiments. 
 
4.1.2  Transcription factor prediction tools 
 
Transcription factor prediction tools are an important area of computational biology 
which enables us to delineate binding sites that are not reported previously. 
Computational methods to identify transcription factor binding sites were developed 
based on consensus sequences or Positional weight matrix (Quandt et al 1997). 
Positional weight matrix (PWM) is a model used to describe the sequence pattern of 
binding sites. As more transcription factors and their binding sites are experimentally 
identified, databases storing transcription regulation information were established, such 
as TRANSFAC, and TRRD. Consensus sequences were used to describe the 
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sequence patterns of cis-elements, and later PWMs were developed to describe the 
sequence motifs more precisely. Most of the prediction tools use the TRANSFAC 
database as the main matrix database for their predictions. 
4.2Results 
 
4.2.1 Sequence Analysis 
 
Two individuals, one homozygous for the for the haplotype associated with high HbF 
across the 6q QTL (blocks 1, 2 and 3), designated as HPFH +/+ and another, 
homozygous for the absence of the SNPs associated with increased HbF levels, 
designated as HPFH -/- were selected for resequencing of a 30kb region that 
encompasses HMIP block 2 (HMIP-2) (Figure 4.1). Sequence analysis revealed that 
there were fifty five variants that differ between the HPFH +/+ and the HPFH -/- 
individuals. Table 4.1 is a list of the different SNPs between the two individuals. The 
HPFH +/+ individual was homozygous for all the SNPs while the HPFH -/- individual 
was homozygous for some but heterozygous for the other SNPs.  The sequencing 
experiments were performed by colloborators at CNG (France). 
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135,440,936 CT CC C rs7763883 
135,442,805 CG CC C rs9389264 
135,443,064 CT CC C rs41294854 
135,444,032 TT CC T rs9399136 
135,444,782 CG CC C c6_snp1 
135,444,837 CG GG G c6_snp2 
135,445,317 CT CC C rs6914564 
HMIP block 2
135,445,512 CT TT T rs9373123 
135,445,564 CT CC C CNG discovered
135,445,620 CT TT T c6_snp3 
135,445,805 AG GG G c6_snp4 
135,447,871 TT GG T rs1331309 
135,447,876 T- GG G rs9402682 
135,448,373 TT CC T c6_snp5 
135,448,491 AT TT T rs9402683 
135,450,165 GT GG G c6_snp6 
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135,450,809 AG AA A rs6913541 
135,452,921 TT CC T rs9376090 
135,453,430 GT GG G rs9389266 
135,454,075 CT CC C rs52090905 
135,454,329 CT TT T rs52090906 
135,455,762 CG CC C rs52090907 
135,455,902 AG GG G rs56076748 
135,456,486 AG AA A rs9494139 
135,456,543 AG GG G rs55731938 
135,456,901 AA GG G rs2210366 
135,459,153 GT GG G CNG discovered
135,460,328 CC -- C
rs7775698 or 
rs66650371 
135,460,330 TAG  ---/--- TAG rs67449035 
135,460,609 AA GG A rs7776054 
135,460,711 TT CC T rs9399137 
135,460,731 CC -- C rs11321816 
135,460,732 CC AA C rs56293029 
135,460,735 GG AA G rs35786788 
135,460,947 CT TT T rs41294862 
135,461,324 AA GG A rs9389268 
135,461,329 CC TT C rs9376091 
135,461,381 TT CC T rs9402685 
135,462,591 AA TT A rs11969203 
135,462,869 CC TT C rs34164109 
135,463,989 AA TT A rs11759553 
135,464,902 TT CC T rs9373124 
135,465,872 CC GG C rs35959442 
135,465,896 GG TT G rs6930223 
135,468,251 AA TT A rs4895440 
135,468,266 AA GG A rs4895441 
135,468,837 CC AA C rs9376092 
135,468,852 TT CC T rs9389269 
135,469,510 GG AA G rs9402686 
135,470,230 AA CC A rs7758845 
135,473,011 TT CC T rs6920211 
135,473,192 GG AA G rs55936352 
135,473,333 TT CC T rs9494142 
135,474,245 TT CC T rs9494145 
HMIP block 3
135,474,576 TT CC T rs7766963 
135,477,194 TT CC T rs9483788 
135,477,547 TT AA T rs56222584 
Table 4-1: HMIP-2 SNPs that were revealed by sequence analysis 
 
  115
4.2.2 Transcription Factor Predictions at Chromosome 6q QTL 
 
Transcription factor prediction tools (Matinspector and Consite) were used to predict 
transcription factor binding sites around the SNPs. Matinspector use the TRANSFAC, 
while Consite use Jaspar database. Initial predictions were performed using 
Matinspector with all SNPs. Consite was used as the second prediction tool to confirm 
binding of MYB , GATA-1 and TAL1 transcription factors around key SNPs. 
 
Further comparison of predicted binding sites in the presence or absence of the 
implicated minor allele of the SNPs was performed to investigate if the SNPs alter 
binding of any transcription factors. 25 base pairs of sequences flanking the SNPs 
were included in the prediction tools and a high dissimilarity threshold was chosen to 
prevent irrelevant results. 
 
4.2.2.1 Transcription Factor Prediction using Matinspector 
 
Matinspector of genomatix site was used as the main tool for predicting transcription 
factor binding site. Matinspector is a software tool that utilizes a large library of matrix 
descriptions for transcription factor binding sites to locate matches in DNA 
sequences.The algorithm of Matinspector was used to calculate the matrix similarity 
with TRANSFAC matrices (TRANSFAC 6.0 public). The matrix similarity thus 
calculated will range from 0 to 1. A higher score indicated higher similarity between the 
sequence scanned and the sequence pattern represented in TRANSFAC matrix 
(Zhenget al2003).Mismatches in highly conserved positions of the matrix decrease the 
matrix similarity more than mismatches in less conserved regions. Matrix similarity 
threshold was set high for a robust and more stringent interpretation since setting the 
threshold low will lead to excessive amount of matches and higher number of false 
positives. Predictions were made for all transcription factor families in the matrix 
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(TRANSFAC 6.0).The same protocol was repeated with the reference sequence. The 
raw results were compared to see if any transcription factor binds differentially to the 
sequences in the presence and the absence of the minor allele of the SNPs.  
 
Any major difference affecting matrix similarity was presented as demolishment of 
binding site enabling detection of differential binding. Table 4.2 shows some of the key 
transcription factors predicted in close proximity to the SNPs. Two regions that include 
key transcription factors are highlighted and will be discussed in detail (Figure 4.2). 
Transcription Factor predictions from Matinspector




Core promoter initiator elements 
135,442,805 rs9389264 
Homeodomain transcription factors 
Homeobox transcription factors 
135,443,064 rs41294854 NKX homeodomain factors
135,444,032 rs9399136 
Cellular and viral myb-like transcriptional regulators
Krueppel like transcription factors 
135,444,782 c6_snp1 
SOX/SRY-sex/testis determining and related 
HMG box factors 
 
Brn POU domain factors 
135,444,837 c6_snp2 PAX-2 binding sites
135,445,317 rs6914564 
GATA binding factors












MEF2, myocyte-specific enhancer binding factor 
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135,445,805 c6_snp4 
 Homeobox transcription factors 
DM domain-containing transcription factors 
135,447,871 rs1331309 C-abl DNA binding sites
135,447,876 rs9402682 C-abl DNA binding sites
135,448,373 c6_snp5 
Human acute myelogenous leukaemia 
factors(RUNX) 
135,448,491 rs9402683 
Hepatic Nuclear Factor 1
Homeobox transcription factors 




Nuclear factor of activated T-cells 




Growth factor independence transcriptional 
repressor 
135,454,075 rs52090905 
Nuclear factor of activated T-cells 
Myeloid zinc finger 1 factors 
135,455,902 rs56076748 MAF and AP1 related factors
135,456,486 rs9494139 Brn POU domain factors
135,456,543 rs55731938 
Hepatic Nuclear Factor 1
Brn POU domain factors 
135,456,901 rs2210366 
Krueppel like transcription factors 




 Hepatic Nuclear Factor 1
 





 Hepatic Nuclear Factor 1, Twist subfamily of class 
B bHLH transcription factors, GATA binding 
factors, Human acute myelogenous leukaemia 
factors 
135,460,330 rs67449035  GATA binding factors
135,460,609 rs7776054 
 SOX/SRY-sex/testis determining and related HMG 
box factors 
POZ domain zinc finger expressed in B-Cells 
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135,460,711 rs9399137 
 Cellular and viral myb-like transcriptional 
regulators, Hepatic Nuclear Factor 1 
Brn-5 POU domain factors 
135,460,731 rs11321816  Cellular and viral myb-like transcriptional regulators
135,460,732 rs56293029  Cellular and viral myb-like transcriptional regulators
135,460,735 rs35786788  Cellular and viral myb-like transcriptional regulators
135,460,947 rs41294862 
 Hepatic Nuclear Factor 1
SOX/SRY-sex/testis determining and related HMG 
box factors 
135,461,324 rs9389268 
 Human acute myelogenous leukaemia factors
Krueppel like transcription factors 
Cellular and viral myb-like transcriptional 
regulators 
135,461,329 rs9376091  Human acute myelogenous leukaemia factors
        
135,461,381 rs9402685 
Krueppel-like C2H2 zinc finger factors 
hypermethylated in cancer 
135,462,591 rs11969203  Vertebrate TATA binding protein factor 
135,462,869 rs34164109  MAF and AP1 related factors
135,463,989 rs11759553  RXR heterodimer binding sites 
135,464,902 rs9373124  Brn POU domain factors 
135,465,872 rs35959442  Heat shock factors
135,465,896 rs6930223  Vertebrate TATA binding protein factor 
135,468,251 rs4895440  Nuclear factor kappa B/c-related  
135,468,266 rs4895441  NKX homeodomain factors
135,468,837 rs9376092 
SOX/SRY-sex/testis determining and related HMG 
box factors ,Brn-5 POU domain factors 
135,468,852 rs9389269 
SOX/SRY-sex/testis determining and related HMG 
box factors 
135,469,510 rs9402686  Heat shock factors
135,470,230 rs7758845 
 cAMP-responsive element binding proteins 
E-box binding factors 
-71 kb hot spot** 
135,473,011 rs6920211 
Nuclear receptor subfamily 2 factors 
Octamer binding protein 
135,473,192 rs55936352 Cellular and viral myb-like transcriptional 
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Table4-2: Key transcription factors predicted in close proximity to the SNPs 
within  the 3 HMIP blocks. 
* = There are two SNPs located at chromosome 6 135,460,328. First one is a 3bp 
deletion rs66650371 (TAC/ ---) and the other one is rs7775698 (T/A). I have performed 
the predictions with rs66650371 (TAC/ ---). 
** = -71kb and -84kb are two hot spots that are homologous to the key transcription 
factor binding regions in mouse demonstrated by Stadhouderset al. These regions also 
coincide with DNase I hypersensitive sites and GATA-1 sites previously detected by 
our group (Wahlberg et al 2009). 
The tracks of high scoring SNPs prepared by Stephen Menzel was uploaded and 
viewed on the online UCSC genome browser (genome.ucsc.edu).  
This provides a more detailed view of the region, with the flexibility of viewing SNP 
tracks, conserved transcription factor binding sites, hypersensitive regions, as well as 
many other tracks available, all in the same view.  Tracks of the GATA-1 peaks at the 
6q23 locus and surrounding area prepared by fellow students Karin Wahlberg and 
Kiran Jawaid were uploaded together for ease of orientation. Transcription factor 
predictions by Matinspector highlighted some SNPs which altered the binding of key 
transcription factors. Some key SNPs were located in two hotspots 71 kb and 84 kb 
away from MYB gene transcription start site and coincided with GATA-1 binding peaks 
detected by ChIP-chip experiments and intergenic transcripts as well as Dnase 
hypersensitive sites (Figure 4.2). 
regulators
135,473,333 rs9494142  GATA binding factors
135,474,245 rs9494145  Ras-responsive element binding protein 
135,474,576 rs7766963  PAX-2 binding sites
HMIP block 3
135,477,194 rs9483788  MEF2, myocyte-specific enhancer binding factor
135,477,547 rs56222584 
 GATA binding factors
EVI1-myleoid transforming protein 
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SNPs rs66650371, rs9393137 rs9389268 and rs9376091 were located around -84kb 
encompassing a region around 1kb (Figure 4.2 B). SNPs rs55936352 and rs9494142 
were located around -71kb encompassing a region around 500bp (Figure 4.2 C). 
Figures 4.3 to 4.7 will focus on some of these important SNPs. The sequences of 
SNPs with flanking sequences are provided in the figures. Predicted sites for some 
important transcription factors are also highlighted. Tables 4.3 to 4.7 provide the 
prediction scores from the matinspector for the important factors around the mentioned 
SNPs.  
 
Matinspector results suggested altered binding of MYB, KLF1 and AML (RUNX) around 
SNPs rs9389268 andrs9376091.  Results also suggested altered binding of MYB 
around SNPs rs9393137 and rs55936352. GATA-1 binding motifs were predicted 
around SNPs rs66650371 and rs9494142 but matinspector prediction did not suggest 
disruption of GATA-1, TAL1 or AML binding motifs in the presence of the alternative 
alleles of these SNPs. 
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Figure4.2: Location of key SNPs 
A: The key SNPs are located in two regions within block 2, around -84kb and -71kb 
away from the transcription start site of MYB gene, respectively.-71kb and -84kb are 
two hot spots that are homologous to the key transcription factor binding regions in 
mouse demonstrated by Stadhouders et al. In mouse LDB1 complexes which include 
GATA-1 and KLF1 transcription factors bind to these sites. 
B: Gata-1 Peak 3 from previous ChIP-chip experiments.  Peak 3 is 84 kb away from the 
MYB transcription start site (-84kb) Conserved GATA motifs, predicted transcription 
factor motifs and high scoring SNPs are found in close proximity. 
C: Gata-1 Peak 4 from previous ChIP-chip experiments.  Peak 4 is 71 kb away from 
the MYB transcription start site (-71kb) Conserved GATA motifs, predicted transcription 
factor motifs and high scoring SNPs are also found in close proximity. 
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4.2.2.2 Transcription Factor Predictions using Consite 
 
Initial transcription factor predictions using matinspector highlighted some SNPs which 
altered the binding of transcription factors. Some of the critical SNPs were reassessed 
using another tool called Consite. The profile collection in Consite is drawn from the 
JASPAR database, another open-access, non-redundant collection of curated profiles. 
The objective of this prediction was to confirm MYB, GATA-1, TAL1 and KLF1 sites 
that were predicted by matinspector. Matrices belonging to transcription factors (GATA-
1, TAL1, and MYB) were presented to Consite. However, KLF transcription factor 
family was not present in the matrices available in which case I had to depend on 
preliminary results from initial predictions by matinspector.  
 
Table 4.8 shows transcription factor prediction results using the consite tool around 
SNPs rs9389268 and rs9376091. Initial predictions by matinspector suggested that 
MYB, KLF and RUNX binding is altered by the minor alleles of SNPs (Table 
4.3).Consite also suggested that MYB binding is altered by the minor alleles of the 
SNPs rs9389268 and rs9376091 (Table 4.8) but failed to provide support for altered 
KLF1 and AML-1 binding. KLF family matrices were not available at Consite when 
predictions were performed and the difference in AML binding with major and minor 
alleles is not significant (0.830 compared to 0.810). Table 4.9 shows transcription factor 
prediction results using the consite tool around rs66650371. Both of the predictions 
tools suggested that none of the binding motifs for key transcription factors  such as 
TAL-1 , GATA-1 and AML are altered significanlty by the 3bp deletion (rs66650371). 
Matinspector predicted that binding of Hepatic Nuclear Factor 1 (HNF1) to the 3bp 
deletion site (rs66650371) is altered but the result is not supported by the Consite 






SNPs rs9389268 and rs9376091      SNPs rs9389268 and rs9376091 
 HPFH -/-         HPFH +/+ 
 
 chr6:135,461,300    chr6 135,461,341                 chr6:135,461,300   chr6 135,461,341 
 
 
 Cellular and viral myb-like transcriptional regulators      Cellular and viral myb-like transcriptional regulators 
V$CMYB.01           V$CMYB.01  
Rs9389268 (G/A)        Rs9389268 (G/A) 
   
  
       CTGAGATTACAGGCGCATGCAACCACACCCGACTAATTTTT                                              CTGAGATTACAGGCGCATGCAACCGCACCTGACTAATTTTT 
       GACTCTAATGTCCGCGTACGTTGGTGTGGGCTGATTAAAAA          GACTCTAATGTCCGCGTACGTTGGCGTGGACTGATTAAAAA 
 
KLF.01  Rs9376091 (T/C)                      KLF.01  Rs9376091 (T/C) 
       Krueppel like transcription factors                Krueppel like transcription factors 
 
Figure4.3: Binding sites for key transcription factors around SNPs rs9389268 and rs9376091. 
Letters in red represents the core binding sequence for MYB (CAAC-G) which is altered in the HPFH -/- genotype. Letters in blue represents the core binding sequence for KLF1 















Table4-3: Transcription Factors around the SNPs rs9389268 and rs9376091 and the binding site prediction scores for the HPFH +/+and HPFH -/- haplotypes. 
Prediction scores are from matinspector where the minimum similarity threshold was set to 0.700 so transcription factors with a similarity less than this threshold was not shown 
in the raw data. Their prediction scores was presented as <0.700 because of this.  
           
 Matinspector  Predictions for  Transcription Factor  Binding Sites 
Matrix 













Human acute myelogenous 
leukaemia factors 
 
GTGG <0.700 0.903 
V$KLFS 




V$BRNF Brn POU domain factors TAAT <0.700 0.894 
V$MYBL 
Cellular and viral myb-like 
transcriptional regulators 
 
CAAC-G 0.904 <0.700 
V$HAND 
Twist subfamily of class B 













SNP rs66650371        SNP rs66650371 
HPFH +/+        HPFH -/- 
 
chr6:135,461,300     chr6 135,461,399  chr6:135,461,300    chr6 135,461,399 
 
 
                           Hepatic Nuclear Factor 1       Hepatic Nuclear Factor1 
V$TAL1.01V$HNF1.01        V$TAL1.01V$HNF1.01     
 
 
TGGACAGCAGATGT---TATATCAAAACCACAAAATGTTATCAGGGC                                     TGGACAGCAGATGTTACTATATCAAAACCACAAAATGTTATCAGGGC 
ACCTGTCGTCTACA---ATATAGTTTTGGTGTTTTACAATAGTCCCG                                       ACCTGTCGTCTACAATGATATAGTTTTGGTGTTTTACAATAGTCCCG 
 
 3bp deletion   V$GATA3.02       3bp deletion       V$GATA3.02  V$GATA1.04 
 GATA binding factors                GATA binding factors (conserved)   GATA binding factors   GATA binding factors (conserved) 
    V$AML3.01            V$AML3.01 
 Human acute myelogenous leukemia factors       Human acute myelogenous leukemia factors 
 
 
Figure 4.4: Binding sites for key transcription factors around 3bp deletion (rs66650371). 
The core binding sequences for some transcription factors are highlighted and demolishment of core sequence for Hepatic Nuclear Factor 1(HNF1) in the HPFH +/+genotype can 
be observed. 
 
Table 4-4: Transcription Factors around the SNP rs66650371 and the binding site prediction scores for the HPFH +/+and HPFH -/- haplotypes. 
Prediction scores are from matinspector where the minimum similarity threshold was set to 0.700 so transcription factors with a similarity less than this threshold was not shown 
in the raw data. Their prediction scores was presented as <0.700 because of this. 
 Matinspector  Predictions for  Transcription Factor  Binding Sites 
Matrix Family Detailed Family Information Matrix 
 
 
















V$GATA GATA binding factors V$GATA3.02 AGAT 0.910 0.910 
V$HNF1 Hepatic Nuclear Factor 1 V$HNF1.01 GTTA <0.700 0.812 
V$HAML 













SNP Rs9494142 HPFH -/-           SNP Rs9494142 HPFH +/+  
Chr6135473308     Chr6135473358      Chr6135473308     Chr6135473358 
   Rs9494142-GATA-1 KLF1    Rs9494142-GATA-1 KLF1 
  AGTCAATTCGATTCTACTACTGACATTTATCAACATGGTGGGTGTGATATC      AGTCAATTCGATTCTACTACTGACACTTATCAACATGGTGGGTGTGATATC 





Figure4.5: Binding sites for key transcription factors around SNP Rs9494142. 



















Table4-5:Transcription Factors around the SNP Rs9494142 and the binding site prediction scores for the HPFH +/+and HPFH -/- haplotypes. 
Prediction scores are from matinspector where the minimum similarity threshold was set to 0.700 so transcription factors with a similarity less than this threshold was not shown 
in the raw data. Their prediction scores was presented as <0.700 because of this. Transcription factor prediction suggested that GATA-1 binding was not altered significantly by 
Rs9494142.  
Matinspector  Predictions for  Transcription Factor  Binding Sites
Matrix 
Family Detailed Family Information Matrix 
Prediction 
Score 










V$TALE TALE homeodomain class recognizing TG motifs V$TGIF.01 1.000 1.000 
V$NKXH NKX homeodomain factors V$BAPX1.01 0.877 0.700> 
V$RUSH 
SWI/SNF related 
nucleophosphoproteins with a 
RING finger DNA binding motif 
V$SMARCA3.02 0.986 0.968 
V$GATA GATA binding factors V$GATA1.03 0.954 0.917 
V$YY1F Activator/repressor binding to transcription initiation site V$YY1.02 0.955 0.955 




   
SNP Rs55936352 (HPFH -/-) genotype    SNP Rs55936352 (HPFH +/+) genotype    
 Chr6 135,473,167                    Chr6 135,473,217    Chr6 135,473,167                           Chr6 135,473,217 
    Rs55936352-MYB         Rs55936352-MYB 
GCACATCTGCCAGTGACCTCTGTCTGTTACTGAAGAAGGCTGCTGGCTTCT    GCACATCTGCCAGTGACCTCTGTCTATTACTGAAGAAGGCTGCTGGCTTCT 
CGTGTAGACGGTCACTGGAGACAGACAATGACTTCTTCCGACGACCGAAGA  CGTGTAGACGGTCACTGGAGACAGATAATGACTTCTTCCGACGACCGAAGA 
 
Figure4.6: Binding sites for key transcription factors around SNP Rs55936352. 






















Table4-6: Transcription Factors around the SNP Rs55936352 and the binding site prediction scores for the HPFH +/+and HPFH -/- haplotypes. 
Prediction scores are from matinspector where the minimum similarity threshold was set to 0.700 so transcription factors with a similarity less than this threshold was not shown 
in the raw data. Their prediction scores was presented as <0.700 because of this. Results suggest differential binding to MYB one of our key transcription factors. 
Matinspector  Predictions for  Transcription Factor  Binding Sites
Matrix 
Family Detailed Family Information Matrix 
Prediction 
Score 










V$RORA v-ERB and RAR-related orphan receptor alpha V$REV-ERBA.01 0.891 0.891 
V$NR2F Nuclear receptor subfamily 2 factors V$HNF4.03 0.864 0.860 
V$NBRE NGFI-B response elements, nur subfamily of nuclear receptors V$NBRE.01 0.867 0.867 
V$RXRF RXR heterodimer binding sites V$RAR_RXR.01 0.830 0.830 
V$CART Cart-1 (cartilage homeoprotein 1) V$PHOX2.01 0.891 0.700> 
V$FAST FAST-1 SMAD interacting proteins V$FAST1.01 0.838 0.700> 
V$PBXC PBX1 – MEIS1 complexes V$PBX1_MEIS1.02 0.772 0.700> 
V$MYBL Cellular and viral myb-like transcriptional regulators V$CMYB.02 0.700> 0.961 







SNP Rs9399137 (HPFH -/-) genotype 
 
chr6:135460686             chr6:135460735 
 








Figure4.7: Binding sites for key transcription factors around SNP rs9399137. 
















Table4-7: Transcription Factors around the SNP Rr9399137 and the binding site prediction scores for the HPFH +/+and HPFH -/- haplotypes. 
Prediction scores are from matinspector where the minimum similarity threshold was set to 0.700 so transcription factors with a similarity less than this threshold was not shown 
in the raw data. Their prediction scores was presented as <0.700 because of this. Results suggest differential binding of MYB one of our key transcription factors.
Matinspector  Predictions for  Transcription Factor  Binding Sites
Matrix 











V$HNF1 Hepatic Nuclear Factor 1 V$HNF1.04 0.912 0.912 
V$MYBL Cellular and viral myb-like transcriptional regulators V$CMYB.02 0.969 0.969 
V$MYBL Cellular and viral myb-like transcriptional regulators V$VMYB.01 0.700> 0.883 
V$PLZF C2H2 zinc finger protein PLZF V$PLZF.01 0.700> 0.874 
SNP Rs9399137 (HPFH +/+) genotype 
 
chr6:135460686                                  chr6:135460735 
 

























leukaemia factors 0.810 0.830 
V$MYBL 
Cellular and viral 
myb-like 
transcriptional 
regulators 0.920 0.770 
 
Table 4-8: Binding sites for transcription factors around the SNPs rs9389268 and 




Transcription Factor Predictions from Consite (Jaspar) for SNP  















Twist subfamily of 
class B bHLH 
transcription factors 0.910 0.890 
V$GATA 
GATA binding 




leukaemia factors 1.000 1.000 
V$GATA 
GATA binding 
factors 0.840 0.840 
 
Table4-9: Binding sites for transcription factors around the SNP rs66650371 and 










Resequencing of a 30kb region that encompasses block 2 SNPs at chromosome 6q 
QTL revealed 55 SNPs that differ between the high F and low F individuals. To direct 
functional investigation of all the key SNPs, we utilized in-silico tools. Computational 
predictions have been successfully utilized for suggesting potential regulatory regions 
for further experimental analysis enabling researchers to determine key regulatory 
elements more efficiently. 
 
Matinspector of genomatix site was used as the main tool for predicting transcription 
factor binding sites. Predictions were performed to investigate presence of transcription 
factors binding motifs and to investigate if alternative alleles at these transcription 
factor binding motifs would affect binding. To reduce false positives, SNPs with 25 
base pairs of flanking sequences were included in the prediction tools. This increases 
the stringency of detection since transcription-factor binding sites (TFBSs) are usually 
short (around 5-15 base-pairs); thus potential binding sites can occur very frequently. 
Matrix similarity threshold was also set to further increase the stringency since setting 
the threshold low will lead to excessive amount of matches. 
 
Matinspector predicted 277 transcription factor binding sites around 55 SNPs, 64 of 
which were altered when the minor allele is present. Table 4.2 demonstrates some of 
the key transcription factors that are predicted in close proximity to the SNPs. 
Matinspector highlighted some SNPs which altered the binding of key transcription 
factors.  
 
The key SNPs were located at regions located at 71 kb and 84 kb away from the MYB 
gene transcription start site. These sites were designated as hotspots because they 
coincided with GATA-1 binding peaks detected by previous ChIP-chip experiments, 
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intergenictranscripts, Dnase hypersensitive sites. In the mouse the homologous 
regions of these sites were bound by LDB1 transcription complexes which include key 
transcription factors like KLF1, GATA-1. These complexes have a key role in the 
interaction of intergenic region with the MYB gene promoter (Figure 4.2). 
Consite prediction tool was used to validate initial predictions around SNPs rs9389268, 
rs9376091 and rs66650371 only with selected transcription factor families (MYB, 
GATA, AML, and TAL1). A total of 6 binding sites were predicted around 3 SNPs, 1 of 
which was altered when the minor allele is present. 
 
There are two SNPs located at chromosome 6 135,460,328. The first is a deletion of 
3bp designated as rs66650371 (TAC/ ---) and the other is SNP rs7775698 (T/A). I have 
performed the predictions with rs66650371 (TAC/ ---). Both of the predictions tools 
suggested presence of binding motifs for key transcription factors  such as TAL-1 , 
GATA-1 and AML in close proximity of the 3bp deletion (rs66650371); but failed to 
suggest that these binding motifs are altered significantly since the deletion is not in the 
core motif of any transcription factor. Matinspector predicted demolishment of binding 
motif for Hepatic Nuclear Factor 1 (HNF1) but HNF1 is not a recognized transcription 
factor in gene regulation. 
Presence of GATA-1 binding sites at -84kb was also suggested by Farrell et al but the 
study did not suggest disruption of key transcription factor binding motifs; instead they 
suggested that the region has enhancer activity and the enhancer potential is disrupted 
by the variants (Farrell et al 2011).Stadhouders et al demonstrated that they are LDB1 
binding sites at -71kb and at -84 kb suggesting that LDB1 complexes including GATA-1 
and TAL1 transcription factors are binding to these  It is possible that the 3bp deletion 
rs66650371 at -84kb affect the spacing between these motifs leading to altered binding. 
Various studies have reported that spacing between TF binding motifs within enhancer is 
crucial for optimal binding of transcription factors which was investigated using EMSA 
(Chapter 5) and ChIP (Chapter 6) experiments. 
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Matinspector suggested the presence of MYB and KLF1 binding sites in close proximity 
to SNPs rs9389268 and rs9376091. The two SNPs are only 4 base pair from each 
other and genetic studies suggested that they are linked so I did not perform separate 
predictions for each SNP. Further predictions suggested that binding motifs of these 
transcription factors are altered in the presence of minor alleles.  Differential binding of 
MYB was also confirmed by Consite prediction tool. MYB and KLF1 are crucial 
transcription factors and altered binding of any of them can potentially lead to 
differential regulation of flanking genes: MYB or HBS1L.Transcription factor binding to 
this region was further investigated using EMSA (Chapter 5) and ChIP (Chapter 6) 
experiments.Matinspector prediction tool also suggested the presence of GATA-1  
binding motifs in close proximity of  the SNP rs9494142 but failed to suggest that this 
binding motif is altered significantly when the alternative allele is present.  Previous 
ChIP-chip experiments demonstrated presence of GATA-1 binding to this region and 
suggested altered binding of GATA-1 in individuals who are homozygous for the minor 
allele of SNP rs9494142. There is also another conserved GATA-1 site at ~100bp 
away from the SNP. Previous studies suggested that GATA-1 can bind as a dimer and 
thus this SNP could potentially affect the dimer binding to this region. Transcription 
factor binding to this region was further investigated using EMSA (Chapter 5) and ChIP 
(Chapter 6) experiments.Matinspector prediction tool suggested presence of two  MYB  
binding motifs in close proximity of  the SNP rs9399137. Predictions suggest that one 
of the binding motifs is altered significantly when the minor allele of SNP is present. 
Another MYB binding site was also predicted in close proximity of  the SNP 
rs55936352. Predictions suggest that one of the binding motifs is altered significantly in 
the presence of the minor allele of the SNP.  As discussed before, MYB is a crucial 
transcription factor so transcription factor binding to these regions were further 
investigated using ChIP (Chapter 6) experiments. 
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5 INVESTIGATION OF TRANSCRIPTION FACTOR BINDING AT 




























Prediction of transcription factor binding performed on all SNPs in 6q intergenic region 
showed that binding sites of some important transcription factors were altered by key 
SNPs in the region. We wanted to investigate binding of these predicted transcription 
factors in vitro using electrophoresis mobility shift assays (EMSA). 
5.1.1 Chromosome 6q QTL 
 
The QTL on chromosome 6q23 was identified by linkage analysis in an extended Asian 
family with β-thalassaemia through the proband who had very mild thalassaemia 
intermedia despite being homozygote for the β0 thalassaemia with the complete 
absence of HbA. The extended family was large enough to perform linkage analysis, 
which mapped the HbF locus to a region spanning 1.5 Mb on chromosome 6q23. The 
6q HbF QTL was validated in the large panel of European twins. Higher resolution 
genotyping refined the locus to a region of 79 kb between the HBS1L and MYB gene. 
The analysis revealed that this was a major QTL which accounted for 35% of total F-
cell variance in the family (Thein et al 1994).  
 
The 6q QTL exists as a set of single nucleotide polymorphisms (SNPs) spanning a 
region of ≈ 79kb that includes the intergenic region 5i to MYB and HBS1L and  5i  part 
of the HBS1L gene.The SNPs are distributed in three linkage disequilibrium (LD) 
blocks referred to as HBS1L –MYB intergenic polymorphism (HMIP ) blocks 1, 2, and 
3. The 3 blocks completely account for the HbF variance attributed to the 6q QTL with 
SNPs in block 2 (24kb) showing the strongest effect and accounting for the majority of 
the variance.  
 
Recent work by our group indicated the presence of regulatory elements in HBS1L-
MYB intergenic region (HMIP) evidenced by GATA-1 binding coinciding with strong 
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histone acetylation, RNA polymerase II activity, and erythroid specific Dnase I 
hypersensitive sites (Wahlberg et al2009). 
 
Genetic studies and resequencing of two key individuals from the family that led to 
discovery of 6q QTL revealed new SNPs in the HBS1L-MYB intergenic region.  
Prediction of transcription factor binding performed on all SNPs in 6q intergenic region 
showed that binding sites of some important transcription factors were altered by key 
SNPs in the region (Chapter 4). Figure 5.1 shows 4 key SNPs that were chosen for 
transcription factor binding investigation using electrophoresis mobility shift assays 
(EMSA). EMSAs using oligonucleotides encompassing these SNPs were carried out to 
demonstrate any differential transcription factor binding. 
 
Figure 5.1: Transcription factor binding investigation around four SNPs, 
three (rs66650371, rs9389268 and rs9376091) in the hot spot at -84kb and one 
(rs9494142)  in the hot spot at -71kb from the  transcription start site of MYB, were 
performed using EMSAs. The main transcription factors of interest were: GATA-1, MYB 
and KLF1.The SNPs are shown in red and core binding motifs of GATA-1 (TATATCA), 
MYB (CAACCG) and KLF1 (CACCC) are underlined. 
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5.1.2 Electrophoretic Mobility Shift Assays (EMSA) 
Electrophoresic mobility shift assay (EMSA) is a technique that is used for investigating 
protein-nucleic acid interactions. It is based on the observation that the electrophoretic 
mobility of a protein-nucleic acid complex is typically less than that of the free nucleic 
acid. The DNA is labelled to enable rapid detection and in its native state, it migrates 
quickly through the gel matrix. Protein binding slows the mobility of the protein-nucleic 
acid complexes that resolve as discrete bands. The method relies on the stability of the 
protein-DNA complexes when subject to non-denaturing polyacrylamide gel 
electrophoresis (Revzin et al 1989) (Figure 5.2). 
 
Different detection methods such as radioactive labelling, fluorescence, 
chemiluminescence and immunohistochemical labeling can be used in EMSAs. 
Oligonucleotides labelled with biotin were used in our experiments to provide sensitive 
detection of the protein-nucleic acid complexes.  
 
The mobility shift assay has a number of strengths. The basic technique is simple to 
perform, yet robust enough to accommodate a wide range of binding conditions.  
A wide range of nucleic acid sizes and structures are compatible with the assay, 
proteins ranging in size from small oligopeptides to transcription factor complexes can 
give useful mobility shifts and the assay works well with both highly purified proteins 
and crude cell extracts. These properties account in a large part for the continuing 
popularity of the assay.  EMSA provides an unbiased way to detect protein complexes 
binding to oligonucleotides but a candidate protein approach is still necessary in order 
to perform the EMSA experiments with the right crude nuclear extracts. Another major 
limitation of the EMSA experiments is the identification of proteins that are present in 
the protein complexes which requires additional steps that are not straight forward.  
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The electrophoretic “supershift” assay and assays that combine EMSA with western 
blotting or mass spectroscopy have been devised to allow identification of nucleic acid-
associated proteins. Another alternative to detect proteins present in the protein 
complex is competing the proteins out with unlabeled oligonucleotides that are known 
to be bound by the proteins of interest (Hellman and Fried 2007). 
 
 
We have performed the experiments using The LightShift Chemiluminescent EMSA Kit 
that uses a non-isotopic method to detect DNA-protein interactions. Biotin end-labelled 
DNA containing the binding site of interest is incubated with a nuclear extract or 
purified factor. The reaction is then subjected to gel electrophoresis on a native 
polyacrylamide gel and transferred to a nylon membrane. The biotin end-labelled DNA 
is detected using the Streptavidin-Horseradish Peroxidase Conjugate and the 
Chemiluminescent Substrate. 
 
Figure 5.2: Electrophoretic Mobility Shift Assays (EMSA). 
The difference in the electrophoretic mobility of free nucleic acid (lane1) and that bound 
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5.2.1Optimization of EMSA 
 
The Thermo Scientific LightShift Chemiluminescent EMSA Kit (Pierce) was used to 
optimize the EMSAs. The kit included nuclear extracts from EBNA cell lines where the 
control protein was highly expressed. Unlabelled and biotin labelled nucleotides were 
also provided. Binding reactions were prepared according to manufacturer’s 
instructions. Reactions without cold competitors were incubated at room temperature 
for 20 minutes. Cold competitions were performed by addition of 200 fold excess 
unlabelled oligo, incubated 5 minutes at room temperature followed by a further 20 
minute incubation at room temperature on addition of the biotin labelled oligonucleotide 
(Figure 5.3 and table 5.1). 
 
Figure 5.3: Cold competition EMSA assay 
 
Results showed the presence of a strong protein-nucleic acid complex ( Figure 5.4, 
lane 2 ) which is absent whenthe nuclear extract was not added (Figure 5.4, lane 
1).The protein-nucleic acid complex is successfully competed out by the cold 
competitor (Figure 5.4, lane 3). Free oligonucleotides can be observed in all three 
lanes. The result shows that binding conditions are appropriate for the following EMSA 
experiments and that the lightshift kit is applicable to our experiments. 
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Binding reactions for Control EBNA System. 
Component Final Amount Control Reactions 




Ultrapure Water ---- 12 μl 11 μl 9 μl 
10X Binding Buffer 
(20148A) 
1X 2 μl 2 μl 2 μl 
50% Glycerol 
(20148F) 
2.5% 1 μl 1 μl 1 μl 
100 mM MgCl2 
(20148I) 
5 mM 1 μl 1 μl 1 μl 
1 μg/μl Poly (dI•dC) 
(20148E) 
50 ng/μl 1 μl 1 μl 1 μl 
1% NP-40 (20148G) 0.05% 1 μl 1 μl 1 μl 
Unlabeled EBNA 
DNA (20148C) 
4 pmol ----- ----- 2 μl 
EBNA Extract 
(20148D) 
1 Unit ----- 1 μl 1 μl 
Biotin–EBNA Control 
DNA (20148B) 
20 fmol 2 μl 2 μl 2 μl 
Total Volume ---- 20 μl 20 μl 20 μl 
 
Table5-1: Binding Reactions for Figure 5.4. 
Three different binding reactions were prepared. The first reaction (negative control) 
was prepared without any extract. The second reaction was prepared with the extract 
provided with the kit. In the third reaction, unlabelled oligonucleotides were included as 





Figure5.4:Electrophoretic Mobility Shift Assays (EMSA). 
The difference in the electrophoretic mobility of a protein-nucleic acid complex (lane 2) 
and free nucleic acid (lane1) is demonstrated. The competition of the complex by 
unlabelled oligonucleotide shows specificity of the binding (lane3). 
 
5.2.2 Transcription factor binding at chromosome 6q 
 
In-silico predictions performed on all SNPs in 6q intergenic region showed that the 
binding sites of some important transcription factors including MYB, KLF1 and 
 GATA-1 were altered by the SNPs that had high association scores (Figure 5.1). 
 EMSAs using oligonucleotides encompassing these SNPs were carried out to 
demonstrate any differential transcription factor binding. 
 
Nuclear extracts used in the experiments were derived from K562 cells. Before setting 
up the EMSAs, western blots were performed to confirm presence of the transcription 
factor protein under investigation. 
 
      Lane1      Lane2    Lane3
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5.2.2.1 Transcription factor binding around rs9389268 (A/G) 
Initial experiments were performed with oligos designed for the site encompassing SNP 
rs9389268 (A/G) and included 10 bases flanking the MYB recognition site (CAACCG). 
This oligo unfortunately also encompassed another SNP Rs9376091 (T/C) and KLF 
binding site (GTGGG) (Figure 5.5). The “old-g” oligonucleotide encompassed a binding 
site for MYB but not for the KLF; while “old-a” oligonucleotide encompassed a binding 




Figure 5.5: EMSA oligonucleotides encompassing SNPs rs9389268 (A>G) 
highlighted in green and rs9376091(C>T) highlighted in red. 
 
Commercial MYB positive (TACAGGCATAACGGTTCCGTAGTGA) and MYB negative 
oligos (TACAGGCATATCGGTTCCGTAGTGA) were also used in the experiments. 
KLF1 positive and negative oligos were designed to encompass a known KLF1 binding 
site at the beta globin gene promoter. 
 
Experiments were performed under the same binding conditions from initial 
optimization experiments. Table 5.2 shows each binding reaction for Figure 5.6. 
 
 1 2 3 4 5 6 7 8 9 
 old-g oligonucleotide old-a oligonucleotide Myb+ oligonucleotide
Extract - K562 K562 - K562 K562 - K562 K562
Oligonucleotide old-g old-g old-g old-a old-a old-a Myb+ Myb+ Myb+
Competitor - - old-g - - old-a - - Myb+
 
Table 5-2: Binding Reactions for figure 5.6. 





                            MYB       KLF1
  old-g oligo 
 
CAGGCGCATGCAACCGCACCTGACT 







Figure5.6: Binding pattern of old-g, old-a, myb+ oligos with K562 nuclear extracts 
under binding conditions from table 5.2. 
Lane 1 and Lane 4 are negative controls with no nuclear extract; thus no protein-
nucleic acid complex is observed. Two specific protein-nucleic acid complexes are 
observed with both old-g and old-a oligonucleotides (X and Y) (Lane 2 and Lane 5, 
respectively) which are competed out with the presence of excess unlabelled 
oligonucleotide (Lane 3 and Lane 6, respectively). No specific protein-nucleic acid 
complex is observed with Myb+ oligonucleotide (Lane 8). 
This EMSA results demonstrates the presence of specific protein-nucleic acid 
complexes with old-g and old-a oligonucleotides (Lane 2 and Lane 5, respectively). The 
bands in yellow circles seem to be specific and competed out by excess unlabelled 
oligonucleotide. The top band(X) is weaker with old-g oligo while the band below (Y) is 
stronger in old-g oligo. No specific binding was observed with commercial Myb+ 
oligonucleotide, as evidenced by the lack of bands after being competed out by excess 
unlabelled competitor. This result suggests potential differential binding between old-g 
and old-a oligonucleotides but fails to demonstrate that differentially bound complexes 
  old-a oligo 
CAGGCGCATGCAACCACACCCGACT 
                           MYB       KLF1 
  old-g oligo 
CAGGCGCATGCAACCGCACCTGACT 
                            MYB       KLF1
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are related to MYB transcription factor. The lack of specific protein-nucleic acid 
complex with Myb+ oligonucleotide suggests binding conditions were not ideal.  
We tested three alternative binding conditions as the next step to select the best 
condition for future experiments (Table 5.3). 
Component Binding condition 1 Binding condition 2  Binding condition 3 
Ultrapure Water 9 μl 9 μl 8μl 
10X Binding Buffer  2 μl 2 μl 2 μl 
50% Glycerol  1 μl 1 μl 1 μl 
MgCl2  1 μl - 1 μl 
Poly (dI•dC) ) 1 μl 1 μl 1 μl 
1% NP-40 1 μl - 1 μl 
KCl - 1 μl - 
EDTA - 1 μl 1 μl 
K562 nuclear extract 3 μl 3 μl 3 μl 
Oligonucleotide 2 μl 2 μl 2 μl 
Total Volume 20 μl 20 μl 20 μl 
    
Table5-3: Three different binding conditions were prepared by alterations of KCL, 
EDTA, MgCl2, 1% NP-40 presence in the binding reaction. 
 
 1 2 3 4 5 6 7 8 9 10 
Extract K562 K562 K562 K562 K562 K562 K562 K562 K562 - 
Oligo old-g old-g old-g old-a old-a old-a Myb+ Myb+ Myb+ Myb+ 
Competitor - - - - - - - - - - 
Binding 
condition 
1 2 3 1 2 3 1 2 3 1 
Table 5-4: Binding Reactions for figure 5.7. 
Three different binding reactions were prepared for each oligonucleotide: old-g, old-a 
and Myb+ with variable binding conditions as indicated in table 5.3 (Binding condition 





Figure5.7: Binding pattern of old-g, old-a, Myb+ oligos with K562 nuclear extracts 
and variable binding conditions. 
Protein-nucleic acid complex (X) is observed with old-a, old-g and Myb+ 
oligonucleotides (lane 2 to lane 9) with all three binding conditions. Protein-nucleic acid 
complex (Y) is observed with old-a and Myb+ oligonucleotides under binding condition 
2 only. 
The titration exercise illustrated the importance of finding appropriate and optimal 
conditions in order to demonstrate the mobility shift for the different oligonucleotides. 
Each oligonucleotide had different binding patterns under different conditions. The 
oligonucleotide share a similar binding pattern when the experiments were performed 
under binding condition 3 (Lanes 3, 6 and 9) while different binding patterns were 
observed under alternative binding conditions (Lanes 2, 5 and 8).  
The presence of a strong band (X) common to old-g, old-a and Myb+ oligonucleotides 




                            MYB       KLF1
  old-g oligo 
CAGGCGCATGCAACCGCACCTGACT 
                            MYB       KLF1
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 A second band (Y) can be observed with the old-a and Myb+ oligonucleotides under 
the binding condition 2; however no band is observed with the old-g oligonucleotide, 
suggesting that an alternative MYB related complex can be present. This band is also 
absent under other binding conditions which suggest that the binding is not robust. I 
have decided to perform experiments using binding condition 2 in order to investigate 
any potential differential binding with the old-a and old-g oligonucleotides. 
5.2.2.1.1 Cold Competition EMSA 
The initial EMSA experiments suggested a subtle differential binding between old-a 
and old-g oligonucleotides (Figure 5.6 and 5.7). I then performed cold competition 
experiments to investigate if the binding was specific to MYB or KLF1. The cold 
competition experiments were performed using excess unlabelled oligonucleotides that 
encompassed consensus binding sequences of MYB and KLF1. Each cold competitor 
was added to the binding reactions separately to validate binding specificity. 
Competition was repeated with oligonucleotides with mutated consensus sequences of 
MYB and KLF1. Table 5.5 shows the binding reactions that were prepared. 
 1 2 3 4 5 6 7 8 9 10 
Extract K562 K562 K562 K562 K562 K562 K562 K562 K562 K562 
Oligo old-a old-a old-a old-a old-a old-g old-g old-g old-g old-g 
Competitor - old-a Myb+ Myb – 
mutant 





2 2 2 2 2 2 2 2 2 2 
Table 5-5: Binding Reactions for figure 5.8. 
Cold competition of old-a and old-g oligonucleotides with Myb + (consensus MYB site), 
Myb – (mutated consensus site), KLF+ (consensus KLF1 site) were performed. All 
reactions were performed under binding condition 2 using 200 fold excess of unlabelled 






Figure5.8: Cold competition patterns of old-a, old-g oligonucleotides with Myb 
+,Myb –, KLF+, old-a and old-g unlabelled oligonucleotides. 
Specific protein-nucleic acid complex (X) is observed with old-a and old-g 
oligonucleotides (lane1 and lane 6, respectively) that are competed out by addition of 
excess self-competitor (lane 2 and lane 7, respectively). Addition of Myb+ and KLF 
+cold competitors with labelled old-a oligonucleotide almost competed out band X and 
led to the presence of new complex (Y) (Lane 3 and 5). Addition of Myb-(mutant) 
oligonucleotide cannot compete out band X and no new complex is observed (Lane 4). 
Addition of Myb+ and KLF+ unlabelled oligonucleotides with labelled old-g 
oligonucleotide partially compete out band X (Lane 8 and 10). Addition of KLF+ also 
led to the presence of new complex (Y) (Lane 10) that was not observed with the 
addition of Myb+ (Lane 8). 
 
The result demonstrates the presence of MYB and KLF1 specific binding of the old-a 
and old-g oligonucleotides. Furthermore, the similar binding patterns of old-
aoligonucleotide in the cold competition with Myb+ and KLF+ oligonucleotides 
suggeststhat the complex contained both of the transcription factors.  
  old-a oligo 
CAGGCGCATGCAACCACACCCGACT 
                            MYB       KLF1
 old-g oligo 
CAGGCGCATGCAACCGCACCTGACT 
                            MYB       KLF1
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The lack of complete competition of complex X by Myb- (mutant) oligonucleotide with 
both old-a and old-g oligonucleotides provides further support that the complex 
observed is MYB specific. 
 
The only difference observed in mobility shifts was the lack of formation of complex Y 
with Myb+ competition with old-g oligonucleotide. The complex binding patterns makes 
it hard to interpret any difference between the two oligonucleotide thus the effect of 
SNPs rs9389268 (A/G) and rs9376091 (T/C) should be validated by alternative 
methods. The results led us to conclude that the region encompasses motifs forming a 
complex pattern of MYB binding. 
 
5.2.2.2 Cross Competition EMSA 
 
The EMSA experiments suggested that the MYB and KLF1 bind to oligonucleotides 
encompassing SNPs rs9389268 and rs9376091; however no obvious differential 
binding was observed due to the complex binding patterns. In order to detect subtle 
differences between old-g and old-a oligonucleotides, cross competition experiments 
were designed. Each oligonucleotide was competed by its own cold competitor and by 
unlabelled oligonucleotide of the alternative competitor. 
Initial experiments were performed with 200 fold excess of unlabelled competitor for 
each oligonucleotide to investigate any difference in the competition patterns. Table 5.6 
shows the reactions prepared. The results failed to suggest any differential binding 
between the different oligonucleotides, since cross competition of each oligonucleotide 





 1 2 3 4 5 6 7 8 
Extract - K562 K562 K562 - K562 K562 K562 
Oligo old-g old-g old-g old-g old-a old-a old-a old-a 










2 2 2 2 2 2 2 2 
Table5-6: Binding Reactions for figure 5.9. 
Cross competition of old-a and old-g oligonucleotides with unlabelled old-g and old-g 
oligonucleotides were performed. All reactions were performed under binding condition 
2 using 200 fold excess of unlabelled oligonucleotide which was added to reaction 5 




Figure5.9: Cross competition patterns of old-g, old-a oligonucleotides with old-g 
and old-a unlabelled oligonucleotides. 
Free oligonucleotides can be observed with reactions without nuclear extract (Lane 1 
and Lane 5). Specific protein-nucleic acid complex (X) is observed with old-a and old-g 
oligonucleotides (lane 2 and lane 6, respectively) that are competed out by addition of 
excess self-competitor (lane 3 and lane 7, respectively) as well as the other competitor 
(Lane 4 and 8, respectively). 
old-a oligo 
CAGGCGCATGCAACCACACCCGACT 
                            MYB       KLF1 
  old-g oligo 
CAGGCGCATGCAACCGCACCTGACT 
                            MYB       KLF1
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5.2.2.3 Transcription factor binding around rs Rs9494142 (T/C) 
 
Previous ChIP-Chip experiments demonstrated the presence of five GATA-1 binding 
peaks at the block 2 of chromosome 6q, three of which were around the conserved 
GATA-1 binding motifs. In-silico tools predicted another GATA-1 motif in close 
proximity to the conserved GATA-1 motifs. There were no SNPs around the conserved 
GATA-1 binding site but there was one SNP rs9494142 (T/C) that was encompassed 
by the predicted GATA-1 binding motif. EMSA experiments were carried out by using 
oligonucleotides encompassing the predicted GATA-1 binding site in order  to 





Figure 5.10: EMSA oligonucleotides encompassing SNP rs9494142 
 
Similarly, experiments were performed initially under variable binding conditions to 
select the most appropriate and optimum binding condition for the oligonucleotides of 
interest.  
 
Table 5.7 demonstrates alternative binding conditions that were tested. Table 5.8 
shows the competition of the reaction mix. Results demonstrated that there is no 
significant difference in the binding patterns of the oligonucleotides with variable 













Component Binding condition 1 Binding condition 2  Binding condition 3 
Ultrapure Water 9 μl 9 μl 8μl 
10X Binding Buffer  2 μl 2 μl 2 μl 
50% Glycerol  1 μl 1 μl 1 μl 
MgCl2  1 μl - 1 μl 
Poly (dI•dC) ) 1 μl 1 μl 1 μl 
1% NP-40 1 μl - 1 μl 
KCl - 1 μl - 
EDTA - 1 μl 1 μl 
K562 nuclear extract 3 μl 3 μl 3 μl 
Oligonucleotide 2 μl 2 μl 2 μl 
Total Volume 20 μl 20 μl 20 μl 
    
 
Table5-7: Three different binding conditions were prepared by alterations of KCL, 
EDTA, MgCl2, 1% NP-40 presence in the binding reaction. 
 
 
 1 2 3 4 5 6 7 8 9 10 
Extract K562 K562 K562 K562 K562 K562 K562 K562 K562 K562 
Oligo t t t t t c c c c c 
Competitor - - t - t - - c - c 
Binding 
condition 
1 2 2 3 3 1 2 2 3 3 
 
Table5-8: Binding Reactions for figure 5.11. 
Three different binding reactions were prepared for each oligonucleotide encompassing 
the alternative allele T or C, referred to as “t” and “c” oligo under variable binding 








Figure5.11: Binding pattern of t and c oligonucleotides with K562 nuclear 
extracts under variable binding conditions. 
Specific protein-nucleic acid complex (X) is observed with both t and c oligonucleotides 
(lane 1,2,4,6,7,9) under all three binding conditions;  the binding is competed out by 
unlabelled oligonucleotides (Lane 3,5,8,10). 
5.2.2.3.1 Cold Competition EMSA 
 
To characterize the complex (X) from Figure 5.11, cold competition experiments were 
performed.  As bioinformatics suggested the presence of GATA-1 binding motifs, 
competition assays were performed using the commercial GATA-1 consensus 
sequences and the mutant GATA-1 sequences as competitors in order to investigate if 
the demonstrated protein-nucleic acid complex is GATA-1 related. Table 5.9 shows the 








 1 2 3 4 5 6 7 8 9 10 
Extract - K562 K562 K562 K562 - K562 K562 K562 K562 
Oligo t t t t t c c c c c 
Competitor - - t GATA-1+ GATA-1- 
Mutant 




3 3 3 3 3 3 3 3 3 3 
Table5-9: Binding Reactions for figure 5.12. Cold competition of t and c 
oligonucleotides with GATA-1 + (consensus GATA-1 site), GATA-1 – (mutated 
consensus site) were performed. 
All reactions were performed under binding condition 3 with the addition of 200 fold 
excess of unlabelled oligonucleotide that was added to reaction 5 minutes before 





Figure5.12: Cold competition patterns of t and c oligonucleotides with GATA-1+, 








Specific protein-nucleic acid complex (X) is observed using t and c oligonucleotides 
(lane 2 and lane 7) that are competed out by addition of excess self-competitor (lane 3 
and lane 8) as well as GATA-1+ competitor.Complete competition is not observed with 
the addition of GATA-1-(mutant) cold competitor (lanes 5 and 10, respectively). 
The EMSA results demonstrated GATA related binding to “t” and “c” oligonucleotides, 
which were designed to encompass the SNP rs9494142 and a predicted GATA-1 site. 
Lane 1 and 6 are the negative controls without any nuclear extracts. The reactions 
were performed using nuclear extracts prepared from K562 cells where the expression 
of GATA-1 transcription factor is validated by western blots (lanes 2-5 and 7-10). 
Lanes 2 and 7 of figure 5.12 show a similar binding pattern of “t” and “c” 
oligonucleotides, respectively to K562 nuclear extracts and suggest similar binding 
pattern. The binding appears to be specific, as it is competed out by excess specific 
cold competitor (lanes 3 and 8, respectively). The complex appears to be GATA-1 
related, as it is competed out using oligonucleotides encompassing the conserved 
GATA motifs but less so with mutated GATA motifs as cold competitors (lanes 4 and 8, 
respectively).  The results failed to suggest that SNP rs9494142 alters GATA-1 binding 
(Figure 5.12). 
 
5.2.2.4 Transcription factor binding around rs 66650371(TAC/---) 
 
Previous ChIP-chip experiments demonstrated the presence of five GATA-1 binding 
peaks at block 2 of chromosome 6q; three of which were around the conserved GATA-
1 binding motifs. Transcription factor prediction tools predicted another GATA-1 motif in 
close proximity to the conserved GATA-1 motif. I have investigated if any SNPs 
associated with elevated HbF levels altered these conserved or predicted motifs. There 
were no SNPs around the conserved GATA-1 binding site; however there was a three 
base pair deletion that was encompassed by the predicted GATA-1 binding motif. I 
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have designed oligonucleotides encompassing the predicted GATA-1 binding site 
(Figure 5.13) to confirm GATA-1 binding by EMSA experiments and to investigate if 
any transcription factor binding is altered by the deletion rs66650371. Initial 
experiments were performed under variable binding conditions to select the most 
appropriate binding condition for the oligonucleotides of interest.  
Table 5.10 shows the alternative binding conditions that were tested. Table 5.11 shows 
the comparison of binding reactions. Initial results suggested that different transcription 
factor complexes are binding to the “wt” and “del” oligonucleotides, which were 
designed to encompass the three base pair deletion rs66650371 and predicted motifs 
for key transcription factors like GATA-1/GATA-2 TAL-1 and RUNX1.  Results also 
demonstrated significant difference in the binding patterns of oligonucleotides with 




Figure5.13: EMSA oligonucleotides encompassing SNP rs66630371 
Component Binding condition 1 Binding condition 2  Binding condition 3 
Ultrapure Water 9 μl 9 μl 8μl 
10X Binding Buffer  2 μl 2 μl 2 μl 
50% Glycerol  1 μl 1 μl 1 μl 
MgCl2  1 μl - 1 μl 
Poly (dI•dC) ) 1 μl 1 μl 1 μl 
1% NP-40 1 μl - 1 μl 
KCl - 1 μl - 
EDTA - 1 μl 1 μl 
K562 nuclear extract 3 μl 3 μl 3 μl 
Oligonucleotide 2 μl 2 μl 2 μl 
Total Volume 20 μl 20 μl 20 μl 
Table5-10: Three different binding conditions were prepared by alterations of 
KCL, EDTA, MgCl2, 1% NP-40 presence in the binding reaction. 
wt oligo 
GATGTTACTATATCAAAACCACAA 
                     GATA-1 
del oligo 
GCAGATGT---TATATCAAAACCACAA 
                     GATA-1 
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 1 2 3 4 5 6 7 8 9 10 
Extract - K562 K562 K562 K562 - K562 K562 K562 K562 
Oligo wt wt wt wt wt del del del del del 
Competitor - - - - wt - - - - wt 
Binding 
condition 
1 1 2 3 3 1 1 2 3 3 
Table 5-11: Binding Reactions for figure 5.14. 
Three different binding reactions were prepared for each oligonucleotide .i.e. (wt and 




Figure 5.14: Binding pattern of “wt” and “del” oligonucleotides with K562 
nuclear extracts under variable binding conditions. 
Protein-nucleic acid complex (X) is observed with “del” oligonucleotide (lane7, 8 and 9)) 
using all three binding conditions. Protein-nucleic acid complex (Z) is observed with the 
“wt” oligonucleotide (lane 2, 3 and 4) using all three binding conditions. Protein-nucleic 
acid complex (Y) is observed with both of the oligonucleotides (lanes3 and 8, 
respectively) under binding condition two only.  
wt oligo 
GATGTTACTATATCAAAACCACAA 
                     GATA-1 
del oligo 
GCAGATGT---TATATCAAAACCACAA 
                     GATA-1 
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Lane 1 and Lane 6 are negative controls with no nuclear extracts. Cold competition 
with cold self-competitor competes out Z and X complexes with wt and del 
oligonucleotides, respectively (Lanes 5 and10, respectively, figure 5.14).The results 
suggest that binding condition two is the most appropriate condition for future 
experiments. 
5.2.2.4.1 Cold Competition EMSA 
Initial EMSA experiments demonstrated the presence of protein-nucleic acid 
complexes that are different and specific to the “wt” and “del” oligonucleotides. Based 
on the information obtained from in-silico predictions, experiments were performed 
using the commercial GATA-1 consensus sequences and the mutant GATA-1 
sequences as cold competitors in order to investigate if any of the demonstrated 
protein-nucleic acid complexes is GATA-1 related. Table 5.12 shows the comparison of 
the prepared binding reactions. 
 1 2 3 4 5 6 7 8 9 10 
Extract - K562 K562 K562 K562 - K562 K562 K562 K562 
Oligo wt wt wt wt wt del del del del Del 










Condition 2 2 2 2 2 2 2 2 2 2 
Table5-12:Binding Reactions for figure 5.15.Cold competition of “wt” and “del” 
oligonucleotides with GATA-1 + (consensus GATA-1 site), GATA-1 – (mutated 
consensus site) were performed. 
All reactions were performed under binding condition 2; for competition 200 fold excess 











Figure 5.15: Cold competition patterns of “wt” and “del” oligonucleotides with 
GATA-1+, GATA-1- , “wt” and “del” unlabelled oligonucleotides (Table 5.11). 
Specific protein-nucleic acid complex (X) is observed with “del” oligonucleotides (lane7) 
that is competed out by addition of excess self-competitor (lane 8). Specific protein-
nucleic acid complex (Z) is observed with wt oligonucleotides (lane 2) that is competed 
out by addition of excess self-competitor (lane 3). Addition of GATA-1+  and GATA-1- 
(mutant) cold competitors with labelled “wt” and “del” oligonucleotides did not compete 
out complex X or complex Z , respectively. 
 
In summary, although protein binding is demonstrated, the results failed to suggest that 
the specific protein-nucleic acid complex (X) and (Z) are GATA-1 related. Specific 
protein-nucleic acid complex (Y) observed in Figure 5.14 cannot be observed probably 
due to unstable nature of the complex. It is possible that this complex (Y) from figure 
5.14 is the GATA-1 related complex. Significant difference in the binding patterns of the 
“wt” and “del” oligos is demonstrated and future experiments should focus on the 
characterization of “X” and “Z” protein-nucleic acid complexes. 
wt oligo 
GATGTTACTATATCAAAACCACAA 
                     GATA-1 
del oligo 
GCAGATGT---TATATCAAAACCACAA 




Two individuals, one homozygous (++) for the for the haplotype across the 6q 
QTL(blocks 1, 2 and 3) associated with high HbF and another homozygous for the 
absence of the SNPs associated with increased HbF levels, were selected for 
resequencing in order to investigate the SNPs that differ between a high F and a low F 
individual. In-silico prediction tools (matinspector and consite) were used to predict the 
transcription factor binding sites around these SNPs. Further comparison of predicted 
binding sites in the presence and absence of the SNPs and the alternative alleles was 
performed to investigate if the SNPs alter binding of the transcription factors. In-silico 
predictions highlighted some SNPs which altered the binding of key transcription 
factors like MYB, KLF1 and GATA-1 family.  
 
The MYB transcription factor has a crucial role in the regulation of proliferation and cell 
lineage commitment of erythroid progenitor cells. Jiang et al showed that over 
expression of MYB in human erythroid progenitor cells results in down regulation of 
γ globin(Jiang et al 2006). These results were also supported by studies of Sankaran et 
al who showed that down regulation of MYB in human erythroid progenitor cells 
resulted in not only increased expression of γ-globin but also έ-globin(Sankaran et al 
2011). The influence of MYB on HbF levels were further supported by Galarneau et al 
who showed that missense mutations in MYB strongly correlates with HbF. The study 
was performed in African Americans with sickle cell anemia (SCA) to characterize 
associations with fetal hemoglobin (HbF) levels using resequencing and genotyping. 
The group suggested that 3 missense variants in the MYB gene was associated with 
elevated HbF levels independently from variants in HMIP variants (Galarneau et al 
2010).Another study also suggested that MYB transcription factor binds to 5’ flanking 
region of the MYB gene, positively autoregulating the expression of the gene in order to 
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maintain high levels of MYB protein in cells that are proliferating (Nicolaides et al 
1991). Levels of MYB clearly influences HbF hence, differential binding of the MYB 
transcription factor to candidate SNPs in the 6q intergenic region may indirectly control 
HbF through control of MYB. 
 
Factors belonging to the KLF family are also crucial in the regulation of globin genes. 
KLF1 binds to the β-globin gene promoter sequence as well as the core of 
hypersensitive sites in the LCR which is essential for the β-globin gene expression. 
KLF1 activates the β –globin gene binding specifically to the CACCC box in the β-
globin promoter. The KLF1 binding enhances the interaction between the β-globin 
promoter and the β-LCR, as a consequence of which, the interaction between the γ-
globin promoter and the β-LCR decreases (Miller & 1993) facilitating the switch from γ-
globin to β-globin gene expression in adults. Recent studies also suggested that KLF1 
regulates the γ–globin to β–globin gene switch by activating transcriptional repressors 
of the γ –globin gene, such as BCL11A, TR2/TR4 and KLF10 (Borg et al 2010,Borg et 
al 2012). 
 
Two different functional assays were performed to study differential binding of these 
factors at the predicted sites. Electrophoretic mobility shift assays (EMSA) were the 
first functional assays that were performed.  
EMSA uses oligonucleotides encompassing the alternative alleles of the SNPs in 
binding reaction of nuclear extracts in which the putative transcription factor is 
expressed to demonstrate any differential transcription factor binding. Specificity of the 
binding can be investigated by cold competition assays as previously described.  
 
Characterization of proteins that are present in the protein complexes requires 
additional steps. The electrophoretic “supershift” assay and assays that combine 
EMSA with western blotting or mass spectroscopy have been devised to allow 
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identification of nucleic acid-associated proteins. Supershift experiments proved to be 
challenging so we have used an alternative method to detect proteins present in the 
protein complex by competing the proteins out with unlabeled oligonucleotides that are 
known to be bound by proteins of interest. 
 
Initial experiments were performed with oligonucleotides encompassing SNPs 
rs9389268 (A/G) and rs9376091 (T/C) that included the MYB (CAACCG) and KLF1 
(GTGGG) binding motifs. Interpretation of EMSA results of rs9289268 proved very 
difficult because the two transcription factor binding sites that were only 4 base pairs 
apart and had to be included in the design of the oligonucleotides (Figure 5.5). It was 
hard to separate the binding sites because that would reduce the flanking sequence on 
one site leading to an artificial environment. On advice from Dr. David Garrick (WIMM, 
Oxford), we used the oligonucleotides encompassing both MYB and KLF1transcription 
factor binding rather than separating them. 
 
Alternative combinations of binding reactions were tried out in order to detect the most 
appropriate one to improve sensitivity. Oligonucleotides suitable for 3 I end radioactive 
labelling were designed according to Dr. David Garrick’s suggestions and Radioactive 
EMSA method was performed to get better results. Unfortunately Radioactive EMSA 
results were not successful. 
The other problem with the EMSA experiments was the failure to super shift the 
protein-nucleic acid complex with antibodies to characterize the bands that were shown 
in the EMSA results. Different MYB and KLF antibodies were used but no consistent 
super shift was observed leading to the failure of characterization of the bands. This 
can result from the conformational changes of proteins after binding to oligonucleotides 
that prevent the binding of antibodies. Experiments were performed in which nuclear 
extracts are incubated with antibodies before the addition of labelled oligonucleotides in 
order to enable super shifts. However, addition of antibodies appears to disrupt the 
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protein-nucleic acid complexes that can be classified as a super shift yet the disruption 
was not specific to the antibodies of interest. Cold competition EMSA experiments were 
performed in order to characterize the demonstrated protein-nucleic acid complexes 
and results suggested that the protein-nucleic acid complexes around SNPs rs9389268 
(A/G) and rs9376091 (T/C) are related to MYB and KLF1. 
 
Binding patterns of old-g and old-a oligonucleotides with K562 nuclear extracts may 
suggest the formation of a trimeric complex which includes the labelled 
oligonucleotides together with the MYB, KLF1. Recent reports have described a 
transcriptional network within the erythroid cells whereby KLF1 and MYB activate each 
other. Bianchi et al suggested that MYB can regulate KLF1; and Stadhouders et al 
demonstrated that KLF1 binds to a site 84 kb from MYB gene transcription start site 
which coincides with a SNP strongly associated with high HbF (Bianchi et al 2010, 
Stadhouderset al 2012). Therefore, it is possible that MYB and KLF1 regulate 
expression of MYB gene. SNPs around the binding motifs may disrupt the complex or 
reduce its binding efficiency. This may explain the differential rate of proliferation and 
differentiation of erythroid progenitor cells from patients with the (++) haplotype. Other 
functional approaches should be taken into consideration in order to investigate the 
binding of these transcription factors in the chromosome 6q QTL. 
EMSA experiments also focused on two other SNPs, rs9494142 and rs66650371, 
which disrupted the predicted GATA-1 binding motifs. Confirmation of differential 
binding of GATA-1 is crucial in understanding the regulatory activity of the region.  
Since GATA-1 can function both as a repressor or an activator of gene expression, 
differential binding of GATA-1 may lead to either upregulation or downregulation of 
flanking genes via its histone remodelling activity or through the complexes formed with 
other transcription factors. In-silico tools predicted GATA-1 binding which was 
supported by EMSA assays.However, although EMSA experiments confirmed GATA 
related complex formation with oligonucleotide encompassing predicted GATA-1 site 
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around SNP rs9494142; it failed to suggest any differential GATA-related binding. Cold 
competition experiments demonstrated that protein-nucleic acid complex is competed 
out with the addition of commercial GATA-1+  motif and  the efficiency of competition is 
significantly less with  GATA-1- (mutant). ChIP-chip experiments demonstrated GATA-
1 binding around this region but initial focus was on the conserved GATA-1 site found 
in the region which is not altered by any SNPs. Potential alteration of GATA-1 predicted 
site can still be important since this site is in close proximity with conserved GATA-1 
site and GATA-1 transcription factor which can function in 161immers as well. 
Disruption of one site may limit the binding of GATA-1 to the region in vivo, but this 
should be investigated by ChIp-qPCR experiments. 
 
EMSA experiments performed with the oligonucleotide encompassing GATA-1 
predicted site and the three base pair deletion (rs66650371) suggested differential 
binding patterns with the “wt” and “del” oligonucleotides. In order to characterize 
protein-nucleic acid complexes, cold competition assays were performed but the 
results failed to suggest that the differentially bound complexes are GATA-related. 
There are other key factor motifs that are present in the oligonucleotides such as: 
RUNX1, Hepatic nuclear factor 1 (HNF1) (Chapter 3) and future experiments should be 
performed in order to characterize these protein-nucleic acid complexes.  Future 
experiments that combine EMSA with mass spectroscopy can be performed to identify 








6 INVESTIGATION OF TRANSCRIPTION FACTOR BINDING AT 




















































Insilico predictions and EMSA experiments suggested presence of key transcription 
factors encompassing the SNPs associated with elevated HbF levels. EMSA 
experiments were performed in vitro with K562 nuclear extracts. I have performed ChIP 
experiments to investigate transcription factor binding using erythroid progenitor cells. 
6.1.1 Chromosome 6q QTL 
 
The QTL on the chromosome 6q23 was identified by linkage analysis in an extended 
Asian family with β-thalassaemia through the proband who had very mild thalassaemia 
intermedia despite being homozygous for β0 thalassaemia with a complete absence of 
HbA (α2β2). He was able to compensate for the lack of HbA due to the ability to 
produce HbF (α2γ2); his steady state total haemoglobin ranged from 11-12 gm/ dl, all of 
which was HbF apart from small amount of HbA2 (α2δ2). Family studies showed that 
several members of the extended family, with and without β thalassaemia had variable 
increases in HbF levels. Segregation studies showed that there was a genetic 
determinant for this innate ability to produce HbF and that the genetic determinants 
segregated independently of the β-globin gene complex. The extended family was 
large enough to perform linkage analysis, which mapped the HbF locus to a region 
spanning 1.5 Mb on chromosome 6q23. The 6q HbF QTL was validated in a large 
panel of European twins. Higher resolution genotyping refined the locus to a region of 
79 kb between the HBS1L and MYB genes. The analysis revealed that this was a 





The 6q QTL exists as a set of single nucleotide polymorphisms (SNPs) spanning a 
region of ≈ 79kb that includes the intergenic region 5i to MYB and HBS1L and  5i  part 
of the HBS1L gene.The SNPs are distributed in three linkage disequilibrium (LD) 
blocks referred to as HBS1L –MYB intergenic polymorphism (HMIP ) blocks 1, 2, and 
3. The 3 blocks completely account for the HbF variance attributed to the 6q QTL with 
SNPs in block 2 (24kb) showing the strongest effect and accounting for the majority of 
the variance.  
Our group has shown that MYB and HBS1L are quantitative trait genes,with variable 
expression in the erythroid progenitor cells of healthy adults. Previous analysis of a 
number of erythroid cultures of individuals has revealed a clear correlation of elevated 
HbF with low levels of MYB and HBS1L expression (Jiang et al 2006). 
Wahlberg et al (2009) identified Dnase I hypersensitive sites in HMIP block 2 
suggesting the presence of regulatory elements in the HBS1L-MYB intergenic region 
further supported by the presence of erythroid specific transcripts. Further experiments 
were performed to analyse the region for transcription factor binding and chromatin 
modification by chromatin immunoprecipitation on microarray (ChIP-chip).  The results 
indicated five GATA-1 binding sites in block 2 (figure 6.1). The use of microarrays 
allowed the investigation of GATA-1 binding to an extensive area of the 6q23 locus. 
 
6.1.2 Chromatin immunoprecipitation (ChIP) 
 
Chromatin immunoprecipitation (ChIP) is a powerful experimental approach that allows 
one to identify the proteins associated with specific regions of the genome. With the 
appropriate antibodies, it can be used to locate both non-histone proteins and histones 
carrying specific covalent modifications, such as acetylation, phosphorylation, or 
methylation. Recent developments in techniques such as quantitative real-time PCR 
and DNA microarrays have enabled efficient analysis of ChIP material.  
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There are two general methodologies for carrying out ChIP experiments. One (XChIP) 
uses chromatin fixed with formaldehyde and fragmented by sonication. The other 
(NChIP) uses native chromatin prepared by nuclease digestion of cell nuclei. Both 
methods have advantages and disadvantages, the method used will depend, among 
other things, on the aims of those experiments and the starting material.  
 
 
Figure 6.1: ChIP-chip data for the HBS1L-MYB intergenic region. 
Results from ChIP-chip experiments for GATA-1, RNA polymerase II, AcH4, and AcH3 
in primary human erythroid precursors are presented. Covering 210-kb of 6q locus 
(position chr6: 135 373 000-135 582 000) including part of the HBS1L gene, the 
intergenic region, and the MYB gene. The HMIP block 1, 2, and 3 are shown above 
indicated by the horizontal brackets. Also shown are the conserved GATA-1 motifs and 
DNase I hypersensitive sites (as identified in hemin induced K562 cells by Wahlberg et 
al2009).Three DNase hypersensitive sites and five conserved GATA-1 motifs are 
highlighted on the figure which coincides with GATA-1 binding. Eyth Ac H4 and H3 
show the histone acetylation patterns and RNAP II shows RNA polymerase activity in 
the region. 
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I have used the XChIP approach in this project. It is possible to start with smaller 
number of cells using XChIP, which enables us to perform additional ChIP experiments 
with different antibodies whose target proteins are expressed at similar stages during 
erythropoiesis. The main problem with this method is the small yield of precipitated 
chromatin limiting the number of real-time PCR experiments that can be performed and 
necessitating a whole genome amplification (WGA) step before analysing material by 
microarrays.Material used for ChIP experiments was harvested from human erythroid 
progenitor cells, derived from primary cultures at a time when our protein of interest is 
expressed. To obtain an idea of the appropriate time of harvest, we generated 
expression profiles for each target protein to be studied. 
Primary human erythroid cells were cultured from whole blood using the method 
adapted from Van den Akker et al as detailed in Chapter 3. RNA was extracted from 
cells at different days of culture and reverse transcribed into cDNA. Using primers 
specific for each target gene, expression was measured by RT-PCR and we used this 
information in order to estimate the optimal day to harvest cells for ChIP experiments. 
On harvesting, cells were cross-linked using 1% formaldehyde; this step fixes the 
proteins to the target DNA sequence in their native state. The material is then 
sonicated to shear the fixed fragments between 200-1000bp (NimbleGen array’s user 
guide for ChIP applications). The material was then immunoprecipitated with an 
antibody to our specific protein of interest with a mock antibody (rabbit IgG) in parallel, 
as a negative control. After an overnight incubation, any excess antibody is washed 
away and the antibody-protein-DNA material is reverse cross-linked, this time 
detaching the protein from its target DNA sequence. At the end of this step, we are left 
with DNA that has been specifically targeted by our protein using a specific antibody. 
The DNA is precipitated and quantitative PCR experiments are performed to quantify 
transcription factor binding to areas of interest (Figure 6.2). The enrichments are 
calculated relative to the IgG negative control using delta CT method. 
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We have performed experiments following two different approaches to measure 
differential binding of transcription factors. Initially, we have comparedtranscription 
factor binding to targetsin HPFH +/+ vs. HPFH -/- erythroid chromatin. Next, we have 
performed allele specific ChIP (HaploChIP) experiments with HPFH +/- individuals, 
heterozygous for the SNPs of interest, to confirm the differential transcription factor 
intraindividually. 
Each approach was performed with different analysis methods of immunoprecipitated 
material. To compare the binding with HPFH +/+ and HPFH -/- erythroid chromatin we 
have performed ChIP-qPCR experiments, where the DNA is precipitated and 
quantitative PCR experiments are performed in order to quantify transcription factor 
binding to areas of interest (Figure 6.2). The enrichments are calculated relative to the 
IgG negative control using delta CT method. For further comparisons, enrichments for 
each target are normalized to relevant positive control to enable us compare the 
transcription factor binding between individuals with different genotypes. The detailed 
ChIP-qPCR protocol can be found in Chapter 2 (Materials and Methods). 
 
 
Figure6.2: Summary of the steps in ChIP-qPCR (The figure was adopted from 
vinci-biochem). 
 
DNA and proteins         DNA is sheared   Magnetic beads    Antibody is  
arecrosslinkedby sonication are added  added 
  Croslinks are reversed&DNA pieces bound by 
            Proteins are denatured antibody are enriched 
 
Q-PCR is performed to  
calculate enrichment 
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The second approach, allele specific ChIP or Haplochip enabled the analysis of 
differential binding of transcription factors to the two alleles representing a SNP in 
HPFH +/- erythroid chromatin. This approach enables us to overcome the limitations of 
ChIP-qPCR experiments performed with different individuals of different genotypes. 
Haplochip uses cells from the same individual who is heterozygous for a SNP of 
interest i.e. HPFH +/- individuals. 
Different approaches of analysis depending on the nature and location of the SNPs can 
be applied to quantitate the biased binding of transcription factors to SNPs. These 
include: restriction digestion, snapshot and sequence analysis. 
 
6.1.3 Transcription Factors at Chromosome 6q QTL 
 
Transcription factors play a crucial role in gene expression. They bind to specific 
recognition sequences or binding motifs and help in the activation or repression of 
genes acting as trans regulators. Several transcription factor-binding motifs have been 
characterized within the β-globin locus and are essential for the formation of the active 
locus and activation and control of individual genes. The core regions of the 
hypersensitive sites in the LCR are particularly rich in such motifs and include binding 
sites for the erythroid specific transcription factors KLF1, GATA-1 and NF-E2 as well as 
ubiquitous factors such as SP1 (Goodwin et al 2001; Ho & Thein 2000).  
 
The chromosome 6q QTL also has several transcription factor-binding motifs of 
GATA-1 and MYB transcription factors. Factors belonging to KLF family: SP1, BKLF, 
KLF1 are also present in the 24 kb region of block 2 where association with increased 
fetal haemoglobin is strongest (Thein et al 2007).  Some of these transcription factors 
were discussed in Chapter 1 in detail because of their crucial roles. Previous work by 
our group demonstrated the presence of GATA-1 binding sites in the 6q intergenic 
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region using ChIP-Chip assay (Wahlberg et al2009). In-silico experiments performed 
also revealed MYB, KLF1 and GATA-1 binding sites in close proximity with SNPs that 
are associated with HbF. 
 
GATA-1 is an erythroid specific transcription factor, required for globin gene regulation 
and erythroid cell maturation. GATA-1 can function both as a repressor or an activator 
of gene expression and the function is partly dependent on its interactions with other 
proteins. GATA-1 can interact with itself as well as other transcription factors including 
KLF1 and SP1 and can form large multiprotein complexes with TAL1, E47, LDB1, and 
LMO2 (Crossley et al1995 ; Merika &Orkin et al 1995; Wadman et al 1997; Morceau et 
al 2004; Cheng et al 2009).  
 
The GATA-1 recognition sequence (T/A) GATA (A/G) is found in the globin-gene 
promoters as well as in the core sequences of the hypersensitive sites of the LCR. It is 
also involved in the establishment of the active chromatin domain in the locus and the 
formation of hypersensitive sites (Orkin et al 1992; Pomeratz et al 1998; Vakoc et al 
2005; Layon et al 2007). GATA-1’s potential as a gene regulator and important 
regulatory roles in erythropoiesis, makes it an ideal candidate to study transcriptional 
activity at the 6q23 locus. 
Another transcription factor of interest was MYB. The MYB gene encodes a protein of 
72k Da comprising  640 amino acids with an isoform of 89 kDa (cMYB-9A) caused by a 
splice variant which leads to an insertion of 363 base pairs (bp) between exon 9 and 10 
(exon 9A). The protein is expressed in most haematopoietic tissues and is highly 
expressed in immature haematopoietic cells (Gonda et al 1982, Westin et al 1982).  
MYB transcription factor plays crucial roles in regulation of proliferation and cell lineage 
commitment of erythroid progenitor cells. It is required for the maintenance of cell 
proliferation by exerting a direct role in cell cycle control. MYB is highly expressed in 
  170
immature haematopoietic cells and is down regulated as the cells differentiate. Down-
regulation of MYB is required for terminal differentiation (Westin et al 1982, Oh et al 
1999).  
 
Krüppel-like factor 1, KLF1, is an erythroid cell-specific transcription factor, homologous 
to the Krüppel family of transcription factors which have roles in cell proliferation, 
differentiation and survival. KLF1 contains three zinc fingers at the C-terminus which 
bind to a CACCC sequence. CACCC sequences are repeated in erythroid enhancers 
and promoters, including the β-globin gene promoter. This sequence is noted as a site 
of point mutations that give rise to β-thalassaemia.Klf1 knockout mice die from anemia 
supporting the role of KLF1 during erythropoiesis (Miller & Bieker, 1993, Bieker et al 
2005). Recent studies suggested that KLF1 has a direct role in globin regulation 


















6.2.1 DNA sonication 
 
Following crosslinking of primary human erythroid cells and cell lysis, the material was 
sonicated to shear the DNA. Electrophoresis of 1µl of the sonicated chromatin was 
performed on 1.5% acrylamide gel to confirm the size of the DNA fragments (Figure 




Figure6.3: Electrophoresis of two sets chromatin sonicated for 15 rounds at 
power 2 for 10 seconds (lanes 2 and 3) with PhiX174 HaeIII DNA ladder (lane 1) 
on 1.5 % w/v agarose gel. 
6.2.2 GATA-1 Binding at chromosome 6q QTL 
 
 Experiments were performed to analyse the region for transcription factor binding and 
chromatin modification by chromatin immunoprecipitation on microarray (ChIP-chip).  
The results indicated five GATA-1 binding sites in block 2 (figure 6.5). The use of 
microarrays allowed the investigation of GATA-1 binding to an extensive area of the 
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6q23 locus. ChIP-chip is not a quantitative method so ChIP-qPCR experiments were 
performed to quantify GATA-1 binding to the previously revealed peaks. 
 
6.2.2.1 Control test for GATA-1 enrichment 
 
Following confirmation of the chromatin size, we proceeded to immunoprecipitation 
using an anti-GATA1 antibody (M-20 sc1234, Santa Cruz). After reverse cross-linking 
and purification of the ChIP DNA, a small amount was tested for enrichment by SYBR 
green RT-PCR. Hypersensitive site 40 (HS-40) upstream of the α-globin locus on 
chromosome 16 (α-HS40) and hypersensitive site 2 (HS-2) at β-globin LCR on 
chromosome 11 are known GATA-1 binding sites. Both sites were used as positive 
controls in GATA-1 ChIP experiments.  This step is a check point to confirm if ChIP 
with the target antibody has been successful.  
 
Figure6.4: SYBR-Green RT-PCR for Alpha-HS40 and Beta-HS2 enrichment was 
performed to confirm GATA-1 ChIP (using antibody GATA-1 M-20 sc-1234, Santa 
Cruz). 
Shown as fold enrichment, normalized to NFM as a housekeeper gene and IgG (ChIP 
with mock antibody). Enrichment results are Mean values of 5 biological replicates +/- 


























6.2.2.2  Quantitative GATA-1 binding at the 6q23 locus (HMIP) 
 
Previous microarray based experiments (ChIP-chip) in the region demonstrated the 
presence of GATA-1 binding at specific positions at the 6q23 locus (HMIP). Although 
the use of microarrays would allow us to see a more extensive area of the 6q23 locus, 
these results are not quantitative and should be validated by qPCR. Hence, we 
designed primers for ChIP-qPCR assays to quantify the detected sites at the 6q23 
locus (HMIP) block 2 (Figure 6.5 A). 
 
Tracks of the GATA-1 peaks at the 6q23 locus and surrounding area prepared by 
fellow students Karin Wahlberg and Kiran Jawaid were uploaded and viewed on the 
online UCSC genome browser (genome.ucsc.edu). This provides a more detailed view 
of the region, with the flexibility of viewing SNP tracks, conserved GATA-1 sites, 
hypersensitive regions, other transcription factor sites, as well as many other tracks 
available, all in the same view.  The tracks of high scoring SNPs prepared by Stephen 
Menzel was uploaded together with GATA-1 tracks to enable us design ChIP-qPCR 
primers at the right area of GATA-1 peaks which covers an area of  ≈ 500bp.  Primers 
were designed for the sites that were consistently detected on array-based 
experiments and three of them coincided with conserved GATA motifs. Experiments 
were performed to optimise conditions for quantitative PCR on GATA-1 ChIP material 
from healthy individuals. Mock IgG method was used in calculation of the enrichment 
on target sites. This method depends on normalization with a mock IgG: Fold 
enrichment = 2(ct IgG-ct ab). 
The analysis suggested strong GATA-1 binding to all peaks with relatively higher 
enrichments observed at peak three and peak four. Two different primer sets were 
used for peak three and there is a significant difference in terms of enrichment between 
the two primer sets. The set amplifying Peak 3-2(Primer 3-2) was selected for future 












Figure6.5. Quantification of ChIP-Chip experiments 
A: Gata-1 Binding Sites from previous ChIP-chip experiment and conserved GATA 
motifs coinciding with the binding sites. B: General designs of qPCR primers.ChIP-
qPCR amplicons encompass the conserved GATA-1 motif and key SNP in the region. 
C: SYBR-Green RT-PCR was performed. Enrichments relative to IgG (rabbit 
immunoglobin G) were calculated to confirm quantitative GATA-1 binding to targets.  












































Alpha Hs40 and Beta Hs2 were used as positive control and NFM was used as a 
negative control. 
6.2.2.3 Investigation of differential GATA-1 binding at the 6q23 locus using ChIP-qPCR 
in HPFH +/+ vs HPFH -/- erythroid chromain 
 
Previous microarray based experiments (ChIP-chip) region suggested differential 
GATA-1 binding at specific positions (Peak 4) at the 6q23 locus (HMIP). These 
experiments were performed with material from individuals that were designated as 
HPFH +/+ and HPFH -/- . The HPFH +/+ individual is homozygous for the SNP alleles 
associated with high HbF across the 6q QTL (blocks 1, 2 and 3) while the HPFH -/- 
individual is homozygous for the absence of the SNP alleles associated with increased 
HbF levels .ChIP-chip experiments suggested differential binding of GATA-1 to one 
region. To further investigate this region, quantitative ChIP-qPCR was used to validate 
the differences suggested by the ChIP-chip experiments. Quantitative ChIP-qPCR was 
also used to identify any other potential differences in GATA-1 binding between the 
HPFH -/- and HPFH +/+ individuals. 
 
Primary erythroid cells were cultured from whole blood taken from three paired sets of 
HPFH +/+ and HPFH -/- individuals. The HPFH +/+ individuals were members of the 
same family in which the QTL was first identified. One +/+ individual donated blood 
twice. ChIP-qPCR was carried out as previously described using the same anti-GATA-
1 antibody (M-20 sc1234, Santa Cruz). To ensure that we harvest the erythroid 
progenitor cells from the +/+ and -/- individuals at equivalent stages of GATA-1 
expression, we initially obtained a profile of GATA-1 expression in cells from the 
individuals of both genotypes. The expression profiles showed that GATA-1 is highly 
expressed at day 7 with no significant difference between individuals of different 
genotypes, hence day 7 would be optimal for harvesting of the erythroid progenitors. 
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As validation, the cells were also closely monitored by FACS analysis as described in 
chapter 3. In performing ChIP on erythroid progenitor cells at similar stages of 
expression, we ensure any difference observed in GATA-1 binding is due to the 
alteration of binding by the SNPs and not because of differential expression of GATA-1. 
 
SYBR-Green RT-PCR was performed with material from six erythroid cultures (three 
HPFH -/- individuals and two HPFH +/+ individuals). Two technical experiments for 
each culture were performed. Enrichments relative to IgG (rabbit immunoglobin G) 
were calculated to confirm quantitative GATA-1 binding to targets. Results are 
normalized to positive control Alpha HS40 enabling us to cross compare GATA-1 
binding to the same target in different individuals.Results confirmed the differential 
binding to GATA-1 peak four as suggested by the ChIP-chip experiments and also 
revealed differential GATA-1 binding to peak three. The results are consistent with the 
same binding pattern observed in all three biological replicates (Figure 6.6). Peaks 3 
and 4 coincide with conserved GATA-1 sites as well as DNase hypersensitive sites 
(HS2 and HS3) which increase the likelihood of causative variants being in these 
regions. 
6.2.2.4 Investigation of allele specific binding of  GATA-1 to high scoring SNPS at the 
6q23 locus in HPFH +/- erythroid chromatin 
 
ChIP-qPCR experiments performed with (+/+) and (-/-) chromatin suggested differential 
GATA-1 binding at GATA-1 peak 3 and peak 4. Resequencing of the HPFH +/+ and 
HPFH -/- individuals revealed SNPs that were in close proximity to GATA-1 binding 
motifs (figure 6.5). We wanted to target individuals that are heterozygous for the key 
SNPs to investigate differential binding of GATA-1 to the minor allele (+) and major 
allele (-) intra-individually by allele specific ChIP. Healthy unrelated individuals were 























Figure6.6: Differential GATA-1 binding at the 6q23 locus. A: SYBR-Green RT-PCR was 
performed with material from six individuals (three -/- and three +/+/). 
Enrichments relative to IgG (rabbit immunoglobin G) were calculated to confirm quantitative 
GATA-1 binding to targets. Results are normalized to positive control Alpha HS40 to enable as 
cross compare GATA-1 binding to same targets with different individuals. B:  Mean of GATA-1 
binding of replicates is presented with error bars for standard deviation.T-test was performed (n: 
3) and suggested that there is no significant difference between two groups. 
Gata peak 1 Gata peak 2 Gata peak 3 Gata peak 3-2 Gata peak 4 Gata peak 5
SM -/- genotype 0.15 0.2 0.14 0.41 0.48 0.18





























Targets at chromosome 6




Cell cultures were performed with erythroid progenitor cells isolated from peripheral 
blood of individuals who were heterozygotes for the candidate SNPs.  
Erythroid progenitor cells were harvested and cross-linked at the stage of peak GATA-
1 expression. Cross-linked material was immunoprecipitated with the same GATA-1 
(M-20) antibody and chromatin was eluted as previously described. Eluted chromatin 
was tested for enrichment by SYBR green RT-PCR. Enrichment of positive control 
Alpha HS40 andGATA-1 sites of interest (peak 3 and peak 4) was calculated (Figure 
6.7). 
Different methods of analyzing the differential binding were applied to each SNP 
because of their different nature. SNP rs66650371 was a deletion which disrupts the 
cutting site of restriction enzyme MaeIII. Material immunoprecipitated with GATA-1 and 
input DNA were used as templates and a 91bp region encompassing the deletion was 
amplified by standard PCR. Restriction enzyme digestion was performed and agarose 
gel electrophoresis of digests was performed on 3% w/v agarose gel. Ratio of pixel 
density of undigested to digested material from input was used as a normalizer and 
differential binding of GATA-1 to each allele was quantified by calculating the pixel 
density of bands by fellow colleague Ralph Stadhouders (Figure 6.8). 
SNPs rs9494142 (T/C) on the other hand, does not involve any restriction enzyme 
cleavage site. The differential binding to each allele was analyzed by snapshot method 
as previously described in Materials and Methods. The region encompassing 
polymorphism was amplified by standard PCR. Snapshot was performed with ChIP 
material and input as described before. Four biological replicates were used in the 
experiments and the T to C ratio of ChIP material was calculated and normalized to 
input (Figure 6.9). 
 
Details of each protocol can be found in materials and methods. 
  179 
 




 Conserved GATA-1                          rs9494142 (T/C) GATA-1               KLF1    
TTCTGCAACTTCTAGATAAGTAAATTTTTTTGATTTATCAGGAAGTGTCTTTGGTCTCTCAGTCAATTCGATTCTACTACTGACATTTATCAACATGGTGGGTGTGAT 
Figure 6.7: A: Gata-1 Peak 3 from previous ChIP-chip experiments.  Peak 3 is 84 kb away from the MYB transcription start site (-84kb). 
Conserved GATA motifs, predicted transcription factor motif s and high scoring SNPs are found in close proximity. B: Gata-1 Peak 4 from previous 
ChIP-chip experiments.  Peak 4 is 71 kb away from the MYB transcription start site (-71kb) .Conserved GATA motifs, predicted transcription factor 






Figure6.8: SYBR-Green RT-PCR  was performed to confirm GATA-1 enrichment 
of positive control Alpha HS40 and target sites Gata-1 peak 3 and 4 . 
Shown as fold enrichment, normalized to NFM as a housekeeper gene and to IgG 
(ChIP with mock antibody). Enrichment results are Mean values of 4 biological 






Figure 6.9: Allele specific GATA-1 binding to rs66650371. 
A: Allele specific binding of GATA-1 to major allele (TAC) and minor allele (deletion) 
was quantified by Mae III digestion. ChIP with GATA-1(m-20) and input were digested 
and agarose gel electrophoresis was performed. B: Pixel density of bands with ChIP 





































































Figure.6.10: Allele specific GATA-1 binding to rs9494142. 
A: Snapshot was performed with chromatin immunoprecipitated with GATA-1(m-20) 
and input. Ratio of GATA-1 binding to major allele T and minor allele C was calculated 
by using gene marker program which provides the peak height of both alleles. 
Calculation were done with both chip material and input for each individual. 
 B: Experiments were performed with four biological samples that were heterozygotes 
for the SNPs of interest .T to C ratio of chip material was calculated and normalized to 
input. T-test was performed (n: 4) and suggested that there is significant difference 







The results suggested weaker binding of GATA-1 to the minor alleles that are 
associated with elevated HbF. These results are consistent with the results observed 
earlier with the experiments performed with HPFH +/+ and -/- individuals. The main 
difference and the main advantage of this approach over ChIP-qPCR experiments is 
that the differential binding is internally controlled, delineating the key variants involved. 
6.2.3 MYB binding at chromosome 6q QTL 
 
ChIP experiments were performed to confirm in-silico experiments that suggested 
presence of MYB binding sites at chromosome 6q. 
 
6.2.3.1 Control test for MYB enrichment 
 
Following confirmation of the chromatin size, we proceeded to immunoprecipitation 
using an anti-MYB antibody (clone 1:1, Millipore). After reverse cross-linking and 
purification of the ChIP DNA, a small amount was tested for enrichment by SYBR 
green RT-PCR. Cathepsin G promoter (ctsg) is a known MYB binding site and was 
used as positive control in MYB ChIP experiments.  This step is a check point to 
confirm if ChIP with the target antibody has been successful.  
 
 
Figure6.11: SYBR-Green RT-PCR for CTSG enrichment was performed to confirm 




















Shown as fold enrichment, normalized to NFM as a housekeeper gene and IgG (ChIP 
with mock antibody). Enrichment results are Mean values of 5 biological replicates +/- 
standard deviation.  
6.2.3.2 Quantitative MYB binding at the 6q23 locus (HMIP) 
 
Previous in-silico experiments demonstrated the presence of MYB binding motifs at 
specific positions at the 6q23 locus (HMIP) (See Chapter 3). The presence of some of 
the MYB binding sites was validated by EMSA experiments (Chapter 4). Although 
EMSA experiments are informative the results were obtained in vitro from K562 cell 
lines. We wanted to validate MYB binding to predicted sites in the 6q23 locus in 
erythroid progenitor cells by ChIP-qPCR. Primers were designed for the sites that were 
strong candidates based on in-silico experiments. Experiments were performed to 
optimise conditions for quantitative PCR on MYB ChIP material from healthy 
individuals. Mock IgG method was used in calculation of the enrichment on target sites: 
This method depends on normalization with a mock IgG: Fold enrichment = 2(ct IgG-ct ab).  
 
Figure6.12: MYB Binding at chromosome 6q: SYBR-Green RT-PCR was 
performed. 
Enrichments relative to IgG (rabbit immunoglobin G) were calculated to confirm 
quantitative MYB binding to targets. CTSG was used as positive control and NFM was 
























MYB ChIP (-/-)  genotype
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Strong MYB binding was observed around SNPs rs9399137 and rs9389268 although 
enrichments observed are significantly less compared to GATA-1 ChIP, and this is 
probably related to the antibody (Figure 6.12). 
A number of different MYB antibodies were tried in the experiments, the MYB antibody 
1:1 Millipore gave the best enrichments for chromatin immunoprecipitation 
experiments. 
 
6.2.3.3 Investigation of differential MYB binding at the 6q23 locus by ChIP-qPCR 
in HPFH +/+ vs HPFH -/- chromatin 
 
Previous in-silico experiments suggested that MYB binding motifs are altered by certain 
high scoring SNPs at specific positions at the 6q23 locus (HMIP). To further investigate 
this region with individuals that are HPFH +/+ or HPFH -/- quantitative, ChIP-qPCR was 
used to validate the differences suggested by the in-silico experiments. 
 
 Erythroid progenitor cells were obtained from primary cultures of three paired sets of 
HPFH +/+ and -/- individuals. The HPFH +/+ individuals were members of the same 
family in which the QTL was first identified. One +/+ individual donated blood twice. 
ChIP-qPCR was carried out as previously described using the same anti-MYB antibody 
(1:1 clone, Millipore). 
 
To ensure that we harvest the erythroid progenitor cells from the +/+ and -/- individuals 
at equivalent stages of the MYB expression, we initially obtained a profile of MYB 
expression in cells from the individuals of both genotypes. MYB expression profiles 
suggested that day 4 would be optimal (peak of MYB expression and there is no 
significant difference between individuals of different genotypes in terms of MYB 
expression). As validation, the cells were also closely monitored by FACS analysis as 
described in Chapter 3. When performing ChIP on erythroid progenitor cells at similar 
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stages of expression, we ensure any difference observed in MYB binding is due to the 
alteration of binding by the SNPs and not because of differential expression of MYB. 
 
SYBR-Green RT-PCR was performed with material from six erythroid cultures (three 
HPFH -/- individuals and two HPFH +/+ individuals). Two technical experiments for 
each culture were performed except for the last pair because of limited material. 
Enrichments relative to IgG (rabbit immunoglobin G) were calculated to confirm 
quantitative MYB binding to targets. Results are normalized to positive control CTSG 
enabling us to cross compare MYB binding to the same target in different individuals. 
 
Our results suggested differential binding of MYB around SNPs rs9399137 and 
rs9389268, but failed to suggest any differential binding around SNP rs55936352. The 
results are consistent with the same binding pattern observed in all three biological 
replicates (Figure 6.12). SNPs rs9399137 and rs9389268 coincide with DNase 


















Figure6.13: Differential MYB binding at the 6q23 locus. 
A: Binding of MYB was assessed by SYBR-Green RT-PCR on MYB ChIPped 
chromatin prepared from HEPs  from three paired individuals, HPFH +/+ vs. HPFH -/- . 
Enrichments relative to IgG (rabbit immunoglobin G) were calculated to confirm 
quantitative MYB binding to targets. Results are normalized to positive control CTSG to 
enable cross comparison of MYB binding to the same targets in different individuals. B:  
Mean of MYB  binding of 3 replicates. T-test was performed (n: 3) and suggested that 
there is a significant difference between two groups around rs399137 and rs9389268 
(p: 0, 02/ 0, 05). 
 
rs9399137 rs9389268 rs55936352
-/- genotype 1.25 1.6 0.73












l MYB ChIP biological replicate 1
rs9399137 rs9389268 rs55936352
-/- genotype 0.78 1.43 0.82













MYB ChIP biological replicate 2
rs9399137 rs9389268 rs55936352
-/- genotype 1.16 0.89 0.75

















6.2.3.4 Investigation of allele specific binding of MYB to high scoring SNPs at the 6q23 
locus inHPFH +/- erythroid chromatin 
 
Bioinformatics analysis revealed SNP rs9389268 in close proximity to a MYB binding 
motif. ChIP-qPCR experiments performed with HPFH +/+ and HPFH -/- erythroid 
chromatin also suggested differential MYB binding around SNP rs9389268.  To further 
investigate and validate differential binding of MYB to the minor allele (+) and major 
allele (-), we selected individuals that are heterozygous for this key SNP for allele 
specific ChIP. Healthy unrelated individuals were recruited and genotyped for the SNP 
of interest (rs9389268). Cell cultures were performed with erythroid progenitor cells 
isolated from peripheral blood of individuals who were heterozygous for the candidate 
SNPs.  
 
Erythroid progenitor cells were harvested and cross-linked at the stage of peak MYB 
expression i.e. day 4 of phase II erythroid cultures. Cross-linked material was 
immunoprecipitated with the same MYB (1:1 Millipore) antibody and chromatin was 
eluted as previously described. Eluted chromatin was tested for enrichment by SYBR 
green RT-PCR. Enrichment of positive control CTSG and targetof interest (rs9389268) 
was calculated (Figure 6.13).  
 
The results suggest weaker binding of MYB in chromatin of HPFH +/- individuals to 
minor allele G that is associated with elevated HbF. These results are consistent with 
the results observed with experiments performed with HPFH +/+ and HPFH -/- 
individuals. The main difference and the main advantage of this approach over ChIP-
qPCR experiments is that the differential binding is internally controlled and the results 




Figure6.14: SYBR-Green RT-PCR was performed to confirm MYB enrichment of 
positive control CTSG and target rs9389238. 
Shown as fold enrichment, normalized to NFM as a housekeeper gene and to IgG 




Figure6.15: Allele specific MYB binding to rs9389268. 
A: Snapshot was performed with chromatin immunoprecipitated with MYB (clone 1:1 
Millipore) and input. Ratio of MYB binding to major allele A and minor allele G was 
calculated by using gene marker program which provides the peak height of both 
alleles. Calculation were done with both chip material and input for each individual. B: 
Experiments were performed with three biological samples that were heterozygotes for 
the SNPs of interest .A to G ratio of chip material was calculated and normalized to 
input. T-test was performed (n: 3) and suggested that there is significant difference 
























6.2.4 KLF1 binding  at chromosome 6q QTL 
 
In-silico experiments suggested the presence of KLF1 binding sites at chromosome 6q 
and this was validated by ChIP experiments. Colleague PhD student Kiran Jawaid 
performed ChIP-chip with KLF1 but failed to suggest any strong KLF1 sites at HMIP 
block two. I applied ChIP-qPCR to investigate the potential binding sites. 
 
6.2.4.1 Control test for KLF1 enrichment 
 
Following confirmation of the chromatin size, we proceeded to immunoprecipitation 
using an anti KLF1 antibody (provided kindly by Prof. Sjaak Philipsen). After reverse 
cross-linking and purification of the ChIP DNA, a small amount was tested for 
enrichment by SYBR green RT-PCR. A site in the promoter region of beta globin gene 
(HBB) is a known KLF1 binding site and was used as positive control in KLF1 ChIP 
experiments.  This step is a check point to confirm if ChIP with the target antibody has 
been successful.  
 
 
Figure6.16: SYBR-Green RT-PCR for HBB enrichment was performed to confirm 
KLF1 ChIP (using antibody KLF provided by Prof. Sjaak Philipsen). 
Shown as fold enrichment, normalized to NFM as a housekeeper gene and IgG (ChIP 
with mock antibody). Enrichment results are Mean values of 5 biological replicates +/- 

























6.2.4.2 Quantitative KLF1  binding at the 6q23 locus (HMIP) 
 
Previous in-silico experiments demonstrated the presence of KLF1 binding motifs at 
specific positions at the 6q23 locus (HMIP) (See Chapter 3). The presence of some of 
the KLF1 binding sites were validated by EMSA experiments (Chapter 4). Although 
EMSA experiments are informative the results were obtained in vitro from k562 cell 
lines. We wanted to validate KLF1 binding to predicted sites 6q23 locus in primary 
human erythroid progenitor cells by ChIP-qPCR.  
 
Primers were designed for the sites that were strong candidates based on in-silico 
experiments. Experiments were performed to optimise conditions for qPCR on KLF1 
ChIP material from healthy individuals. Mock IgG method was used in calculation of the 
enrichment on target sites. This method depends on normalization with a mock IgG: 
Fold enrichment = 2(ct IgG-ct ab) (Figure 6.16). 
 
Figure6.17: KLF1 Binding at chromosome 6q: SYBR-Green RT-PCR was 
performed. 
Enrichments relative to IgG (rabbit immunoglobin G) were calculated to confirm 
quantitative KLF1 binding to targets. HBB was used as positive control and NFM was 
used as a negative control. 
 
Strong KLF1 binding was observed around SNPs rs9389268 and rs9494142  
(Figure 6.17). We investigated different KLF1 antibodies and the best enrichment was 























KLF1 ChIP -/- genotype
-/- genotype
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6.2.4.3 Investigation of differential KLF1 binding at the 6q23 locus using ChIP-qPCR in 
HPFH +/+ vs HPFH -/- erythroid chromatin 
 
Erythroid progenitor cells were obtained from primary cultures of whole blood taken 
from three paired sets of HPFH +/+ and HPFH -/- individuals. The +/+ individuals were 
members of the same family in which the QTL was first identified. One +/+ individual 
donated blood twice. ChIP-qPCR was carried out as previously described using the 
same anti-KLF1 antibody. To ensure that we harvest the erythroid progenitor cells from 
the HPFH +/+ and -/- individuals at equivalent stages of KLF1 expression, we initially 
obtained a profile of KLF1 expression in cells from individuals of both genotypes. KLF1 
expression profiles suggested that phase II day 7 would be optimal, when KLF1 is at 
the peak of its expression and there is no significant difference between individuals of 
different genotypes in terms of KLF1 expression. As validation, the cells were also 
closely monitored by FACS analysis as described in Chapter 3. Hence chromatin 
obtained at phase II day 7 of erythroid progenitor cells was used for both GATA-1 and 
KLF1 ChIP-qPCR experiments. In performing ChIP on erythroid progenitor cells at 
similar stages of expression, we ensure any difference observed in KLF1 binding is due 
to the alteration of binding by the SNPs and not because of differential expression of 
KLF1.SYBR-Green RT-PCR was performed with material from six erythroid cultures 
(three HPFH -/- individuals and two HPFH +/+ individuals). Two technical experiments 
for each culture was performed except the last paired because of limited material. 
Enrichments relative to IgG (rabbit immunoglobin G) were calculated to confirm 
quantitative KLF1 binding to targets. Results are normalized to positive control HBB 
enabling us to cross compare KLF1 binding to the same target in different individuals. 
Results suggested the differential binding of KLF1 around SNPs rs9389268 and 
rs9494142. The results are consistent with the same binding pattern observed in all 
three biological replicates (Figure 6.17). SNPs rs9389268 and rs9494142 coincide with 






Figure6.18: Differential KLF1 binding at the 6q23 locus. 
A: Binding of KLF1 was assessed by SYBR-Green RT-PCR on 
KLF1immunoprecipitated chromatin prepared from HEPs  from three paired individuals, 
HPFH +/+ vs. -/- . Enrichments relative to IgG (rabbit immunoglobin G) were calculated 
to confirm quantitative KLF1 binding to targets. Results are normalized to positive 
control HBB to enable cross comparison of KLF1 binding to the same targets in 
different individuals. B:  Mean of KLF1  binding of replicates. T-test was performed (n: 




(-/-) genotype 0.67 0.8










B KLF1 ChIP biological replicate 1
rs9494142 rs9389268
(-/-) genotype 0.57 0.69












B KLF1 ChIP biological replicate 2
rs9494142 rs9389268
(-/-) genotype 1.17 1.01











B KLF1 ChIP biological replicate 3
rs9494142 rs9389268
(-/-) genotype 0.8 0.84



















A QTL for HbF levels and F cells was localized to chromosome 6 by genetic 
association studies. High-resolution genotyping and further analysis refined the location 
to an intergenic region between the HBS1L and MYB genes (HMIP). These SNPs lie in 
3 linkage disequilibrium blocks, HMIP 1-3. 
 
HMIP2 accounts for the strongest effect on FC variance at this locus. Using chromatin 
immunoprecipitation experiments, our group showed that this area has significant 
histone acetylation and RNA polymerase II activity. Several strong GATA-1 binding 
sites are concentrated within HMIP2, three of which coincide with DNase I 
hypersensitive sites. Such patterns of RNA polymerase II binding, histone acetylation 
and GATA-1 binding around DNase I hypersensitive sites is seen in known erythroid 
control regions, suggesting that this intergenic space may contain major distal 
regulatory elements (Wahlberg et al 2009). 
 
GATA-1 is a well-known erythroid transcription factor, which acts as an activator of the 
globin genes. Its role as a transcription factor is critical to erythropoiesis, which made it 
an important factor to investigate at the 6q QTL. Investigating GATA-1 binding at this 
locus would lead to a better understanding of how this QTL is regulated and how it may 
be directly or indirectly influence HbF levels.  
 
In this thesis, I report the GATA-1 binding profile of the previously detected sites 
quantitatively. The results confirm the binding of GATA-1 to all sites that were 
previously detected by ChIP-chip. GATA-1 ChIP using erythroid chromatin from three 
paired sets of erythroid progenitor cells from HPFH +/+ and -/- individuals confirmed 
the differential GATA-1 binding patterns between the HPFH +/+ and HPFH -/- 
genotypes previously shown by fellow colleague Kiran Jawaid.    
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In the previous ChIP-chip experiments, GATA-1 bound strongly a site designated as 
GATA-1 peak 4 in the individuals with -/- genotype, however no GATA-1 binding 
signals were detected in the individual with +/+ genotype. Although these binding 
signals were confirmed by two technical repeats on one biological sample for each 
individual (Figure 6.5), these results are not quantitative and should be validated by 
qPCR. To confirm the differential binding quantitatively, quantitative Real Time PCR 
(qPCR) on GATA-1 immunoprecipitated chromatin was performed on the previously 
detected sites. Results suggested that GATA-1 binding is altered in the region 
encompassing the SNP rs94944142. The GATA-1 binding is weaker in peak four in 
individuals homozygous for SNPs associated with elevated HbF (Figure 6.6). ChIP-
qPCR results also suggested differential binding of GATA-1 to another key area: 
GATA-1 peak 3. This region also encompasses key variant i.e. (SNP rs66650371) 
that is associated with elevated HbF and coincides with conserved GATA-1 sites and 
DNase hypersensitive sites.  
 
ChIP-qPCR results suggest differential GATA-1 binding to key regions, which also 
encompass variants that are associated with elevated HbF (Figure 6.6). As further 
validation, I have performed allele specific ChIP experiments on erythroid chromatin 
from individuals heterozygous for these SNPs. In both cases, the results confirmed 
differential GATA-1 binding to specific SNPs (rs9494142 and rs66650371) and 
additionally, weaker binding of GATA-1 to the minor (+) allele that is genetically 
associated with elevated HbF levels is demonstrated. These results are consistent with 
previous ChIP-qPCR results and increase the likelihood of these SNPs being the 
causative variants in the region. Here, we provide functional confirmation for the  
in-silico transcription factor predictions. The differential GATA-1 binding at this site 
supported the recent study by Farrell et al who identified enhancement activity of a 
region in the chromosome 6q which includes GATA-1 binding motifs.  
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Differential binding of GATA-1 to our target sites may lead to a decrease in the 
enhancement activity around those target sites and to differential expression of flanking 
genes (Farrell et al 2011). 
 
Another recent study by Stadhouders et al demonstrated that a transcription factor 
complex including LDB1, GATA-1, TAL1, ETO2 and KLF1 is also present at the 
chromosome 6q. The group proposed a model for Myb activation by distal enhancers 
which are dynamically bound by KLF1 and the GATA1/TAL1/LDB1 complex, primarily 
functioning as a transcription elongation element through chromatin looping. Previous 
studies showed that this complex is required to maintain chromatin looping to form an 
active chromatin hub (ACH) at the β-globin locus to initiate transcription (Tolhuis et 
al2002, Song et al2007).  
 
The study by Stadhouders et al also demonstrated that in the proliferating cells 
expressing Myb, enhancers within the Myb-Hbs1l intergenic region were shown to form 
an active chromatin hub (ACH). The Myb promoter and first intron are included within 
the ACH and it is lost when cells terminally differentiate, concomitant with the 
downregulation of Myb and decreased binding of TF complexes at the distal 
enhancers. These LDB1 complexes were found to bind at sites in the HBS1L-MYB 
intergenic region in MEL cells and primary mouse erythroid progenitors . These sites 
coincide with GATA-1 peak three and four in our primary human erythroid progenitors. 
Further experiments showed characteristic features supporting enhancer activity 
(including the presence of histone acetyl transferase p300) and led to the conclusion 
that these binding sites contain active regulatory elements in erythroid 
progenitors(Stadhouders et al 2012). 
This study provided further understanding about the function of the HBS1L-MYB 
intergenic region and supports the idea that regions around GATA-1 peak three and 
four located at -84kb and -71kb away from the MYB transcription start site are key 
regions of HMIP block two. 
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The altered KLF1 binding observed around SNP rs9494142 can be due to the 
presence of KLF1 and GATA-1 in the same complex. Tallack et al demonstrated that 
the vast majority of KLF1 binding sites are located at large genomic distances from 
known transcription start sites and are co-occupied by GATA-1 (Tallack et al 
2010).GATA-1 binding could be necessary to initiate the binding of the complex and 
the altered binding of GATA-1 may lead to altered binding of other transcription factors 
in the complex. Tallack et al also suggests that KLF1 is not only capable of, but 
necessary for, long-distance gene regulation within erythroid cells which could explain 
the differential regulation of MYB and/or HBS1L genes due to disruption of KLF1 
binding. 
Differential binding of KLF1 around SNP rs9389268 was also suggested from the work 
carried out in this thesis. EMSA results suggested a potential complex formation 
between KLF1 and MYB and ChIP results suggested altered binding of MYB and KLF1 
factors around SNP rs9389268. Co-occupation of a region could suggest a complex 
formation between MYB and KLF1 but further studies are necessary to support this 
suggestion. 
 
MYB and KLF1 transcription factors are both crucial regulators of erythropoiesis and 
several studies show that there is a correlation between the expression profiles of 
these factors. Bianchi et al suggested that MYB transcription factor promotes 
erythropoiesis by transactivation of human KLF1, likely within the upstream enhancer 
region. ChIP and enhancer assays by the same group demonstrated that MYB binds to 
KLF1 promoter.  
Another study by Suzuki et al suggested KLF1 expression is downregulated in Myb 
knockdown mouse (Bianchi et al 2010, Suzuki et al 2013). The importance of KLF1 
binding in long-distance regulation is already stated and in this case, it is possible that 
MYB with KLF1 regulate the flanking gene MYB which would explain the difference in 
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MYB expression observed in individuals with different genotypes in this region (Jiang et 
al 2007). 
 
 Another possibility is the auto regulation of MYB gene by its own transcription factor 
and the altered binding of MYB can lead to down regulation of MYB due to altered 
activation by the transcription factor. MYB gene expression should be strictly regulated 
because of its key roles during erythropoiesis. A feedback mechanism of MYB would 
prevent overexpression of MYB and a positive autoregulation would enable quick 
response in expression when MYB transcription factor is needed. Studies showed that 
key transcription factors like GATA-1 bind to their own promoters to regulate the 
expression. Nishikawaet al showed, in transgenic zebra fish, that Gata1 positively 
auto-regulates its own expression. The group demonstrated that mutations of Gata1 
that decreased self-association greatly reduced the transactivation activity of Gata1.  
A similar mechanism is possible for MYB regulation. A study suggested that MYB 
transcription factor binds to 5' flanking region of the MYB gene positively autoregulating 
the expression of the gene in order to maintain high levels of MYB protein in cells that 
are proliferating (Nicolaides et al 1991). Hence, differential binding of the MYB 
transcription factor to candidate SNPs may lead to differential expression of MYB which 



















































7.1.1 Chromosome 6q QTL 
 
A quantitative trait locus (QTL) controlling HbF levels was mapped to a 1.5 Mbregion 
on chromosome 6q23 in an Asian-Indian kindred with beta thalassaemia and 
heterocellular hereditary persistence of fetal hemoglobin (HPFH). Annotation of this 
region showed that it contained five protein coding genes, ALDH8A1, HBS1L, MYB, 
AHI1, and PDE7Bof which two (MYB andHBS1L)were expressed in erythroid tissue . 
The region also contained 5 pseudo genes and 4 non-coding transcripts(Close et al 
2004, Jiang et al 2006). 
 
Further experiments focused on the 6q23 transcriptome to investigate if 5 candidate 
genes in the region are expressed in the erythroid progenitor cells and if there is 
differential expression of these genes between high F and low F individuals. A panel of 
high F and low F individuals were recruited for primary erythroid cultures and 
expression profiles of the 5 genes at different stages of phase II were obtained. The 
results demonstrated that onlyMYB and HBS1L genes are expressed in erythroid 
progenitor cells. Further analysis of the results suggested that MYB and HBS1L are 
quantitative trait genes, with variable expression in the erythroid progenitor cells of 
healthy adults. Analysis of erythroid cultures from a number of individuals has revealed 
a clear correlation of elevated peripheral blood HbF with low levels of MYB and HBS1L 
expression in erythroid cultures. Furthermore, over expression of MYB in K562 cells 
inhibited γ-globin gene expression when compared with the parental cell line. However, 




High resolution genetic mapping subsequently refined the 1.5 Mbintervals to an 
intergenic region of 79 kb located between the HBS1L and MYB genes. It would seem 
that the QTL which reside in the intergenic region regulate HbF indirectly via control of 
the flanking genes. Our group then showed the presence of regulatory elements in the 
HBS1L-MYB intergenic region (HMIP) evidenced by GATA-1 binding coinciding with 
strong histone acetylation, RNA polymerase II activity, and erythroid specific DNase I 
hypersensitive sites(Wahlberg et al 2009). The presence of enhancer elements were 
supported by mouse studies in which interaction of the homologous region with the 
promoter and first intron of the flanking Myb gene via chromatin looping was 
demonstrated (Stadhouders et al 2012).  
 
The next step towards discovery of the causative SNPs involved comparing the 
detailed sequence of the region between the high F and low F individuals. 
Resequencing of two key individuals (HPFH +/+ vs. HPFH -/-) from the family that led 
to discovery of the 6q QTL revealed new SNPs in the HBS1L-MYB intergenic region.  
Genetic studies suggested some of the key SNPs were strongly associated with 
elevated HbF levels. The key SNPs were located in two regions that coincided with 
transcription factor binding sites. Importance of these sites was supported by EMSA 
and ChIP experiments that suggested these variants alter transcription factor binding. 
 
The next step was to associate these variants with the expression of the flanking genes 
i.e. MYB and/or HBS1L. We hypothesise that these SNPs affect expression of the 
flanking MYB gene but not that ofHBS1L .To demonstrate unequal expression, we 
recruited individuals who are heterozygous for both the intergenic SNPs and 
heterozygous for the expression markers in the flanking genes. Individuals who are 
homozygous (HPFH +/+ and HPFH -/-) for intergenic SNPs but heterozygous for 





The MYB gene (also known as c-Myb) was first identified as the cellular homologue of 
v-Myb, an oncogene found in two avian retroviruses that induce leukemia.  
The MYB gene is highly conserved through evolution (Lipsick, 1996); the major product 
of the human gene is a 72kDa nuclear protein of 640 amino acids. The protein is 
expressed in most haematopoietic tissues and is highly expressed in immature 
haematopoietic cells (Gonda et al 1982, Westin et al 1982) (Figure 7.1). 
 
The MYB protein (72 kDa) has an isoform of 89 kDa (MYB-9A) caused by a splice 
variant which leads to an insertion of 363 base pairs (bp) between exon 9 and 10 (exon 
9A). The p89 form of MYB displays higher transactivation activity, however little is 
known about its functional relevance. Jiang et al confirmed that the pattern of MYB-9A 
expression was similar to that of the total MYB expression in erythroid progenitors.   
 
The MYB transcription factor plays crucial roles in regulation of proliferation and cell 
lineage commitment of erythroid progenitor cells. This is supported by the fact that 
mice with myb knock-down will die at embryo stage due to the lack of erythroid and 
myeloid development.MYB is required for maintenance of proliferation by exerting a 
direct role in cell cycle control. This transcription factor is highly expressed in immature 
haematopoietic cells and is down-regulated as the cells differentiate. Expression of 
MYB blocks differentiation in neuroblastoma cell lines, suggesting down-regulation of 
MYB is also required for terminal differentiation (Westin et al 1982, Oh et al 1999). 
In addition to controlling erythropoiesis, the MYB transcription factor has several other 
essential roles throughout the different stages of haematopoiesis as well as being 
involved in leukaemogenesis (Greig et al 2008). Despite its importance in many 
biological systems, the regulatory mechanisms controlling MYB expression are still not 
clear. Various factors including GATA-1 (Bartunek et al 2003), Ets-1 (Sullivan et al 
1997) have been suggested to regulate MYB expression. Other studies have shown 
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that MYB introns contain regulatory sequences which play an important part in MYB 
control and are represented by an attenuation block in the first intron (Bender et al 
1987) and enhancer elements in introns 1 and 4 (Dooley et al 1996;Seib et al 1994).  
 
Studies have demonstrated that MYB is a key target of the microRNA (miRNA) miR-
150 (Xiao et al 2007)and that one pathway of MYB regulation is through the two 
conserved miR-150 binding sites in the 3' UTR of MYB mRNA. miR-150 repression of 
MYB in CD34+ human bone marrow cells not only supported MYB’s key role in 
erythroid and megakaryocytic differentiation, but also suggested that modulations of its 
level is critical to its role in haematopoiesis (Lu et al 2008).  
Jiang et al demonstrated that MYB expression in erythroid progenitor cells of healthy 
adults is variable and that individuals with higher HbF levels have relatively lower MYB 
levels. It is likely that MYB is a quantitative trait gene and that level of the MYB product 
is controlled by cis-regulatory and trans-acting factors.MYB thus appear to be the prime 
candidate for our allele specific expression study since altered expression of MYB 
clearly influences HbF levels. 
 
Figure 7.1: MYB gene and MYB protein structure. 
MYB gene spans a region of 37.8 kb and consists of 15 exons coding for a protein that 
is formed of 640 amino acids. The MYB transcription factor has a DNA binding domain 





The Hsp70 subfamily B suppressor 1-like gene (HBS1L) is the human ortholog of the 
Sacharomyces cerevisiae HBS1 gene. It encodes a GTP-binding protein which shares 
structural features with elongation factor eEF-1A and release factor 3 (eRF3) families 
(Wallrapp et al 1998).Multiple alternatively spliced transcript variants encoding different 
protein isoforms have been found for this gene but they are not well characterized. 
HBS1L is expressed in multiple tissues with the highest expression in heart and 
skeletal muscle. 
Recent genome-wide datasets generated by the ENCODE consortium shows that 
HBS1L was expressed at similar levels in all cell types and was not restricted to 
hematopoietic cells. Analysis of the results also reveals that there is no correlation 
between the expression of HBS1L and the HBS1L-MYB intergenic regulatory activity. 
Its role, if any, and to what extent in the regulation of HbF, is yet to be determined. QTL 
mapping together with previous genome-wide association study involving 
approximately 110,000 gene-based SNPs in mild and severe beta-0-thalassemia/Hb E 
patients revealed SNPs in HBS1L significantly associated with Hb F levels and severity 
of the disease. One study focused on a SNP located in HBS1L exon 1 that was 
suggested to be associated with severity in beta thalassemia/Hb E patients 
The variant was a C32T polymorphism that was identified in a potential E-box binding 
site of HBS1L exon 1 and it was speculated that disruption of the binding site can lead 
to the elevated HbF levels. The SNP was genotyped in 455 beta thalassemia/Hb E 
patients and results suggested that C allele is associated with elevated HbF levels 
(Pandit et al 2008). 
 
7.1.2 Allele specific expression 
 
Various studies have indicated that expressions of a large proportion of human genes 
are subject to variable cis-acting influences (Bray et al 2003). Cis-acting variants 
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affecting gene expression may be located in the transcribed sequence itself, 
promoters, intronic sequence or in distant regulatory elements (Levine and Tjian, 
2003). In the absence of cis-acting influences differentially affecting the transcription or 
stability of the mRNA from each copy of an autosomal gene, both copies of that gene 
will be equally expressed. Identification of unequal allelic expression in an individual 
heterozygous for any cis-acting polymorphism affecting transcription suggests that the 
gene is subject to cis control. 
 
Assays of relative allelic expression is an effective approach for exploring the influence 
of cis-acting regulatory SNPs. Assays of relative allelic expression expose only the 
variance in gene expression resulting from cis-acting effects since it is an intra-
individual approach. Each allele acts as an internal control for the other, allowing 
detection of genuine cis-acting effects, while controlling for the trans-acting 
environment. Thus assay of relative allelic expression is a powerful approach for 
examining the influence of specific haplotypes on expression of the target gene (Bray 
et al 2005). Our allelic expression experiments have been performed using Snapshot, a 
technique with quantitative properties with the aid of Nicholas Bray and Matthew Hill 























We have performed experiments following two different approaches to associate the 
intergenic variants with the expression of the flanking MYB and HBS1L genes. Initially, 
we have compared MYB and HBS1L expression profiles in HPFH +/+ vs. HPFH -/- 
individuals. Next, we have performed allele specific expression experiments with HPFH 
+/- individuals to confirm the association of intergenic variants in HMIP-2 with the 
expression of the flanking MYB and HBS1L genes intraindividually. 
 
7.2.1 Expression profiles of MYB and HBS1L within erythroid progenitor cells 
 
Previous studies in our group have shown that MYB and HBS1L are quantitative trait 
genes with variable expression during erythropoiesis. Expression profiles of each gene 
at different stages of erythropoiesis in primary cultures of individuals with different HbF 
levels and different genotypes at the 6q intergenic interval would be most informative. 
The profiles would also provide information for harvesting cells at the optimum stage 
for allele specific gene expression experiments 
 
We constructed expression profiles of the MYB and HBS1L genes from erythroid cells 
at sequential days of Phase II. Ct values were normalised to the house-keepingHPRT 
gene. MYB expression peaks at early stages of phase II day (2-4), then gradually 
decreases as the cells differentiate (Figure 7.1 A). In contrast, HBS1L expression 
fluctuates during phase II with no clear expression pattern during differentiation (Figure 
7.1 B). From the expression profile it would appear that phase II day 3 is an ideal stage 
for harvest since both genes are at the peak of their expression. This stage coincides 




7.2.2 Comparison of MYB and HBS1L expression profiles in HPFH +/+ vs. HPFH -/- 
individuals 
 
The study by Jiang et al was performed using erythroid progenitor cells from individuals 
who were phenotypically selected as high HbF or low HbF. Here, we obtained primary 
erythroid cells from high HbF individuals who were also homozygous for all the variants 
in the HBS1L- MYB intergenic region that are associated with elevated HbF levels, and 
low HbF individuals who are also homozygous for the absence of variants associated 
with elevated HbF levels. These individuals were referred to as HPFH +/+ and  
HPFH -/-, respectively. Cells cultured from individuals of both genotypic haplotypes 
shared a similar expression pattern with peak of expression for MYB gene at day 2-4 of 
phase II and variable expression for HBS1L.  
 
MYB expression peaks at relatively early stages of phase II and then gradually 
decreases in both genotypes (Figure 7.3). Cells cultured from HPFH +/+ individuals 
showed lower MYB expression levels at later stages (day5 –day 10) of the culture 
when compared to MYB expression levels of erythroid cells cultured from low HbF 
individuals. The result is more striking when MYB expression is normalized to day 4 
(Figure 7.4). The sharpest decrease in MYB expression can be observed at day 5 in 
HPFH +/+ individuals; in contrast, the sharp decrease is observed later at day 7 in 
HPFH -/- individuals suggesting a difference in the MYB expression pattern between 
two genotypeslater stages os culture. These are preliminary results and experiments 
with 20 individuals (3 +/+, 8-/- and 9+/-) are being performed to investigate expression 
patterns of MYB with different genotypes.  
Expression pattern of HBS1L between individuals of the two different genotypes (HPFH 
+/+ vs. HPFH -/-) was presented. The results are from a pair of individulas and 
suggests that a larger sample size for verification of MYB expression with genotype in 
the HBS1L-MYB  is needed.(Figure 7.3).Experiments on erythroid RNA from an 
additional20 individuals (3 +/+,  8-/- ,and 9+/-) are being performed to investigate 





Figure7.2:  Relative MYB and HBS1L expression profile from phase II day1-10 
HEPs: 
Expression profiles of MYB and HBS1L in primary human erythroid progenitor cells 
taken on sequential days (1 - 10) of Phase II culture. Results are analysed by RT-PCR 
in duplicate using gene specific primers on erythroid RNA from a single erythroid 
culture. Individual designated as -/- is homozygous for the absence of HMIP block 2 






















































Figure7.3: Relative MYB and HBS1L expression profile from phase II day1-10 
HEPs: 
 Expression profiles of MYB and HBS1L in primary human erythroid progenitor cells 
taken on sequential days (1 - 10) of Phase II culture. Results are analysed by RT-PCR 


































































































 Individual designated as -/- is homozygous for the absence of HMIP block 2 SNPs 
associated with elevated HbF. Individual designated as +/+ is homozygous for the 
presence of HMIP block 2 SNPs associated with elevated HbF. To cross compare 
expression profiles of +/+ vs. -/- individuals, expression profiles were normalized to 
HPRT (Figure 7.3 A) and then normalized to d1 expression (Figure 7.3 B). 
 
Figure7.4: Relative decrease in MYB expression from day 4 to day 10. 
To cross compare relative decrease in MYB expression with +/+ vs. -/- individuals, 
expression profiles were further normalized to day 4 expression. 
 
7.2.3 Allele Specific Expression of MYB intronic SNP rs210796 
 
 
Comparing expression profiles of HPFH +/+ and HPFH -/- individuals has many 
limitations. We need to culture the cells from all individuals under the same exact 
conditions and use housekeeping genes as internal control to normalise for the 
differences that can be observed between cultures because of the influence from 
potential trans-acting factors. Comparing expression of the allele intra-individually 
overcomes many of these limitations by controlling the trans-acting environment and 
this enables detection of cis-acting regulatory haplotypes with far greater sensitivity. 
Ideally, allele specific expression is applied using exonic (coding) SNPs. We wanted to 
apply this approach to investigate allele specific expression of MYB but the absence of 





























suggested that intronic polymorphisms may be used to tag un-spliced heteronuclear 
RNA (hnRNA).  
It has also been suggested that assays based on hnRNA provide a more specific test 
of transcriptional effects, as RNA-processing effects can be excluded but low 
abundance of hnRNA in total RNA preparations leads to “noise” in the assay. I 
screened four intronic SNPs (non-coding) of high frequency selected from the database 
(genome.ucsc.edu) to find appropriate SNPs for the allele specific expression 
experiments, and performed experiments using unspliced (primary) RNA (Figure 7.5). 
 Eventually the rs210796 (A/T) SNP in MYB intron 4 was selected based on its 
robustness in the assay. According to Hap Map data SNP rs210796 had a frequency of 
0.456 increasing the likelihood of detecting heterozygous genotypes. A total of 50 
healthy unrelated individuals of diverse ethnic backgrounds were recruited. DNA was 
isolated from peripheral blood of these individuals and genotyped for the relevant 
HBS1L-MYB intergenic variants, for the MYB intronic rs210796 SNP on chromosome 
6q23 and for HBS1L exonic SNP rs13064 (as control) (See appendix for genotyping 
results).  
 
Figure 7.5: Informative SNP selection in MYB gene. 
4 SNPs one from intron 4(rs210796) and three from intron 14 (rs9385719, rs210946 
and rs2179308) were selected as informative SNPs. Each SNP had a frequency of > 
0.45 increasing likelihood of heterozygosity. 
 
 







              Intron 4                 Intron 14 
 
                        -----------------I----------- A/T--------I---------------------------------------------------I----------------- A/G ---------- G/T ----------------- A/G---------I---------
- 
                       
             
   Position 39615537             39628945 39637713            39643021 
        4B                         14C   14B                    14A 
 
     
 
   SNP ID          rs210796        rs9385719  rs210946                 rs2179308  
 








7.2.3.1 Erythroid Cultures and Snapshot 
 
 Individuals with the appropriate intergenic and MYB intron 4 genotypes were selected 
for culture studies. SNP rs210796 (T/A) in MYB gene intron 4 was selected as the 
informative SNP to asses allele specific expression of MYB gene. Five healthy 
unrelated individuals heterozygous for both the HMIP block 2 haplotype i.e. (+/-) and 
MYB intronic SNP rs210796 were used as test samples. The (+) haplotype contains 
SNPs associated with elevated HbF; while the (-) haplotype does not contain any SNP 
associated with elevated HbF. Five healthy unrelated individuals homozygous for the 
HMIP block 2 haplotype( 1 +/+ and 4  -/-) but heterozygous for MYB SNP rs210796 
acted as controls for assessment of T:A expression imbalance. 
 
 
RNA was isolated from phase II day 4 HEP cells and converted to cDNA with random 
hexamers instead of oligo dT since the SNP rs210796 was an intronic SNP.  A 
fragment of 260bp encompassing rs210796 was specifically PCR amplified using 
genomic DNA and cDNA samples from the same individual. Genomic DNA samples 
were analysed by Snapshot in parallel with cDNA samples from the same individuals to 
assess relative expression of T and A alleles, and acted as controls. To control for 
variable amplification efficiency of T and A alleles, the T: A expression in cDNA 
samples were normalized in each individual internally with the genomic DNA T: A ratio 
and the T: A allele specific expression was derived. Experiments were performed in 
duplicates (Table 7.1 A).Five healthy unrelated individuals homozygous for the HMIP 
block 2 haplotype i.e. (+/+ or -/-) were used as controls for assessment of T:A 
expression imbalance. Individual 6 is HMIP-2 +/+ while the other 4 controls are HMIP-2 
-/- (Table 7.1 B).The results suggest that individuals who are heterozygous for 
HMIPblock two haplotype display greater imbalance in the relative expression of each 
allele when compared with individuals who are homozygous for the HMIP block 2 




Table7-1: Allele Specific Expression of MYB intronic SNP rs210796. 
The T: A ratio of DNA samples and cDNA samples from both technical replicate is 
presented in the table. The T: A expression in cDNA samples were normalized in each 
individual internally with the genomic DNA T: A ratio.  
Test Samples  
( +/- genotype ) 
Technical 
Replicate 1   
Technical 












T/A cDNA T/A    
      normalized     normalized T:A 
1 1.78 1.86 1.04 1.04 1.26 1.21 1.13 
2 1.95 2.04 1.05 2.4 2.61 1.09 1.07 
3 1.87 1.89 1.01 2.87 3.39 1.19 1.10 
4 1.68 1.92 1.14 0.98 1.06 1.08 1.11 
5 1.77 1.85 1.05 2.1 2.35 1.12 1.08 
Controls  
( +/+ or  -/- 
genotype ) 
Technical Replicate 1 
  













T/A cDNA T/A   
      normalized   normalized T:A
6 1.68 1.52 0.90 2.13 2.07 0.97 0.94
7 1.8 1.67 0.93 2.25 2.17 0.96 0.94
8 1.88 1.93 1.03 2.17 1.87 0.87 0.95
9 1.81 1.69 0.93 2.78 2.2 0.79 0.86




Figure7.6:  Allele specific expression of MYB SNP rs210796 T/A. 
Five healthy unrelated individuals whose genotype was +/- for the HMIP block 2 SNPs 
associated with elevated HbF were used as test samples. DNA and cDNA samples 
were analysed by Snapshot method for the relative expression of T and A alleles. The 
relative expression of T to A with cDNA samples were normalized to each individuals 
own T/A ratio with genomic DNA .Control samples refer to healthy unrelated individuals 
whose genotypes were +/+ or -/- for the HMIP block 2 SNPs associated with elevated 
HbF. Test samples refer to healthy unrelated individuals whose genotype was +/- for 
the HMIP block 2 SNPs associated with elevated HbF. Two sets of experiments were 
performed for each individual and both results are presented in the figure. T-test was 
performed (n: 10) and suggested that there is a significance difference between two 
groups (p: 0.03). 
 
7.2.4  Allele Specific Expression of HBS1L exonic  SNP rs13064 
 
Allele specific expression of HBS1L was also investigated in relation to the HMIP block 
2 variants. Presence of high frequency exonic SNP rs13064 (A/G) in HBS1L gene exon 
17 enabled us to perform experiments using this coding SNP as our informative SNP.  
Individuals who were recruited for investigation of allele specific expression of MYB 




























were genotyped for SNP rs13064. The experiments should be performed with the 
same cDNA samples to limit inconsistencies coming from sample preparation.  
 
The five individuals who were heterozygous for both the HMIP block 2 haplotype i.e. 
(+/-) and MYB intronic SNP rs210796, were genotyped for SNP rs13064 in HBS1L; but 
only 3 of the 5 individuals were heterozygous for SNP rs13064 (A/G) while other 2 
individuals were homozygous for the major allele (A/A). The 5 healthy unrelated 
individuals who were homozygous for the HMIP block 2 haplotype i.e. (+/+ or -/-) were 
also genotyped and four individuals were heterozygous for HBS1L SNP rs13064 (A/G) 
while one individual was homozygous for the major allele (A/A). 
The three healthy unrelated individuals heterozygous for the HMIP block 2 haplotype 
i.e. (+/-) were used as test samples. The (+) haplotype contains SNPs associated with 
elevated HbF; while the (-) haplotype does not contain any SNP associated with 
elevated HbF. All samples are heterozygous for this SNP.  The cDNA samples were 
analysed by Snapshot in parallel with genomic DNA samples from same individuals to 
asses relative expression of A and G alleles. To control for variable amplification 
efficiency of A and G alleles, the A: G expression in cDNA samples were normalized in 
each individual internally with the genomic DNA A: G ratio and the A: G allele specific 
expression was derived (Table 7.2 A).The four healthy unrelated individuals 
homozygous for the HMIP block 2 haplotype i.e. (-/-) were used as controls for 
assessment of A:G expression imbalance. These individuals are also heterozygous for 
the HBS1L exonic rs13064 SNP (Table 7.2 B). 
There was imbalanced expression of the A and G alleles both with controls and test 
samples, but there was no clear pattern with the A/GHBS1L allelic expression ratio 
ranging 0.40 to 1.60. The wide-range imbalanced expression was noted even in 
controls. The results suggest that the imbalanced expression may be related to other 
cis-acting polymorphisms that are not controlled in this experiment. Our sample size is 
limited because of restricted presence of heterozygotes for HBS1L exonic rs13064 
SNP (Figure 7.7). 
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Test Samples ( +/- genotype ) 
Sample ID DNA A/G cDNA A/G cDNA A/G  normalized
6 1.31 0.58 0.44 
13 1.19 0.97 0.81 
14 0.93 0.6 0.65 
Controls (  -/- genotype )  
Sample ID DNA A/G cDNA A/G cDNA A/G normalized
8 1.35 0.54 0.40 
11 0.93 1.48 1.58 
29 0.96 1.16 1.21 
47 1.19 0.99 0.84 
 
Table7-2: Allele Specific Expression of HBS1L exonic rs13064 SNP. 
The A: G ratio of DNA samples and cDNA samples from single experiment is 
presented in the table. The A: G expressions in cDNA samples were normalized in 





Figure7.7: Relative expression of A/G alleles of cDNA normalized to A/G ratio of 
genomic DNA is presented in the figure. 
One set of experiment was performed from the erythroid RNA sample of each 
individual and the result is presented in the figure. Control samples refer to individuals 
whose genotypes were +/+ or -/- for the HMIP block 2 SNPs. Test samples refer to 





























A quantitative trait locus (QTL) controlling HbF levels was mapped to chromosome 
6q23 in an Asian- Indian kindred with beta thalassaemia and heterocellular hereditary 
persistence of fetal hemoglobin (HPFH). The locus was refined to a region of 79 kbin 
the interval between HBS1L and MYB that has also been associated with other 
haematological traits. 
 
Earlier on, before the interval was refined, Jiang et al demonstrated that MYB and 
HBS1L (two genes flanking the intergenic transcripts) are quantitative trait genes,with 
variable expression in erythroid progenitor cells of healthy adults. Analysis of a number 
of erythroid cultures of individuals has revealed a clear correlation of elevated HbF with 
low levels of MYB and HBS1L expression. It was hypothesized that the intergenic 
variants indirectly regulate HbF through influence of the expression of the flanking MYB 
and/or HBS1L genes by altering erythropoietic and cell cycle kinetics; but the 
mechanism of regulation remained elusive. 
 
Recent genome-wide datasets generated by the ENCODE consortium were analysed 
to explore gene expression and intergenic regulatory potential within the HBS1L-MYB 
region for a variety of tissues. This analysis indicated that MYB expression was 
restricted to hematopoietic cells (erythroid K562 and lymphoid GM12878 cells) while 
HBS1L was expressed at similar levels in all cell types (ENCODE University of 
Washington DNase I Hypersensitivity by Digital DNase I; data not shown). 
 
Further assessment of intergenic regulatory activity using a combination of genome-
wide histone modification, DNaseI hypersensivity and genomic footprinting datasets 
suggested strong positive correlation between MYB expression levels and intergenic 
regulatory activity. In erythroid K562 cells, which express the highest levels of MYB, the 
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intergenic interval was transcribed and also contained numerous enhancer chromatin 
signatures and DNaseI hypersensitive sites (ENCODE University of Washington 
DNase I Hypersensitivity by Digital DNase I; data not shown). 
 
Lymphoid Gm12878 cells expressing lower levels of MYB displayed fewer areas of 
regulatory activity and DNaseI hypersensitive sites. Cell types not expressing MYB (i.e. 
HUVEC, NHEK, and HepG2) displayed heterochromatinized or polycomb-repressed 
intergenic regions with an absence of DNaseI-hypersensitivity, while still expressing 
HBS1L at high levels.  
 
Mukai et al reported a mouse model in which a transgene was inserted 77 kb upstream 
of the c-myb gene. The study was originally designed to examine the domain function 
of Erythropoietin receptor (EPOR) and the group generated three transgenic mouse 
lines bearing EPOR cDNA ligated to the Gata1 gene-hematopoietic regulatory domain.  
In one of the transgenic mouse c-Myb expression was markedly decreased in 
megakaryocyte/erythrocyte lineage-restricted progenitors (MEPs) of the homozygous 
mutant mice leading to an imbalance between erythroid and megakaryocytic cellsdue 
to insertion mutagenesis and causing severe anaemia, thrombocythemia and 
splenomegaly. The group demonstrated that these haematological abnormalities did 
not correlate directly to the transgenic expression of EPOR since level of the EPOR 
transgene was about 64 times higher in another transgenic mouse which showed no 
haematological abnormalities. The group then suggested that the transgene insertion 
could block the function of an important enhancer for c-myb gene expression.The 
results clearly demonstrated that c-Myb is an essential regulator of the erythroid-
megakaryocytic lineage bifurcation. Following on this, Suzuki et al confirmedthat 
insertion of this reported transgene in the intergenic region between the Hbs1l and Myb 
genes led to significant reduction of Myb expression, and reported slight reduction of 
Hbs1l expression.  
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The group also indicated that the mutant mouse exhibited typically elevated expression 
of embryonic globins and hematopoietic parameters similar to those observed in 
human HPFH and called this mouse a new mouse model of hereditary persistence of 
fetal haemoglobin (HPFH).  Further expression profiling of key transcription factors 
have demonstrated direct correlation of Hbs1l-Myb locus disruption and TR2/TR4 
(DRED pathway) expression and the group suggested that Myb activates DRED (direct 
repeat erythroid definitive) complex, a known repressor of embryonic and fetal globin 
genes in the adult. TR2/TR4 are repressors of embryonic globin genes. It was 
demonstrated that TR/TR4 recruit multiple epigenetic transcriptional corepressors such 
as DNA (cytosine-5)-methyltransferase 1 (DNMT1), nucleosome remodelling and 
histone deacetylase (NuRD), and lysine-specific demethylase-1 and its corepressor 
protein (LSD1/CoREST) and specially repress embryonic globin genes in differentiated 
erythroid progenitor cells (Cui et al 2011). 
 
These results support the findings that variation in the HBS1L-MYB genomic domain is 
responsible for elevated expression of the fetal globin genes and suggest the 
involvement of Myb and DRED complex in this regulatory pathway. 
The observations are in agreement with previous work by our group that demonstrated 
presence of regulatory elements in HBS1L-MYB intergenic region (HMIP) evidenced by 
GATA-1 binding coinciding with strong histone acetylation, RNA polymerase II activity, 
and erythroid specific DNase I hypersensitive sites. However, molecular insight into 
how this region regulates the flanking genes and which flanking gene is regulated 
remained elusive. 
 
Studies indicated that variants associated with many diseases are localized in non-
coding regulatory sequences that can regulate flanking genes though cis-acting 
influences on their expression (Bray et al 2003, Maurano et al 2012). This influence 
can be assessed by investigating the mRNA abundance. Assessing the relative 
expression levels of two SNP alleles (allelic imbalance) of a gene in the same sample, 
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instead of the total expression level as the quantitative phenotype is a powerful 
approach for identifying cis-acting regulatory SNPs or haplotypes. The major 
advantage of this approach is that the two SNP alleles are measured in the same 
environment, and serve as internal controls for each other. This excludes effects of 
environmental factors that may cause differences in the expression levels between 
samples.  
 
A recent study by Schodel et al demonstrated how a polymorphism at a remote 
intergenic region on chromosome 11q13.3, a susceptibility locus for renal cell 
carcinoma, can lead to an allelic imbalance in cyclin D1 expression. This locus was 
identified by a GWAS study that investigatedpopulation-based cancer susceptibility 
loci; but until recently the mechanistic insights remained limited (Schodel et al 2012). 
The locus coincided with strong hypoxia-inducible factor (HIF) signals detected by 
ChIP-seq and the group identified two SNPs (rs7948643 and rs7939721) that lie only 
10 bp and 15 bp from the HIF-binding motif at 11q13.3. The group showed that these 
variantsmodulates the binding and function of hypoxia-inducible factor (HIF), and also 
demonstrated that this region is a previously unrecognized transcriptional enhancer of 
CCND1 (encoding cyclin D1) that is located 230 kb upstream of HIF binding site. 
 
Further experiments demonstrated that modulation of HIF binding alter the allelic 
balance of CCND1 expression. Using the allele specific expression approach the group 
identified two informative SNPs (rs7177 and rs678653) in the 3′ UTR of CCND1 and 
demonstrated the allelic imbalance of CCND1 expression. This study demonstrates the 
power of allele specific expression approach to provide insights into functions of 
variants in the intergenic regions (Schodel et al 2012). 
 
We first constructed the expression profiles of each gene to select the appropriate 
stage for experiments. Healthy unrelated individuals were genotyped, and recruitments 
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with the appropriate genotypes were selected for culture studies. Our allelic expression 
experiments were performed using Snapshot-PCR, a technique that is quantitative. 
 
Extensive optimization of the assays was carried out; and the Snapshot assays 
showed that alleles are not equally represented even with genomic DNA (where alleles 
are usually present in equimolar concentrations). This can be explained by a bias 
towards specific nucleotides (Moskvina et al 2005). Because of this, it was necessary 
to correct observed cDNA ratios by the ratios observed in genomic DNA, which, in the 
absence of copy number polymorphisms, should reflect a perfect 1: 1 ratio of the two 
alleles. 
 
Our results suggested that individuals who are heterozygous for HMIP-2 haplotype 
display greater imbalance in the relative expression of each MYB allele when 
compared with controls i.e. individuals who are homozygous for the HMIP block 2 
haplotype (Figure 7.3). Departure from the defined 1: 1 ratio with cDNA samples ( after 
normalization to genomic DNA)  is suggested to  reflect either epigenetic modification 
that results in preferential transcription from one parental chromosome or  
heterozygosity for DNA sequence variants that affect the transcription, splicing or 
stability of a gene. In the case of HBS1L the results were harder to interpret. Results 
suggested imbalanced expression of alleles both with controls and test samples. 
HBS1L allelic expression fluctuates from individual to individual from 0.40 to 1.60 even 
in controls. The results suggest that the imbalanced expression may be related to other 
cis-acting polymorphisms that are not controlled for in this experiment (Figure 7.4). 
 
The direction of effect, in terms of allelic expression of the informative SNP, will depend 
upon the phase of the regulatory variant(s) with respect to the informative MYB SNP. In 
our case we have unrelated samples where phase between regulatory variant(s) with 
respect to the informative MYB SNP is not known.  
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Experiments should be repeated using erythroid progenitor material from the family 
members, who are heterozygotes for both HMIP block 2 SNPs and MYB intronic SNP 
rs210796 and in whom the linkage phase of these SNPs are known. 
 
If the HMIP block 2 haplotype is associated with altered HBS1L expression, individuals 
who are heterozygous should display greater relative differences in the expression of 
each gene copy than those who are not. This relies on the assumption that no other 
regulatory haplotypes are present that influence expression of the gene. 
 It is possible that other potential variants present in control samples influence the 
HBS1L gene expression causing the observed imbalanced expression. The limitation 
of the experiment is the small sample size. Recruitment of appropriate individuals 
heterozygous for HBS1L exonic rs13064 SNP and HMIP-2 was difficult.  
 
MYB is a crucial factor with key roles in regulation of proliferation and cell lineage 
commitment of erythroid progenitor cells, thus its expression should be strictly 
regulated. The commitment of haematopoietic stem cells to the erythroid lineage is 
dependent on distinct threshold levels of MYB. We know from results that down 
regulation of MYB alter erythropoietic kinetics (Chapter 3); thus we were not expecting 
massive differences in the allele specific expression of MYB alleles. Association of the 
genetic variants in the HMIP variants with MYB control provides a functional link of the 
region with control of HbF and other haematological parameters. 
 
Accelerated erythropoiesis as a response to relatively low MYB levels generates 
prematurely terminated erythroid cells that are still synthesising more HbF (Jiang et al 
2006). We propose that the SNPs in the HBS1L-MYB intergenic region modulate MYB 
expression and this affects the variation in erythroid, platelet and monocyte counts as 
well as erythroid differentiation kinetics, the number of F cells and HbF. 
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Independently, Sankaran et al showed that downregulation of MYB in human erythroid 
progenitor cells resulted in increased expression of γ-globin and έ-globin. This study 
also demonstrated that MYB gene was a target for two microRNAs: miR-15a and miR-
16-1, which are expressed in erythroid precursor cells. These miRNAs are 
overexpressed in trisomy 13 patients and the presence of high levels of miR-15a and 
miR-16-1 is the probable cause of the HbF levels, one of the features of the disease. 
MYB protein levels were reduced with even a slight over-expression of these miRNAs 
(Sankaran et al 2012). The influence of MYB on HbF levels were further supported by 
the findings that missense mutations in MYB strongly correlate with HbF (Galarneauet 
al 2010). 
 
Altogether these studies (Jiang et al 2006, Galarneau et al 2010, and Sankaran et al 
2012) demonstrate that MYB modulates HbF levels. We show that the intergenic 
variants modulate MYB levels providing the functional link for the genetic association of 













































The QTL on chromosome 6q23 was initially identified by linkage analysis in an 
extended Asian family with β-thalassaemia (Thein et al 1989). Subsequently, genetic 
variants in the HBS1L-MYB interval on chromosome 6q were shown to be highly 
associated, not only with HbF levels, but also linked to the control of other 
haematological parameters (Thein et al 2007, Menzel et al 2007). Genetic studies and 
resequencing of two key individuals from the family that led to the discovery of the 6q 
QTL revealed new SNPs in the HBS1L-MYB intergenic region that differ between 
individuals with HPFH and those without.This study was pursued to delineate key 
variants in the HBS1L-MYB intergenic region by performing functional experiments and 
the main conclusions were: 
 
1. Key transcription factor binding sites are present at the HBS1L-MYB 
intergenic region  
In-silico predictions and previous ChIP-Chip experiments suggested presence 
of key transcription factor binding sites in the HBS1L-MYB intergenic region. 
ChIP-qPCR experiments confirmed  and refined the GATA-1, KLF1 and MYB 
binding sites. Electrophoretic mobilty shift assays also confirmed the presence 
of these sites. 
 
2. High scoring variants located in two defined regions of HMIP block 2 that 
coincide with LDB1 binding sites alter binding of key transcription factors 
that may distrupt interactions with the MYB gene. 
 
Electrophoretic Mobility Shift Assays (EMSAs) , Chromatin immunoprecipitation 
followed by real time PCR (ChIP-qPCR) and HaploChIP results suggested that 
variants altered the binding of key transcription factors such as GATA-1, KLF1 
and MYB. The variants were located in two regions at 71kb and 84kb away 
from the MYB transcription start site and encompassed GATA-1 binding sites; 
coinciding with DNase I hypersensitive sites  and intergenic transcripts. 
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Such enhancer regions were demonstrated in the homolgous region in mice. A 
study in mouse eryhtroid progenitors showed that these homologous regions 
physically interact with the promoter and first intron of the flanking Myb gene via 
chromatin looping suggesting that these two regions can be crucial in regulation 
of the flankingMyb gene (Stadhouders et al 2012). 
 
3. Erythroid culture kinetics of HPFH +/+ individuals is altered compared to 
that of HPFH -/- individuals. 
 
Comparisons of ex-vivo primary erythroid cell culture kinetics of HPFH +/+ 
individuals with HPFH -/- individuals showed that the kinetics of erythroid 
differentiation was noticeably different. HPFH +/+ erythroid progenitors 
differentiated much faster and monopoiesis was relativley higher in HPFH +/+ 
individuals compared to HPFH -/- individuals. 
 
4. There are strong indications that enhancer elements in the HMIP- 2 
regulate the flanking MYB but not HBS1L gene.  
 
Ex-vivo erythroid cell culture expression profiles in HPFH +/+ individuals 
compared to HPFH -/- individuals demonstrated that MYB expression was 
noticeably different; whereas expression of HBS1L ,the other flanking gene, 
was not. By comparing MYB expression intra-individually, we could confirm the 
imbalanced expression of MYB using the informative SNP rs201796 located in 
the intron 4 of MYB gene in HPFH +/- individuals.  
Unfortunately, as the linkage phase of the SNPs in HMIP-2 and the MYB intron 
4 SNP rs201796 was not known, we could not determine the direction of the 
influence of the HMIP-2 variants on MYB expression. Using the same approach 
in the same HPFH +/- individuals, we could not show imbalanced expression of 
HBS1L. 
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Taken together, our findings suggest the presence of a regulatory region in HMIP-2 
that regulates the flanking MYB gene distally. We have highlighted some functional 
variants that alter the binding of key transcription factors, providing further support to 
the importance of MYB in the regulation of erythroid development and demonstrated 
indications of a link between the intergenic variants and MYB expression. The results 
from this thesis were submitted to Journal of Clinical Investigation as a research article. 
 
 In 2006, Jiang et al demonstrated that MYB expression in ex-vivo erythroid progenitor 
cells of healthy adults is variable and individuals with high HbF had reduced MYB 
levels when compared to individuals with low HbF. Over expression of MYB in K562 
cells resulted in low gamma globin gene expression. It was proposed then that MYB 
modulates HbF indirectly through the modulation of the number of F cells by altering 
the kinetics of erythroid differentiation. Accelerated erythropoiesis as a response to 
relatively low MYB levels could generate prematurely terminated erythroid cells 
synthesising more HbF (Jiang et al 2006).This proposal is not entirely speculative. It is 
already evident from previous studies of other groups that MYB is involved in cell 
proliferation and differentiation. The commitment of haematopoietic stem cells to the 
erythroid lineage is dependent on the distinct threshold levels of MYB. Reduced MYB 
levels favours commitment of haematopoietic progenitors to the megakaryocytic 
(platelet precursor) and monocytic lineages over the erythroid lineage (Emambokus et 
al 2003;Lu et al 2008). Our group also showed that HMIP-2 genetic variants were 
associated with erythroid count and size, platelet and monocyte counts (Menzel et al 
2007). 
Thus, modulations in MYB levels could well underlie the variation in erythroid, platelet 
and monocyte counts as well as HbF levels associated with HMIP. 
 
Later, genetic association studies by our group demonstrated the association of key 
variants in HMIP-2 with HbF regulation (Thein et al 2007). Functional studies by 
Wahlberg et al indicated the presence of distal regulatory elements in HBS1L-MYB 
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intergenic region (HMIP) evidenced by GATA-1 binding coinciding with strong histone 
acetylation, RNA polymerase II activity, and erythroid specific DNase I hypersensitive 
sites (Wahlberg et al2009). It was proposed that the variants highly associated with 
HbF/ F cells in HMIP-2 could regulate HbF indirectly via the control of its flanking MYB 
gene.  
 
Several studies have related the 6q intergenic transcripts with altered MYB levels. 
The functional importance of the intergenic region was reported by Mukai et al who 
reported a mouse model in which a transgene bearing EPOR was inserted 77 kb 
upstream of the myb gene and caused insertion mutagenesis of the region.This led to 
marked decrease in myb expression in megakaryocyte/erythrocyte lineage-restricted 
progenitors (MEPs). Homozygous mutant mice were severely anaemic with a threefold 
increase in the platelet counts. The results suggested an association between the 
intergenic region and the myb gene; and clearly demonstrated that Myb is an essential 
regulator of the erythroid-megakaryocytic lineage bifurcation (Mukai et al 2006).  
 
Analysis of recent ENCODE data also demonstrated a strong positive correlation 
between MYB expression levels and intergenic regulatory activity. In erythroid K562 
cells, which express the highest levels of MYB, the intergenic interval was transcribed 
and contained numerous enhancer chromatin signatures and DNaseI hypersensitive 
sites.  
On the other hand; cell types not expressing MYB for example, HUVEC, NHEK, and 
HepG2 displayed heterochromatinized or polycomb-repressed intergenic regions with 
an absence of DNaseI-hypersensitivity, while still expressing HBS1L at high levels. 
These results provide further support to the hypothesis that the region would 
preferentially be involved in MYB but not HBS1L regulation. 
 
Results from this thesis clearly demonstrated a link between the 6q intergenic variants 
and MYB expression and provided additional insights into how these variants alter 
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MYB expression. We proposed that the region upstream of MYB contains distal 
regulatory elements occupied by key erythroid transcription factors that interact with 
MYB gene and form a key part of the overall control of MYB transcription. We showed 
that several of the variants alter transcription factor binding. The altered transcription 
factor binding can affect long range interactions with MYB gene by disrupting the 
complex including LDB1, GATA-1, and TAL1, ETO2 and KLF1 and leading to altered 
MYBexpression as discussed at Chapter 6 (Figure 8.1). 
 
MYB has been associated with the control of HbF by various studies other than Jiang 
et al.Sankaran et al also showed that downregulation of MYB in erythroid progenitor 
cells resulted in increased expression of γ-globin and έ-globin (Sankaran et al 2012). 
Previous case studies suggested that raised HbF is a feature of trisomy 13 (Huehns et 
al1964). Sankaran et al(2011) mapped this elevation of HbF in Trisomy 13 cases to 
chromosomal band 13q14 which encodes two microRNAs: miR-15a and miR-16-1 
expressed in erythroid precursor cells. Increasing the expression of these miRNAs in 
haematopoietic progenitor cells by 1.5 fold (as would be expected in a trisomy), 
resulted in an increase in γ-globin levels by 2.4 fold, which suggests that the elevated 
HbF levels seen in Trisomy 13 cases are likely due to the increased expression of 
these miRNAs. Interestingly, when the authors investigated the targets of these 
miRNAs, the MYB gene was found to have two conserved 8mer miR-15a/16-1 
targeting sites. MYB protein levels were reduced with even a slight increase in the 
expression of these miRNAs suggesting that MYB gene influences the increased HbF 
levels observed in the trisomy 13 infants. The influence of MYB on HbF levels was 
further supported by the findings that missense mutations in MYB strongly correlate 
with HbF (Galarneauet al 2010).  
 
Further studies of the mouse with the transgene insertion in the Hbs1l-Myb intergenic 
region showed that the position of the transgene coincided with the 24kb of HMIP-2. 
The transgene insertion led to a significant reduction of Myb gene expression, but only 
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to slight reduction of expression of the other flanking gene HBS1L. The mutant mouse 
exhibited typically elevated expression of embryonic globins and hematopoietic 
parameters similar to those observed in human HPFH. The group referred to the 
mutant mouse as a model of HPFH (Suzuki et al 2013).HMIP-2 encompasses the two 
key regions -71kb and -84kb that physically interact with the promoter and first intron of 
the flanking Myb gene via chromatin looping suggesting that these two regions can be 
crucial in regulation of flanking genes (Stadhouders et al 2012). 
 
Recently, other mechanisms whereby MYB can influence HbF levels have been 
proposed. A study in human erythroid progenitors suggests that MYB activates KLF1, 
in which case MYB can influence gamma globin expression via KLF1 activation of 
BCL11A (Bianchi et al 2010). Suzuki et al also demonstrated that reduction in MYB 
expression led to the downregulation of KLF1 expression in mice which suggests a 
correlation between MYB and KLF1 (Suzuki et al 2013). 
 
Another mechanism of how MYB can influence HbF and gamma-globin gene 
expression is provided by the mouse model of HPFH in which the disruption of 
theHbs1l-Myb locus led to a downregulation of TR2/TR4, nuclear receptors involved in 
the DRED complex.  
The group suggested that Myb activates the DRED (direct repeat erythroid definitive) 
complex, a known repressor of embryonic and fetal globin genes in the adult (Suzuki et 
al 2013). These results support the findings that mutation of the HBS1L-MYB genomic 
domain is responsible for the elevated expression of the fetal globin genes via 
involvement of Myb and DRED complex in this regulatory pathway.   
 
Overall, these results strongly indicate the functional importance of the intergenic 
region and suggest that the regions control HbF indirectly via the flanking MYB gene. 




• By altering erythropoietic kinetics that results in increased F cells and elevated 
HbF levels 
 
• By altering expression of BCL11A, a known gamma globin repressor, via 
altering KLF1 expression 
 
• By altering expression of TR2/TR4 (DRED pathway), another repressor of 






































































8.1.1 Characterization of non-coding transcripts in the intergenic region 
 
Previous tiling arrays revealed presence of transcription peaks at chromosome 6q QTL 
in erythroid progenitor cells (Wahlberg et al 2009). Transcripts were in two major peaks 
and were more recently confirmed in samples from other erythroid cultures. Previous 
studies by our group also showed that there are DNase 1 hypersensitive sites 
coinciding with these transcripts. Other studies also confirmed presence of DNase 1 
hypersensitive sites at cd34+ progenitor cells around similar positions. 
 
ENCODE data also showed that the intergenic interval is transcribed in erythroid K562 
cells, which express the highest levels of MYB. The non-coding transcripts could be 
silenced to investigate their effects on MYB expression and to check the potential 
alterations at the kinetics of erythroid cultures. Such non-coding RNAs (ncRNA) have 
been known to contribute to gene regulation as well as physiological cellular 
processes. 
Various non-coding RNAs are up-regulated at specific stages during the hematopoietic 
development and the functional relevance of non-coding RNAs has been proven at 
many different stages of lineage specification. Knockout of specific non-coding RNAs 
can produce dramatic phenotypes leading to severe hematopoietic defects. Several 
studies identified regions of intergenic transcription in the human β-globin locus. These 
intergenic transcripts coincided with DNase I hypersensitive sites and active histone 
modifications. It has been proposed that intergenic transcription in the globin gene 




Targeting the 6q intergenic transcripts with siRNAs could be a potential strategy to 
induce HbF via altering MYB expression.  Another direct method of targeting MYB 
transcription factor with siRNA is possible but can have undesirable side effects, 
particularly given the pleiotropic role of MYB in haematopoiesis (Emambokus et al 
2003; Carpinelli et al 2004). However, targeting intergenic region can lead to a partial 
knockdown of MYB and recent work suggests that such strategies may actually hold 
promise, because partial knockdown of Myb in mice had little effect on normal in vivo 
haematopoiesis while dramatically blocking progression of leukaemia (Zuber et al 
2011). It is also possible to disrupt protein-DNA interactions by small molecules but it’s 
a complicated task (Koehler et al 2010). The targeting of exogenous siRNAs to the 
desired cell type remains a major challenge, although on-going advances in siRNA 
delivery suggest that specific approaches to target erythroid cells may be developed in 
the future (Leuschner et al 2011). 
 
8.1.2 Expression profiling of TR2/TR4 
 
 
The recent study by Suzuki et al demonstrated that the intergenic region between 
Hbs1l and Myb is responsible for the persistence of murine embryonic globin gene in 
adult life. 
They showed that the levels of expression of the flanking genes, Hbs1l and Myb, are 
reduced in the mutant erythroid progenitors. The erythroid progenitors of this 
transgenic mutant mouse also showeddiminished expression of the DNA binding 
subunits of the DRED complex (TR2/TR4). 
 
These findings should be investigated in human erythroid progenitor cells. The 
correlation of MYB and TR2/TR4 expression should be investigated in erythroid 









Electrophoretic Mobility Shift Assays (EMSAs) and Chromatin immunoprecipitation 
followed by real time PCR (ChIP-qPCR) and HaploChIP showed the presence of MYB 
binding sites at the HMIP-2 yet the experiments only focused on a limited area of the 
intergenic region coinciding with SNPs associated with HbF.  
A broader study for MYB binding can be performed by MYB ChIP-chip with a custom 
array encompassing globin cluster, KLF1, MYB, and the intergenic region that would 
provide further insights in understanding its role in gene regulation and its association 
with HbF. 
 
8.1.4 Characterization of transcription factor complex around rs66650371 
 
EMSA experiments performed with oligonucleotide encompassing the three base pair 
deletion (rs66650371) demonstrated differential binding patterns with “wt” and “del” 
oligonucleotides (Chapter 5). To characterize protein-nucleic acid complexes, cold 
competition assays were performed but the results failed to suggest a relation between 
differentially bound complexes and GATA-1. There are other key transcription factor 
motifs that are encompassed by the oligonucleotides such as: RUNX1, Hepatic nuclear 
factor 1 (HNF1) (Chapter 4) and future experiments should be performed in order to 
characterize these protein-nucleic acid complexes. Further cold competition assays 
can be performed to investigate the presence of candidate transcription factors in the 
complex. If these experiments fail to suggest any correlation, experiments combining 





8.1.5 Characterization of HBS1L-MYB intergenic region in other cell lineages 
 
 
In this study, we have focused on the function of the HMIP block two in erythroid cells 
and only discussed its potential involvement in the control of MYB or HBS1L which are 
highly expressed in erythroid lineages. We should however not exclude the idea that 
the region could also influence expression of other genes in the locus in other cell 
lineages, especially monocytic lineage.  
 
The mouse model of HPFH, with a transgenic insertion in the HBS1L-MYB intergenic 
region, also had reduced Myb. Interestingly, the same mouse model showed increased 
Myb mRNA in T-cells, suggesting that the transgenic insertion affected Myb expression 
differently in different haematopoietic lineages of the transgenic mouse (Mukai et al 
2006).   
Increased Myb levels have also been observed in feline T-cell lymphoma as a result of 
retroviral insertions in a region proximal to HMIP block 2 (Hanlon et al 2003). From 
these findings, it appears that the regulatory influence on MYB expression from this 
region differs between lineages. This suggests that the 6q intergenic variants may act 
as a MYB enhancer or silencer depending on the specific environment of the effector 
proteins (i.e. transcription factors and chromatin remodelling proteins) in the respective 
cell type. In the erythroid environment, the distal element appear to function as a 
control region involved in fine tuning of MYB levels required for normal haematopoietic 
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Appendix 1: Genotyping Results 








HMIP block 2 MYB  
rs210796 A/T 
HBS1L Exon 17 
rs13064(A/G)  
 
1 6 0.3 4.2 (+/-) genotype A/T A/G 
2 7 0.5 10 (+/-) genotype A/A - 
3 9 0.5 9 (+/-) genotype T/T A/G 
4 13 0.3 6 (+/-) genotype A/A A/G 
5 14 0.2 3 (+/-) genotype A/T A/G 
6 15 0.4 6 (+/-) genotype A/T A/G 
7 20 0.3 4.6 (+/-) genotype A/A - 
8 21 0.3 5 (+/-) genotype A/T - 
9 31 1 13 (+/-) genotype A/T - 
10 34 0.2 4 (+/-) genotype A/T - 
11 35 0.3 7 (+/-) genotype A/T - 
12 38 0.2 4 (+/-) genotype A/T - 
13 41 0.4 7 (+/-) genotype A/A A/G 
14 45 0.4 7 (+/-) genotype A/A - 
15 48 0.4 6 (+/-) genotype A/A - 
16 51 0.2 4 (+/-) genotype A/A - 
17 19 0.2 4 (+/-) genotype A/A - 
18 8 0.1 2 (-/-) genotype T/T A/G 
19 11 0.2 4.5 (-/-) genotype T/T A/G 
20 18 0.2 3.5 (-/-) genotype A/T - 
21 22 0.2 2.5 (-/-) genotype A/A - 
22 23 0.3 3.5 (-/-) genotype A/T - 
23 24 0.2 3 (-/-) genotype A/T - 
24 25 0.2 3.5 (-/-) genotype A/A - 
25 26 0.6 9 (-/-) genotype A/T - 
26 27 0.4 7 (-/-) genotype A/A - 
27 28 0.3 6 (-/-) genotype A/T - 
28 29 0.2 5 (-/-) genotype A/T A/G 
29 30 0.4 7 (-/-) genotype A/T - 
30 33 0.2 7 (-/-) genotype T/T - 
31 36 0.2 3 (-/-) genotype A/A - 
32 39 0.3 5 (-/-) genotype A/A - 
33 40 0.3 4 (-/-) genotype A/T A/A 
34 42 0.2 4.5 (-/-) genotype A/A A/G 
35 43 0.3 6 (-/-) genotype A/A - 
36 44 0.2 5 (-/-) genotype A/A - 
37 47 0.4 5 (-/-) genotype A/T A/G 
38 49 0.3 4 (-/-) genotype A/T - 
39 16 0.2 3 (-/-) genotype A/T - 
42 12 1 15 (+/+) genotype A/T A/A 
41 46 1 15 (+/+) genotype A/A - 





















Oligonucleotide Sequence Encompassed SNPs 




Del oligo  5I-AGATGTTATATCAAAACCACAAAA3I 
3I TCTACAATATAGTTTTGGTGTTTT5I- 
rs66650371(TAC/---) 








Rs9494142 T oligo 5I ACTACTGACATTTATCAACATGGTG3I 
3ITGATGACTGTAAATAGTTGTACCAC5I 
Rs9494142(T/C) 







Table 2.2: Snapshot Extension Primers 
 
Extension Primer Primer Sequence Encompassed SNP 








5I ACCTCCCCAGCTCTTT3I rs13064(A/G)  







Rs9494142 ext F 
 











Table 2.3 ChIP-qPCR primers for GATA-1 ChIP 
 
Primer target Forward primer sequence Reverse primer sequence Amplicon 
Size 
α-HS40                                         
Positive control for GATA1 
binding  
5I CGACCCTCTGGAACCTATCAG3I 5I TTGGCCTCCAGAAGCACTG3I 151bp 
β-HS 2   
Positive control for GATA1 
binding 
5GGGAGCAGTCCCATGTAGTAGT3I 5TAGGTGGTTAGGTCAGGTTGGT3I 153bp 
NEFM                                            
Housekeeping gene, negative 
control and normaliser 
5I AGCTGGACAAGAAGGTGCAG3I 5I CCGTCGAGATGTCTGTCTTC3I 150bp 
Gata-1 Peak 1 5I TGGCATCACCTGGCCTCATAA3I 5I TGGCTATCAGATCAAGTCACCAAA3I 105bp 
Gata-1 Peak 2 5I CTCCATGGACAGCTGCCACTTTAA3I 5I TCCAGTGCCTCTGCTCCCATCC3I 118bp 
Gata-1 Peak 3 5I AAAGCACACCTCTAACTGATGGAA3I 5I TCCGGTTACCATAGAGGAGAAGAA3I 111bp 
Gata-1 Peak 3-2 5I TGGTTTTAGGCTCGGTTGTGAAAA3I 5I GTAAGTGTCTTCTGAGGGAACCG3I 181bp 
Gata-1 Peak 4 5I AGGCTGCTGGCTTCTTTGCT3I 5I TCAACATGGTGGGTGTGATATCTT3I 158bp 
Gata-1 Peak 5 5I TCACCTCACCACACCACTGCATA3I 5I TGACAGGTTGTTCCAACCCATTGT3I 161bp 






Table 2.4 ChIP-qPCR primer sequences for MYB and KLF1 ChIP 
 
Table 2.5: Allele Specific Expression Primers 





5I CGTAGCATGAACCTCCCCAG3I 5I GCCAGAATGCATTGGTAGAGC3I 91bp 
    
MYB 5I ACCGTATTTCTGTACAAGCTCTA3I 5I ATTATGAGTCACACACCAATGAAGA3I 260bp 
CTSG  Cathepsin-G promoter 
Positive control for MYB binding 
5TTGATGGGTTGAGGGTTCTGG3I 5CAGTCAGTTGCTGCTGTGCTTC3I 304bp 
HBB promoter   (β-globin)                    
Positive control for KLF1 binding  
5I CAATAGATGGCTCTGCCCTGAC3I 5I CAGGTACGGCTGTCATCACTTA3I 129bp 
NEFM                                                  
Housekeeping gene, negative 
control and normaliser 
5I AGCTGGACAAGAAGGTGCAG3I 5I CCGTCGAGATGTCTGTCTTC3I 150bp 
MYB / KLF ChIP primer for 
rs9399137 
5I AACATCACCTTAAAAGGCGGT 5I TCCACTTTCAGAACTTATCCCAAG3I 147bp 




5I ACTGAGGCAGGTGGATTGCCTGAGC3I 131bp 









Intron 4b  
 
 















Table 2.7 List of Antibodies 
Gene  Forward primer sequence  Reverse primer sequence  Probe sequence  
MYB 5I ATGATGAAGACCATGAGAAGGAAA3I 5I AACAGGTGCACTGTCTCCATGA3I 5I TGCTACCAACACAGAACCACACATGCA3I 
HBS1L 5I ACAAGAATGAGGCAACAGTATCTACAG3I 5I TCAGATTCACTTCGCGATGTCT3I 5I CAAAAGGAAAACCAGTAGATTCC3I 
GATA-1 5I CAATGCCTGCGGCCTCTA3I 5I CATCCTTCCGCATGGTCAGT3I 5I CTACAAGCTACACCAGGTGA3I 
KLF1 5I CCCAGTCACTAGGAGAGTCCAA3I 5I GCTACACCAAGAGCTCCCACCT3I No probe (SYBR Green detection) 





















Appendix 3: ChIP results 
Figure 3.1: GATA-1 ChIP (not normalized) 
target protein weight (kDa) 
of target 
protein 
Actin Abcam 40 
MYB Millipore 1:1 75 























































































































Figure 3.3: MYB ChIP (not normalized) 
 
 











































































































































Figure 4.1: Snapshot for MYB SNP rs210796 (A/T)                Figure 4.2: Snapshot for HBS1L SNP rs13064 (G/A) 















List of abbreviations 
 
ACH   Active chromatin hub 
AcH3   Acetylated histone H3 
AcH4   Acetylated histone H4 
αHS40   α-globin locus DNase I hypersensitive site 40 
AML   Acute myeloid leukaemia 
βHS3   β-globin LCR DNase I hypersensitive site 3 
BFU-e   Burst forming unit erythroid 
Bp   Base pairs 
CFU-e   Colony forming unit erythroid 
ChIP-chip  Chromatin immunoprecipitation on microarray 
EPO   Erythropoietin 
F   Fetal haemoglobin 
FACS   Fluorescence activated cell sorting  
FC   F-cells 
FCS   Foetal calf serum 
FOG-1   Friend of GATA-1 
GM-CSF  Granulocyte-macrophage colony stimulating factor 
GPA   Glycophorin A 
HbA   Adult haemoglobin (α2β2) 
HBA   α-globin  
HbA2   Haemoglobin minor (α2δ2) 
HbAS   Sickle trait, heterozygous for HbS 
HBB   β-globin 
HBBP1  βψ-pseudogene 
HBD   δ-globin 
HBE   ε-globin 
HbF   Foetal haemoglobin (α2γ2) 





HBM   ψα2-pseudogene 
HBQ1   θ-globin 
HbS   Sickle haemoglobin, α2βs2  
HBZ   ζ-globin 
HMIP   HBS1L-MYB intergenic polymorphism 
HPFH   Hereditary persistence of foetal haemoglobin 
HS   Hypersensitive site (to Dnase I) 
HSC   Haematopoietic stem cell 
IL-3   Interleukin 3 
Kb   Kilo base pairs 
KLF   Krüpple like factor-1 
LCR   Locus control region 
LD   Likage disequilibrium 
Mb   Mega base pair 
MYB   Myeloblastosis oncogene 
NEFM   Neurofilament medium gene 
PB   Peripheral blood 
PBS   Phosphate buffered saline 
PCR   Polymerasechainreaction 
Q-PCR  Quantitative PCR 
QTL   Quantitative trait locus 
RNAP II  RNA polymerase II 
RT-PCR  Reverse transcription PCR 
SCD   Sickle cell disease 
SCF   Stem cell factor 
SNP   Single nucleotide polymorphism 
TFBS   Transcription factor binding site 
TF   Transcription factor 
TSS   Transcriptional start site 
UTR   Untranslated region 
